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ABSTRACT
Tumour hypoxia, a phenomenon described within many solid tumours, arises 
primarily from the development of a deficient vasculative system. The failure of 
conventional radiotherapy and chemotherapy in the treatment of solid tumours has been 
related to the presence of hypoxia within such tumours. For this reason, several methods 
have been introduced in an attempt to overcome these problems, and hence, lead to 
effective killing of the whole tumour. The development of bioreductive anticancer agents 
as a means of exploiting hypoxic cells within solid tumours has been based upon their 
ability to be preferentially cytotoxic towards hypoxic cells. Furthermore, these agents 
express a requirement for enzyme-mediated reductive activation in order to exert their 
cytotoxic effects. The implementation of an enzyme-directed bioreductive drug 
development programme, therefore, has been based not only upon understanding the 
mechanism of action of particular bioreductive anticancer agents, but also upon 
determining the level of expression of reductases within both normal and tumour tissues.
The National Cancer Institute (NCI) possesses a panel of over 60 human tumour 
cell lines from at least nine different tumour origins. This cell line panel was used, 
therefore, as a means of determining the expression of several important reductase 
enzymes (DT-diaphorase; NAD PH : cytochrome P450 reductase and NADH : 
cytochrome b$ reductase) within cell lines from different tumour origins. Importantly, 
patterns of expression were found for each of the reductase enzymes studied. Subsequent 
incorporation of this data into the NCI database demonstrated the potential benefits of 
such a system by indicating possible mechanisms of action of various anticancer agents. 
For example, a large number of quinone compounds were among those showing positive 
correlations between DT-diaphorase activity and cell sensitivity under oxic conditions. Of 
particular importance, were the correlations between DT-diaphorase activity and cell 
sensitivity towards both the prototype bioreductive, mitomycin C and the investigative 
indoloquinone agent E09.
A group of novel ZENECA pharmaceutical compounds were selected for study as 
potential bioreductive agents due to their structural similarities to some of the more active 
compounds already under investigation. These compounds consisted of a nitroacridine, a 
large nitroheterocycline and a series of quinoxaline di-N-oxides. The ability of these 
compounds to act as hypoxia-selective bioreductives was investigated using a small panel 
of human tumour cell lines selected from the NCI panel and hence, known to possess 
different enzyme activity levels. Of the three structurally distinct compounds, the 
quinoxaline di-N-oxide ZM 81853 showed the best potential as a bioreductive agent. 
Furthermore, ZM 81853 was the only compound from a series of structurally-related 
quinoxaline di-A-oxides to exhibit hypoxia-selective cytotoxicity. This finding indicated 
that small structural changes greatly influenced the ability of the compounds to act as a
hypoxia-selective cytotoxins. Interestingly, ZM 81853 demonstrated similar hypoxic : 
oxic differentials as the benzotriazine di-A-oxide currently in Phase II clinical trial, 
tirapazamine. Importantly, this differential was greatest in T47D cells which were shown 
to possess the highest NADPH : cytochrome P450 reductase activity. In vitro metabolism 
studies in the presence of various chemical inhibitors, in combination with high 
performance liquid chromatography (HPLC), were used to confirm the predominant role 
of NADPH : cytochrome P450 reductase in the metabolism of ZM 81853 under hypoxic 
conditions. Furthermore, these studies were used in conjunction with the technique of 
mass spectroscopy, to identify a four-electron reduced product as the predominant 
metabolite. Collectively, therefore, these studies suggest that ZM 81853 undergoes a 
series of one-electron reductions by NADPH : cytochrome P450 reductase to form the 
four-electron reduced product. Kinetic analysis of ZM 81853 metabolism in the presence 
of several enzyme preparations, including a purified, recombinant human form of 
NADPH : cytochrome P450 reductase, suggested that ZM 81853 was reduced under 
hypoxic conditions with reasonable efficiency. The ability of NADPH : cytochrome P450 
reductase to activate ZM 81853 to a cytotoxic species was further supported by the 
demonstration of DNA damage in the presence of the purified, recombinant human form 
of the enzyme. Interestingly, the lack of inhibitory effect of the oxygen radical 
scavengers, superoxide dismutase and catalase, suggested a possible role for a free 
radical, such as a nitroxide based species, in causing DNA damage under hypoxic 
conditions.
In conclusion, this- thesis has determined the expression and activity of several 
important reductases within human tumour cells. The potential use of this information in 
determining the mechanism of action of anticancer agents has been demonstrated with 
respect to both the NCI database and also to the novel compounds investigated within this 
thesis. In this regard, the quinoxaline di-A-oxide ZM 81853 was shown to possess the 
ability to act as a hypoxia-selective bioreductive agent. Importantly, ZM 81853 exhibited 
similar cytotoxic and metabolic characteristics as the benzotriazine di-A-oxide, 
tirapazamine. The work of this thesis, therefore, will aid selection of potential 
bioreductive anticancer agents for further in vivo studies within ZENECA 
Pharmaceuticals.
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CHAPTER 1 
GENERAL INTRODUCTION
More than 300,000 people develop cancer each year in the U.K (Cancer Research 
Campaign [CRC] Scientific Yearbook 1994 - 1995). Furthermore, this condition accounts 
for 20% of annual deaths in the U. K.. At present, the most common form of the disease 
in men is lung cancer (22% of all male cancers) whilst in women, it is cancer of the breast 
(approximately 30,000 new cases annually) (CRC Scientific Yearbook 1994 - 1995). 
Survival is dependent upon the type and stage of the disease, with the majority of deaths 
arising from metastatic spread (CRC Scientific Yearbook 1994 - 1995).
Conventional treatments of cancer include surgery, radiotherapy and 
chemotherapy. The former two regimes are used in the treatment of localised disease but 
neither is suitable on their own for the treatment of metastatic disease. In addition, the 
dose of radiation which can be delivered to the tumour site is often limited by damage to 
surrounding normal tissues. This is particularly applicable to tumours located deep inside 
the body. Chemotherapy plays an important role in cancer treatment, particularly in cases 
of metastatic disease. It can be used as adjuvant treatment before and after surgery or in 
combination with other treatments such as radiotherapy. Chemotherapeutic treatments 
have exhibited major curative effects for rare types of malignancy such as Hodgkin's 
lymphoma and testicular cancer in men. Unfortunately, however, successful drug 
treatment of common solid tumours such as lung, colon and breast has been limited. As 
with radiotherapeutic treatments, problems of toxicity towards normal cells occurs with 
conventional chemotherapeutic agents. Selection of drugs is generally based upon their 
ability to inhibit DNA synthesis and hence, interfere with the uncontrolled proliferation 
that is associated with tumour cells (Pratt et al. , 1994: Schwartsmann & Workman, 
1992). Normal cell toxicity arises, however, as many of these cells are also undergoing 
rapid proliferation, for example those within the bone marrow, hair follicles and 
gastrointestinal tract. In addition to toxicity, a further problem with current
chemotherapeutic treatment is resistance of the tumour towards the cytotoxic agents used. 
This resistance can either be intrinsic, i.e. be present before treatment begins, as for many 
colon tumours, or it can be acquired. In this latter case, a tumour which has previously 
been treated with chemotherapeutic agents becomes resistant to those agents when the 
patient relapses and fails to respond to therapy (Kaye, 1988). To further complicate 
matters, in certain cases, the tumour frequently becomes cross resistant towards agents 
other than those already used (Kaye, 1988). Clearly there is a need, therefore, for more 
effective radiotherapeutic treatments and chemotherapeutic agents to be developed, with 
particular emphasis on the treatment of the major common solid tumours. In the case of 
chemotherapeutic treatment, for example, the selectivity of agents towards tumour cells 
could be improved as this would increase the effectiveness of the agents.
1.1 Hypoxia as a Target for Cancer Therapy
1.1.1. Existence of Hypoxic Cells within Solid Tumours
The histological structure of solid tumours, for example those of the lung, 
indicated that such tumours possessed a central necrotic region surrounded by intact 
tumour cells (Gray et al. , 1953). This is caused by the existence of a deficient 
vasculature, and a decreasing gradient of oxygen tension between the periphery and the 
central region of the tumour, so much so that those cells in the centre of the tumour are 
deprived of both oxygen and nutrients and as a result are necrotic. Cells at the periphery 
of the tumour, and at sites close to blood vessels are known as the oxic cell population as 
oxygen and nutrients are in abundant supply. Hypoxic cells are those cells which exist at 
an intermediate oxygen tension sufficient to maintain viability but only a low level of 
growth and metabolism. Two types of hypoxia exist within the solid tumours (Figure 1.1) 
(Workman, 1993). The first, chronic hypoxia, is caused by the limited diffusion distance 
of molecular oxygen (150 - 200 microns), in which cells at this distance from the blood 
capillary become hypoxic. This is often referred to as diffusion limited hypoxia. The 
second form of hypoxia, acute hypoxia, results from the intermittent opening and closing
Vessel Ooen A e ra te d  Call
/
Anoxic 
Necrotic  Cell
C hron ica l ly  Hypoxic 
Viable Cell
Acutely 
Hypoxic Call
V esse l
C lo sed
interm it ten tly
Figure 1.1 Hypoxia within solid tumours.
Two types of hvpioxia are descnbed within solid tumours.C/zmrtic hypoxia is frequently 
described as the diffusion limited form due to a lack of diffusion of oxygen beyond 200 
LiM from the blood vessels. Acme hypoxia is the more transient form of hypoxia and is 
described as perfusion limited.
i  taken from Workman, 1993]
of blood vessels and hence is perfusion limited. Closure of a capillary, therefore, results 
in rapid consumption of available oxygen by the surrounding cells and subsequent 
hypoxia. Cells then become reoxygenated upon re-opening of the capillary. Importantly, 
hypoxic regions have been identified in various solid tumours including head and neck 
(Gatenby et al. , 1988), breast (Vaupel et ai. , 1991), cervix (Hockel et al. , 1993) and 
brain (Rampling et al. , 1994) using a computer-linked needle electrode (Eppindorf) to 
measure tumour partial oxygen pressure (p0 2 ).
1.1.2. Hypoxia and Resistance
Advances in the treatment of solid tumours have been limited due to the resistance 
of many of these tumours to conventional chemotherapy and radiotherapy (Coleman, 
1988). In the case of chemotherapeutic agents, resistance is believed to be due, in part, to 
the presence of deficient vasculature such that movement of the agents within the 
tumours is restricted. Resistance may also arise from a lack of oxygen-mediated 
activation or because of hypoxia-induced cell cycle effects (Workman, 1993). In addition, 
the presence of hypoxic cells within solid tumours are thought to be responsible for 
resistance towards radiotherapy, as these cells have been shown to be 2 - 3 fold more 
resistant than oxic cells towards the effects of radiation (Gray et a i, 1953; Hall, 1988). 
This phenomenon is frequently referred to as the oxygen effect. Under normal 
circumstances, i.e. in well-oxygenated areas, molecular oxygen would interact with short­
lived radicals in DNA to cause irreversible damage to the cells (Coleman, 1988). In the 
case of hypoxic cells, however, such a reaction cannot occur, thereby rendering the cells 
more resistant to the action of radiation. As a consequence, the presence of hypoxic cells, 
and the subsequent marked resistance towards conventional treatments, has been viewed 
as a major clinical problem in the treatment of solid tumours.
1.1.3. Mechanisms of Overcoming Resistance
Various clinical strategies have been designed in an attempt to overcome the 
resistance of hypoxic cells to treatment. Solid tumours are known to undergo a
reoxygenation step following radiation treatment (Hall, 1988) such that the number of 
hypoxic cells within the tumour remains relatively constant. As a result, fractionated 
radiation dosing schedules were implemented to exploit this reoxygenation step and 
thereby, to improve the treatment of solid tumours by radiotherapy. In addition, the 
administration of hyperbaric oxygen to patients was proposed as a means of 
reoxygenating the tumour before subsequent radiotherapy treatment (Coleman, 1988: 
Henk. 1981). Although positive results have been obtained in head and neck and cervical 
cancers (Henk, 1981), results on the whole have been inconsistent. This may, however, be 
partly explained by the logistic difficulty of administration of such therapy to patients. 
More recent studies, however, have focused on the combined use of nicotinamide and 
carbogen (95% oxygen, 5% carbon dioxide) to improve the oxygen status of tumours 
(Laurence et al. , 1995). These studies have shown that in patients with advanced disease, 
significant increases in pO? values were obtained with only low levels of toxicity. As a 
result, the combined use of nicotinamide and carbogen breathing has been proposed as a 
possible means of tumour radio sensitisation.
Hypoxic cell radiosensitisers have also been introduced with a view to specifically 
increasing the radiation sensitivity of hypoxic cells (Adams et al. , 1979) by mimicing 
oxygen and causing irreversible damage following interaction with the target DNA 
radical (Coleman, 1988). It was predicted that these agents would be more beneficial over 
the use of hyperbaric oxygen as the diffusion distance of the agents would be greater 
(Adams et al., 1979). The earliest hypoxic cell radiosensitisers to be developed were the 
nitroimidazoles, such as the 5-nitroimidazole, metronidazole, and the 2-nitroimidazole, 
misonidazole (Figure 1.2). More recently, new developments have included the dual- 
functioning' agents such as RSU 1069 (Stratford et al. , 1986) and its derivative RB 6145 
(Jenkins et al. , 1990) which contain not only the sensitising nitro group but also an 
alkylating aziridine group or a prodrug. A common problem with these agents has been 
the severe dose-limiting toxicities observed during clinical trials (Overgaard, 1994). For 
example, progress of misonidazole was marred by the dose-limiting peripheral and 
central neurotoxicity, while for RSU 1069, the dose-limiting toxicity observed was in the
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Figure 1.2 Chemical structures of 2-nitroimidazole radiosensitisers.
gastrointestinal tract. Attempts to overcome the neurotoxicity of nitroimidazoles have 
included the discovery of the hydrophilic analogue etanidazole (Brown & Workman, 
1980) and the more potent, basic analogue pimonidazole (Smithen et al. , 1980). RB 6145 
and one of its enantiomers have also shown less gastrointestinal toxicity than RSU 1069 
(Jenkins et a i,  1990). Encouragingly, a meta-analysis of all clinical trials with 
nitroimidazole radiosensitisers has shown small but significant advantages in terms of 
local control and survival (Overgaard, 1992). This provides added support for the view 
that hypoxia is indeed a limiting feature in radiation therapy.
Sartorelli and co-workers (Lin et al. , 1972) hypothesised that hypoxic cells 
within solid tumours would possess a greater ability to cause reductive reactions than the 
surrounding well-oxygenated cells. As a consequence, the presence of a hypoxic 
environment could be exploited by developing chemotherapeutic prodrugs with the 
potential to be reduced to more cytotoxic species under these conditions. During the 
development of the hypoxic cell radiosensitisers, it was noted that certain agents such as 
misonidazole were preferentially cytotoxic under hypoxic conditions (Stratford et al. , 
1980). The selective cytotoxicity was believed to be due to the production of toxic 
metabolites following specific reduction under hypoxic conditions. These agents, 
therefore, formed a new class of anticancer agent, namely the bioreductive hypoxic cell 
cy to toxins (Workman & Stratford, 1993).
1.2 Bioreductive Hypoxic Cell Cytotoxins
1.2.1. Selectivity of Bioreductive Hypoxic Cell Cytotoxins
The bioreductive cytotoxins exist as inactive prodrugs which are able to undergo 
selective reductive metabolism under hypoxic conditions to form species capable of 
causing cellular damage (Workman & Stratford, 1993). Several different classes of these 
agents have been studied. Examples are shown in Figiues 1.2 and 1.3, and include the 
nitro compounds, misonidazole, RSU 1069, nitracrine and CB 1954, and the quinone
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Figure 1.3 Structures of various bioreductive hypoxic ceil cytotoxins.
alkylating agents such as mitomycin C and E09. More recent developments have seen 
the introduction of the A-oxides, of which tirapazamine is the lead compound (see Figure
1.3 for structure). Many of these agents possess the ability to exhibit selective toxicity 
towards hypoxic versus oxic cells (Plumb et al. , 1994b; Stratford & Stephens, 1989; 
Wilson et al. , 1984) by virtue of their preferential reduction to cytotoxic metabolites 
under hypoxic conditions (Workman, 1992). For example, tirapazamine has been shown 
by Plumb and Workman (Plumb & Workman, 1994) to exhibit an oxic : hypoxic 
differential of approximately 95 against the BE human colon tumour cell line, while for 
mitomycin C, the hypoxic differential was shown to be significantly lower with a value of 
only 9. These results were consistent with reported studies by Stratford and Stephens 
(Stratford & Stephens, 1989) in which mitomycin C exhibited a much lower oxic : 
hypoxic differential than tirapazamine (2 compared to 50). Although these HCR results 
do not directly relate to the in vivo activity of the compounds, they are important for 
determining the ability of such compounds to be selectively active under hypoxic 
conditions. In vitro screening has therefore demonstrated that bioreductive cytotoxins 
exhibit quite variable degrees of selectivity under hypoxic conditions. In addition, the 
variability in selectivity is also seen for the same agents in different human tumour cell 
lines. For example, the indoloquinone E09 has been shown to exhibit oxic ; hypoxic 
differentials of approximately 1700 and 3 in BE and HT-29 human colon tumour cell 
lines, respectively (Plumb & Workman, 1994). These differences between bioreductive 
anticancer agents and also between different cell lines, result from the varying pathways 
of metabolic reduction of the individual agents (see Section 1.2.2. below) and those 
enzymes involved in these pathways (see Section 1.2.3).
1.2.2. Metabolic Reduction of Bioreductive Cytotoxins
The reductive metabolism of several bioreductive agents has been widely studied 
but while reduction products have been identified for many of these agents, the precise 
pathway of metabolism is often complex and as yet not completely understood.
The reductive pathway proposed for quinones such as menadione, E09 and 
mitomycin C is shown in Figure 1.4. Under hypoxic conditions, quinones can undergo 
one-electron reduction to form the semiquinone free radical product. This product is 
relatively unstable, and in the presence of oxygen back-oxidises to the parent product 
with the subsequent production of toxic oxygen species (Workman & Walton, 1990). 
These radicals, for example superoxide and hydroxyl radicals, are capable of causing 
oxidative stress and cell death. In the case of simple quinones such as menadione, toxicity 
under oxic conditions is caused by oxidative stress alone (Workman & Walton, 1990). In 
contrast, however, the situation is more complicated in the case of bioreductive alkylating 
agents such as mitomycin C and E09 since toxicity arises from both oxidative stress and 
activation to DNA-alkylating species (Workman & Walton, 1990). For example, electron 
spin resonance (ESR) (Bailey et al. , 1993) and DNA damage (Bailey et al. , 1994b; 
Walton et al. , 1991) studies involving E09 have indicated that aerobic toxicity, 
involving DNA strand breaks, resulted from the action of the semiquinone radical product 
and also the oxygen radicals. Further one-electron reduction under hypoxic conditions 
would lead to the production of the stable product, the hydroquinone. In addition, 
obligate two-electron reduction of quinones can also occur (lyanagi & Yamazaki, 1970), 
under both oxic and hypoxic conditions, to yield the more stable hydroquinone product 
(Pan et al. , 1984). In the case of E09, for example, it has been proposed that the 
hydroquinone possessed the ability to alkylate DNA and cause both DNA strand breaks 
and DNA adduct formation in the form of cross-links (Bailey et al., 1994b; Walton et al.,
1991).
Nitro compounds, for example the 2-nitroimidazoles misonidazole and RSU 1069, 
are similar to the quinone compounds in their complexity of metabolism. The reduction 
products which appear to be important are the nitroradical anion (1-electron), the nitroso 
(2-electron) and the hydroxy lamine (4-electron) as these are believed to be the toxic 
species, unlike the amine (6-electron) (Workman, 1992). Whilst the predominant reaction 
under aerobic conditions is thought to be redox cycling via the radical anion, less is 
known about those reactions occurring under hypoxic conditions. Toxicity, however, is
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thought to be caused by the actions of the nitroso and the hydroxyiamine reduction 
products (Workman, 1992). In addition, fragmentation products such as giyoxal and 
species obtained from the reaction of the hydroxyiamine intermediate with water are 
believed to be responsible, in part at least, for toxicity of the 2-nitroimidazoles (Franko, 
1986; Raleigh & Liu, 1984; Varghese & Whitmore, 1984a; Varghese & Whitmore, 
1984b). In contrast, the 'dual-function' nitroimidazoles such as RSU 1069 are believed to 
exert their toxic effects via DNA alkylation involving the aziridine moiety (Silver & 
O'Neill, 1986).
The nitroacridines such as nitracrine (1-NC) and 5-nitraquine have been studied 
for their selective toxicity towards hypoxic cells (Wilson et al., 1984; Wilson et al. , 
1992), however, only preliminary reports have been made in the literature concerning 
their reductive metabolism. Collectively, these studies suggest that cytotoxicity of 1-NC 
arose from nitroreduction of the compound (Wilson et al. , 1986) and subsequent 
production of a reactive metabolite capable of forming DNA adducts (Konopa et al. , 
1983; Pawlak et al. , 1983). Problems of a lack of inhibition of the reaction by oxygen 
have, however, complicated the issue and as a result, more oxygen-sensitive 
nitroacridines are being sought whose reductive metabolism would be more restricted to 
the hypoxic environment.
In contrast to both the quinones and the nitro agents, the reduction pathway of N- 
oxides such as tirapazamine is relatively more straight forward. Therapeutic toxicity is 
believed to be caused by one-electron reduction of the agent to produce a toxic free 
radical species, capable of causing DNA damage (Figure 1.5) (Laderoute et al. , 1988). A 
nitroxide radical has since been identified following reduction of tirapazamine under 
hypoxic conditions (Lloyd et al. , 1991). Furthermore, the ability of tirapazamine to be 
reduced by one-electron reducing enzymes under hypoxic conditions to a DNA damaging 
species has been previously demonstrated (Fitzsimmons et al. , 1994; Walker gf al. , 
1994). Such damage is believed to arise by hydrogen abstraction from sugar residues in 
the DNA (Laderoute etal., 1988).
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As mentioned in the previous section (1.2.1.), variations between the activities of 
different bioreductive agents are not only dependent upon the metabolic pathway of the 
agents, but also on those enzymes involved in such a pathway. For this reason, 
investigations to establish those enzymes of importance in the metabolic pathway of 
bioreductive agents are important.
1.2.3. Enzymology of the Metabolic Reduction of Bioreductive Cytotoxins
As described in the previous section, both one- and two-electron reducing 
enzymes are involved in the reduction of bioreductive agents. This area of research has, 
therefore, attracted a great deal of attention in recent years (Workman, 1992; Workman, 
1994 and references therein). Examples of those enzymes involved in the reduction of 
bioreductive agents include the one-electron reducing enzymes NADPH : cytochrome 
P450s (Lewis et al. , 1995; Riley et al. , 1993), NADPH : cytochrome P450 reductase 
(Fitzsimmons et al. , 1994; Walton et al. , 1992b), xanthine oxidase (Gustafson & Pritsos, 
1992; Gustafson & Pritsos, 1993), and the two-electron reducing enzyme DT-diaphorase 
(Bailey et al. , 1994b; Knox et al. , 1988; Walton et al., 1991). Depending on the 
chemistry of the individual agent and the particular enzyme involved, reduction can be 
either bioactivating or bioprotective (Workman, 1992). Examples of the enzymology of 
known reduction pathways are described below.
Tlie benzotriazine di-A-oxide, tirapazamine, is perhaps the best understood of all 
the bioreductive agents developed so far, in terms of enzymes responsible for either 
bioactivation and bioprotection. For example, the obligate two-electron reducing enzyme 
DT-diaphorase has been shown to directly reduce tirapazamine (Riley & Workman, 
1992b) to the inactive two-electron and more predominantly the four-electron reduced 
products (Baker et al. , 1988; Zeman et al. , 1986) (Figure 1.5). Reduction in this case, 
therefore, may cause a bioprotective effect. Interestingly, however, more recent studies 
have indicated that DNA damage may occur following metabolism of tirapazamine by 
DT-diaphorase (Walker et al., 1994). In contrast, the one-electron reducing enzymes
NADPH : cytochrome P450 reductase and NADPH : cytochrome P450 2B6 are believed 
to cause bioactivation of tirapazamine, through the production of a nitroxide radical 
capable of exerting DNA damage (Fitzsimmons et al., 1994: Laderoute et al., 1988; 
Lewis et a l . , 1995; Riley etal.. 1993; Walker a/., 1994).
In contrast to tirapazamine, the nitro compounds have a more complex reduction 
pathway in that different enzymes have been shown to reduce the compounds at different 
stages of the reaction. For example, NADPH ; cytochrome P450 reductase has been 
shown to be responsible for reduction of the misonidazole analogue, benznidazole, during 
the early stages, i.e. formation of the one- and two-electron reduced products. In contrast, 
NADPH : cytochrome P450s are responsible for production of the amine product in the 
latter stages of the reduction pathway (Walton & Workman, 1987). Furthermore, the 
cytosolic enzyme aldehyde oxidase has also been shown to play a minor role in the 
reduction of this particular agent. Similar studies using the 2-nitroimidazole hypoxic 
probe SR 4554 (Aboagye et a l . , 1995) have also shown that NADPH : cytochrome P450 
reductase is involved in the early stages of reduction of this agent.
Perhaps the most studied reduction pathway of a potential bioreductive agent to 
date is that of the prototype quinone compound mitomycin C (Sartorelli et al. , 1994). 
Xanthine oxidase, xanthine dehydrogenase (Gustafson & Pritsos, 1992; Gustafson & 
Pritsos, 1993), NADPH ; cytochrome P450 reductase (Hoban et a l., 1990; Keyes et al. , 
1984), NADH : cytochrome b5 reductase (Hodnick & Sartorelli, 1993) and DT- 
diaphorase (Beall et al. , 1994a; Ross et al. , 1994; Siegel et al. , 1990a) have all been 
associated with the reductive metabolism of this bioreductive compound. However, the 
precise role of these enzymes in the reduction of mitomycin C has still to be determined, 
particularly in the case of DT-diaphorase. A great deal of controversy has surrounded the 
role of DT-diaphorase in the activation of mitomycin C (Ross et al., 1994; Schlager & 
Powis, 1988; Workman, 1994; Workman & Walton, 1989). It is now known, however, 
that the ability of DT-diaphorase to metabolise mitomycin C is very much dependent 
upon pH conditions (Siegel et al. , 1990a). In addition, hypoxic conditions appear to 
cause only a small increase in the cytotoxic effects of mitomycin C (Plumb & Workman,
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1994: Stratford & Stephens, 1989). Although this is perhaps the most studied reduction 
pathway, it has thus far proved to be extremely complex.
Although enzymology of reduction is certainly important, recent studies (Plumb 
& Workman, 1994) have shown the importance of considering both enzymological 
effects and environmental effects together. For example, although several studies have 
found a direct relationship between DT-diaphorase activity and E 09 sensitivity 
(Robertson et al. , 1992; Smitskamp-Wilms et al. , 1994; Walton et al. , 1992a), these 
studies have been performed only under oxic conditions. Plumb and colleagues (Plumb & 
Workman, 1994; Plumb et al. , 1994a; Plumb et al., 1994b) have found that while high 
levels of DT-diaphorase, for example in HT-29 cells, related to sensitivity towards E09 
under oxic conditions, little increase in sensitivity occurred under hypoxic conditions. In 
contrast, those cells possessing low levels of DT-diaphorase activity, for example BE 
cells, exhibited increased sensitivity to E09 under hypoxic conditions. It is now believed 
that this is due to the activating effects of one-electron reducing enzymes such as 
NADPH : cytochrome P450 reductase under these hypoxic conditions. Similar findings 
were reported by Robertson and colleagues (Robertson et al. , 1994). Collectively, they 
show the importance of considering all possible influential factors when studying the 
enzymology of bioreductive reduction.
It is clear that those enzymes demonstrated above are extremely important for 
bioreductive drug activation. They are of interest, therefore, in this thesis and as a result, 
are discussed below.
1.2.4. DT-diaphorase
1.2.4.1. Background and Nomenclature
DT-diaphorase (NAD(P)H : quinone oxidoreductase, NQO%, E.G. 1.6.99.2) was 
discovered in 1958 as a highly active enzyme form in the soluble fraction of rat liver 
homogenates (Emster & Navazio, 1958). Interestingly, early studies indicated the ability 
of this enzyme to utilise either NADH and NADPH with equal efficiency (Emster &
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Navazio, 1958). Subsequent purification and characterisation of DT-diaphorase revealed 
a high degree of sensitivity towards dicoumarol (Emster et al. , 1962), a property which 
has led to the increased use of dicoumarol as a diagnostic inhibitor of this enzyme 
(Dulhanty et al. , 1989: Keyes et al. , 1985). A further characteristic of DT-diaphorase 
was its ability to catalyse obligatory two-electron reduction reactions (Lind et a l . , 1982).
1.2.4.2. Purification, Protein and Gene Sequence
DT-diaphorase has been purified from several sources, including rat liver (Emster 
et al.. 1962: Segura-Aguilar et a l . , 1992), mouse liver (Prochaska & Talalay, 1986) and 
human Hep G2 cells (Boland et a l . , 1991). Tlie enzyme is known to exist as a dimer with 
two subunits of equal size (molecular weight approximately 27,500 each) and two 
molecules of flavin adenine dinucleotide (FAD) (Lind et al. , 1990; Lind et al., 1982). 
Currently, two isoforms of DT-diaphorase are known to exist within the mouse 
(Prochaska & Talalay, 19861 while in the rat, at least three isoforms have been identified 
(Hojeberg et al. , 1981; Segura-Aguilar et al., 1992). The presence of four genetically 
distinct isoforms of DT-diaphorase has been suggested in the case of humans, with each 
isoform encoded by a separate gene locus (Edwards et a l . , 1980). Two such isoforms 
have been identified. The first is a dioxin-inducible form of DT-diaphorase, known as 
NQOi (Shaw et al. , 1991), which is believed to account for the majority of DT- 
diaphorase activity within tissues. The gene for NQOi has been identified on human 
chromosome 16 and codes for a protein similar in size to that of rat liver NQOi, i-G. 274 
residues (Jaiswal et a l. , 1988). Further sequence analysis has revealed that 83% and 85% 
homology exists between human NQOi ^tid rat NQOi cDNA and protein, respectively 
(Jaiswal et al., 1988) and therefore it is not surprising to find that antisera raised towards 
the rat enzyme cross-react with the human form of NQOi (Shaw et al., 1991).
Tlie second form of human DT-diaphorase to be identified is that of NQO% which 
differs from NQOi in several ways : (a) it is not dioxin-inducible, (b) the gene is present 
on chromosome 6, and (c) the protein is 231 residues in size (Jaiswal et al. , 1990). 
Importantly, however, NQO2 cDNA and protein are 54% and 49% homologous to the
1 2
NQOi form previously identified (Jaiswal et al., 1990). In addition, antisera raised 
against the rat form of NQOi cross-reacted with human NQO2 suggesting that both 
NQOi and NQO2 are immunologically related (Jaiswal et al., 1990).
Expression of DT-diaphorase (NQOi) in human tissues is variable and has been 
shown to change when tissues convert to the tumourogenic phenotype (Schlager & 
Powis, 1990). These differences between normal and tumour tissues will be discussed in 
more detail later (see Chapter 2). Deletion and mutagenesis studies in the DT-diaphorase 
promoter region have indicated that the presence of an antioxidant response element 
(ARE), a xenobiotic response element (XRE) and an AP2 element are important for the 
regulation of NQOi expression in human tissues (Joseph et al. , 1994). The human ARE 
(hARE) is believed to be the most important region for basal expression of DT- 
diaphorase and for induction in response to xenobiotics and antioxidants (Belinsky & 
Jaiswal. 1993) as it contains an API binding site (important for transcriptional 
regulation), and a GCA box (important for optimal expression and induction of DT- 
diaphorase gene expression) (Joseph et al., 1994). Analysis of protein binding to the 
hARE element and subsequent induction of DT-diaphorase expression have suggested a 
role for Jun and Eos proteins and indeed other nuclear proteins (Joseph et al., 1994; Li & 
Jaiswal, 1992a; Li & Jaiswal, 1992b), however, this remains a complex area requiring 
further study.
1.2.4.3. Role of DT-diaphorase in Cancer Chemotherapy
An important feature of DT-diaphorase is its ability to catalyse obligatory two- 
electron reductions of cytotoxic quinones and their derivatives (Lind et al., 1982). Such a 
reaction by-passes the production of free radicals and toxic oxygen metabolites which 
would form during one-electron reductions of the compounds (Riley & Workman, 1992a) 
(see Figure 1.4). DT-diaphorase, therefore, acts in a protective manner in the case of 
simple quinones such as menadione. Although protection from natinrally occurring toxic 
agents is the first and foremost role of DT-diaphorase, it is by no means its only role. DT- 
diaphorase also has the potential to cause bioprotection and / or bioactivation of a
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number of anticancer agents, for example, the bioreductive alkylating aziridinyl 
benzoquinones mitomycin C, E09 and diaziquone (AZQ) (Riley & Workman, 1992a; 
Ross et al. , 1994: Workman, 1994). The controversial role of this enzyme in the 
metabolism of both mitomycin C and E09 has been mentioned previously in Section
1.2.3. The fact that DT-diaphorase levels are frequently raised in human tumours 
(Schlager & Powis, 1990) compared to normal tissue suggests that this enzyme could be 
important for successful treatment of tumours with anticancer agents as these agents may 
be designed to be activated by the enzyme and targeted towards the tumour (Riley & 
Workman, 1992a).
1.2.5 NADPH : Cytochrome P450 Reductase
1.2.5.1. Background and Nomenclature
NADPH : cytochrome P450 reductase (NADPH : cytochrome P450 
oxidoreductase, NADPH : cytochrome c reductase, E.C. 1.6.2.4.) was first isolated in 
1950 (Horecker, 1950). Along with NADPH : cytochrome P450, this enzyme forms an 
essential component of the mixed function oxidase system in the endoplasmic reticulum 
(lyanagi & Mason, 1973). The role of NADPH : cytochrome P450 reductase is to transfer 
reducing equivalents from NADPH and H+ to NADPH : cytochrome P450 (Vermillion et 
al. , 1981). NADPH : cytochrome P450 reductase acts by accepting two-electrons 
donated by NADPH and H"*" and subsequently passing them to the electron acceptor, 
NADPH : cytochrome P450, as single electrons. In addition, enzymes can also be 
transferred to other microsomal enzyme systems, such as haem oxygenase (Schacter et 
al., 1972) and NADH : cytochrome b5 (Enoch & Strittmatter, 1979). This system is 
important for the metabolism of lipids, drugs and other foreign compounds including 
anticancer agents (Conney, 1967: Gillette e ta l . , 1972).
1.2.5.2. Purification, Protein and Gene Structure
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NADPH : cytochrome P450 reductase has been purified from the microsomal 
component of many species of liver including rat, pig, rabbit and human (Guengerich et 
al. , 1981: McManus et a l . , 1987; Yasukochi & Masters, 1976). The enzyme exists as a 
single polypeptide (molecular weight approximately 78,000), and contains equal amounts 
of flavin adenine dinucleotide (FAD) and flavin mononucleotide (FMN) (lyanagi & 
Mason, 1973). A high level of sequence homology has been shown between NADPH : 
cytochrome P450 reductase and ferredoxin : NADP""" reductase (Porter & Kasper, 1986). 
Furthermore, homology between the FMN-binding domain of NADPH : cytochrome 
P450 reductase and the bacterial flavodoxins has been noted (Porter & Kasper, 1986). 
These studies have suggested, therefore, that NADPH : cytochrome P450 reductase arose 
from the fusion of the two ancestral genes of these flavoproteins. More recent studies by 
Smith et al (Smith et al. , 1994) have supported this finding. In addition, they have also 
reported the potential role of the functional domains (Figure 1.6). For example, the 
FAD/NADPH domain alone was able to catalyse reduction of certain compounds 
suggesting that it is important for the one-electron reduction of many compounds. In 
contrast, the FMN binding domain appeared to be important for binding NADPH : 
cytochrome P450 and subsequent transfer of electrons. The passage of electrons, 
therefore, is believed to proceed as follows (Vermillion et al., 1981) :
NADPH -> FAD [NADPH : cytochrome P450 reductase] FMN >
NADPH : cytochrome P450
1.2.5.3. Role of NADPH : Cytochrome P450 Reductase in Cancer Chemotherapy
As mentioned in 1.2.5.1., NADPH : cytochrome P450 reductase is important in 
the monooxygenase system for successful metabolism of lipids and other foreign 
compounds (Conney, 1967: Gillette et al., 1972). In addition, however, NADPH : 
cytochrome P450 reductase also possesses the ability to reduce a number of bioreductive 
anticancer agents (Section 1.2.3.). The enzyme operates by causing one-electron 
reductions of the compounds to form toxic metabolites. For example, in the case of the 
benzotriazine di-A-oxide, tirapazamine, both NADPH : cytochrome P450 and NADPH ;
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Figure 1.6 Functional segments of the NADPH : cytochrome P450 reductase 
molecule.
[taken from Gibson and Skett, 1994]
cytochrome P450 reductase have been shown to activate the compound following one- 
electron reduction (Riley et al., 1993; Walton et al., 1992b). Unlike NADPH : 
cytochrome P450 enzymes, however, NADPH : cytochrome P450 reductase has been 
shown to directly metabolise tirapazamine to a DNA damaging species (Fitzsimmons et 
al., 1994; Walker et al., 1994). The role for NADPH : cytochrome P450 reductase in the 
activation of the bioreductive E09 has also been reported recently (Bailey et al., 1994a; 
Plumb & Workman, 1994; Plumb et al., 1994a; Plumb et a i, 1994b). From these studies, 
therefore, it is clear that the level of expression of NADPH : cytochrome P450 and 
NADPH : cytochrome P450 reductase within human tissues, in particular tumour tissues, 
is an important factor in the ability of these enzymes to cause selective activation of 
anticancer agents. To date, very little is known regarding expression within human 
tissues. However. Rampling et al (Rampling et a i, 1994) have reported the presence of 
the enzyme within a series of human glioma biopsy material. If anything though, the 
levels of NADPH : cytochrome P450 reductase and NADPH : cytochrome P450 appear 
to be decreased within tumour tissues (de Waziers et al. , 1991; Massaad et al. , 1992; 
Philip et al. . 1994). Further studies are therefore required to fully investigate NADPH : 
cytochrome P450 reductase enzyme expression in human tumour cell lines and biopsies.
1.2.6 NADH : Cytochrome b$ Reductase
1.2.6.1. Background and Nomenclature
A second haem protein involved in the mixed function oxidase system is 
cytochrome 65 (Chance & Williams, 1954; Noshiro & Omura, 1978). This haem protein 
can be reduced by the FAD containing flavoprotein NADH : cytochrome b5 reductase 
(NADH : ferricytochrome b5 oxidoreductase, E.C. 1.6.2.2.) (Strittmatter & Velick, 1957) 
as well as NADPH : cytochrome P450 reductase (Enoch & Strittmatter, 1979). 
Interestingly, these latter two enzymes have been shown to express a high degree of 
similarity in their amino acid sequences (Porter & Kasper, 1986) suggesting common 
ancestry. NADH : cytochrome 65 reductase has been purified from both microsomal and
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mitochondrial membranes of cells and was genetically similar in both cases (Kuwahara et 
al. , 1978). As well as a role in methemoglobin reduction in erythrocytes (Kuma & 
Inomata, 1972), evidence of a role for NADH : cytochrome b$ reductase in the transfer of 
electrons from cytochrome b$ to NADPH : cytochrome P450 has been provided by 
Noshiro and Omura (Noshiro & Omura, 1978). The importance of NADH : cytochrome 
b5 reductase in the mixed oxidase system was noted by the suggestion that NADPH : 
cytochrome P450 reductase and NADH : cytochrome b$ reductase were involved in the 
transfer of the first and second electrons, respectively, to the terminal electron acceptor 
NADPH : cytochrome P450 (Peterson & Prough, 1986). As a result, NADH : cytochrome 
b5 reductase may also be important for the metabolism of lipids, drugs and other foreign 
compounds (Conney, 1967; Gillette et al., 1972).
1.2.6.2. Role of NADH : Cytochrome 65 Reductase in Cancer Chemotherapy
NADH : cytochrome 65 reductase is perhaps one of the less studied enzymes both 
in terms of its levels of expression in human tissues, and also its role in the metabolic 
reduction of therapeutic agents. Due to its participation in the mixed oxidase system, 
however, it is clearly an important enzyme. Fisher and Olsen (Fisher & Olsen, 1982) first 
reported the role of human NADH : cytochrome b$ reductase in the activation of the 
prototype quinone bioreductive agent mitomycin C. Subsequent reports by Hodnick and 
Sartorelli (Hodnick & Sartorelli, 1993) have shown that the enzyme can, in fact, reduce 
mitomycin C to an alkylating species under both oxic and hypoxic conditions. These 
studies indicate that this enzyme may be important for activation of other potential 
bioreductive anticancer agents and as a consequence merits further study.
1.2.7 Enzyme-directed Bioreductive Drug Development
Bioreductive cytotoxins have been developed with a view to exploiting the 
presence of hypoxic cells within solid tumours. It is clear from the prior discussion, 
however, that both the level of hypoxia and the role of specific enzymes are important in
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determining the effects of bioreductive cytotoxin treatment, i.e. bioprotection or 
bioactivation. This has led to the proposal of an 'enzyme-directed' approach to 
bioreductive drug development (Workman, 1994; Workman & Walton, 1990) as a means 
of enhancing the antitumour selectivity of these agents. Such an approach would involve 
gaining a better understanding of those enzymes involved in activation of different 
bioreductive classes. This would give a clearer picture as to the mode of action of 
bioreductive anticancer agents. Based on this knowledge, improved prodrugs could be 
designed to suit the catalytic preferences of particular reductases. From studies mentioned 
in section 1.2.3., it is clear that information is accumulating in this area. In addition, the 
determination of expression levels of different enzymes within human tumours would be 
extremely important as patient selection based on 'enzyme profiling' would then be 
possible. To date, only a limited amount of information is known regarding enzyme 
expression within both normal and tumour tissues (discussed in more detail in Chapters 2 
and 3). The ultimate goal would be to use this information as a basis for future 'enzyme- 
directed' bioreductive drug development by designing agents which would be selectively 
activated by those enzymes present at high levels within human tumours (Workman,
1992).
1.2.8 Bioreductive Anticancer Agents in Clinical Trial
Progression of bioreductive anticancer agents towards routine clinical use has not 
been straight forward. Frequent problems of toxicity have been noted during clinical 
trials. For example, misonidazole and RSU 1069, exhibited peripheral neuropathy and 
gastro-intestinal dose-limiting toxicities, respectively (Overgaard, 1994). These studies, 
however, indicated a possible role for these agents in head and neck, and bladder cancers 
if the problems of toxicity could be overcome (Overgaard, 1994). Interestingly, the RB 
6145 enantiomer (Jenkins et al., 1990) will enter clinical trial shortly. In a similar manner 
to those mentioned above. Phase I clinical trials with the indoloquinone agent E09 
revealed problems of reversible renal toxicity (Schellens et al. , 1994); however, unlike
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the prototype quinone compound mitomycin C (Sartorelli et al., 1994), no evidence of 
myelosuppression was noted. Interestingly, however, some tumour responses were 
observed in the case of E09 (Schellens et al., 1994). The benzotriazine di-N-oxide, 
tirapazamine, is another bioreductive anticancer agent which has undergone Phase I and 
Phase II clinical trial. These trials have involved treatment with tirapazamine as a 
chemotherapeutic agent alone (Senan et al. , 1994), or in combination with either 
cisplatin (O'Dwyer et a l . , 1995) or radiation (Doherty et al. , 1994). Muscle toxicity, in 
the form of muscle cramping was the major form of toxicity in Phase I studies (Doherty 
et al.. 1994). Although this was a problem, however, it was not shown to be dose- 
limiting. It is clear that toxicity is a major obstacle to be overcome in the treatment of 
solid tumours with bioreductive anticancer agents.
1.3 Aims of this Thesis
The main aims of these studies can be summarised as follows :
(i) To measure the levels of expression and activity of three important reductase
enzymes within the NCI panel of human tumour cell lines.
(ii) To determine whether this information can be used within the National Cancer 
Institute database to establish correlations between different enzyme activities and cell 
sensitivities towards both existing and novel anticancer agents.
(iii) To determine the potential of several novel, structurally distinct and also a small
series of structurally-related compounds to act as hypoxia-selective bioreductive
anticancer agents.
(iv) To extend the above study to determine structure-activity effects of a small series 
of quinoxaline A-oxides.
(v) To investigate the enzymology and DNA damaging capacity of any of the above
compounds shown to act as hypoxia-selective bioreductive anticancer agents.
These questions were addressed within the overall context of improving our 
knowledge of the reductase enzymology of human tumours and the relationships between
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enzyme expression and bioreductive sensitivity, as well as identifying novel structures 
which possess the potential to act as bioreductive anticancer agents.
1.4 Lay-out of Thesis
To address the existing problem of limited availability of information regarding 
enzyme expression within human tumours. Chapter 2 describes the expression and 
activity of three important reductase enzymes within the National Cancer Institute (NCI) 
human tumour cell line panel. Analysis in over 60 cell lines from at least nine different 
tumour origins provides a detailed picture of possible enzyme expression patterns within 
human tumours. The potential use of such information in determining mechanisms of 
action of established and novel anticancer agents is described in Chapter 3, with 
particular reference to the prototype quinone alkylating agent mitomycin C and the 
indoloquinone agent E09.
A small series of human tumour cell lines were selected from the NCI panel, 
based upon enzyme expression levels, for subsequent analysis of a group of structurally 
novel compounds. Chapter 4 describes the ability of these compounds to act as potential 
bioreductive anticancer agents, with particular reference to enzyme levels within each cell 
line. To establish possible reasons for differences in the activity of a small series of novel 
quinoxaline di-N-oxide compounds under oxic and hypoxic conditions, information 
regarding the metabolic properties of their reduction were obtained.
Chapter 5 describes the development of sensitive high performance liquid 
chromatography assays for detection of each of the five quinoxaline di-N-oxide 
compounds. The ability of these compounds to be metabolised in the presence of mouse 
liver enzymes is described in Chapter 6. In addition, chemical inhibition studies to 
establish those enzymes responsible for metabolism of the compound ZM 81853 are also 
discussed within this chapter. Finally, Chapter 7 compares the kinetics of ZM 81853 
reduction in the presence of several enzyme preparations with those of previously
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published anticancer agents. Furthermore, the ability of ZM 81853 to be metabolised to a 
DNA damaging species and hence cause strand breaks within DNA was investigated.
The final chapter. Chapter 8, summarises the work of this thesis and states the 
conclusions from the work. Suggestions for further investigations are also put forward in 
this chapter.
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CHAPTER 2 
DIFFERENTIAL EXPRESSION OF REDUCTASE ENZYMES IN THE 
NATIONAL CANCER INSTITUTE (NCI) HUMAN TUMOUR CELL LINE 
PANEL
2.1 Introduction
In many cases, antitumour agents require to be metabolised in order to exert their 
therapeutic activity. A good example of this is the so-called bioreductive drugs which 
require enzyme-catalysed reduction (Workman & Stratford, 1993). Preferential 
bioactivation in tumour versus normal tissue may provide a means of achieving improved 
therapeutic selectivity. The level of expression of these enzymes within human tumours, 
therefore, is thought to be very important in determining the outcome of tumour treatment 
with these particular agents. Depending on the chemistry of the individual agent 
concerned and the enzyme(s) involved, reduction can either be bioactivating or 
bioprotecting (Workman, 1992). The distribution of these drug-metabolising enzymes is, 
therefore, important in determining the outcome of specific drug treatments. To date, only 
a limited knowledge has been gained concerning the distribution of important drug- 
metabolising enzymes within human tumour tissues or cell lines. This chapter describes a 
detailed study to determine the differential expression of three important bioreductive 
reductase enzymes within a large panel of human tumour cell lines. This may help to 
establish a better understanding of the distribution of enzymes within human tumours, 
and hence, support the proposal that 'enzyme-profiling' of tumour biopsies would enable 
selection of antitumour agents for particular tumour treatments based upon their 
enzymology (Workman, 1994).
A wide variety of enzymes are involved in the metabolism of anticancer agents 
and could therefore be analysed for expression within human tumours and cell lines. 
Examples include the one-electron reducing enzymes such as NADPH : cytochrome
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P450s, NADPH : cytochrome P450 reductase and xanthine oxidase, and the two-electron 
reducing enzymes such as DT-diaphorase and carbonyl reductase.
The presence of NADPH : cytochrome P450s and NADPH : cytochrome P450 
reductase proteins within normal skin, breast and prostate tissues have been shown using 
immunohistochemical staining (Baron et al. , 1983). Furthermore, NADPH : cytochrome 
P450 reductase protein has been demonstrated in human liver, gastrointestinal tract, 
pancreas, lung and kidney by Western blot procedure (de la Hall et al. , 1989; Stralka & 
Strobel, 1991). While these studies are important, possible differences between normal 
and tumour tissues need to be identified. In this regard, the level of DT-diaphorase RNA 
within tumours and surrounding tissues of patients with hepatocarcinoma has been 
measured to be 20 to 50-fold higher than in the livers of normal individuals (Cresteil & 
Jaiswal, 1991). Similarly, Schlager and Powis (Schlager & Powis, 1990) have reported 
increased levels of DT-diaphorase activity in primary tumours of liver, lung, colon and 
breast compared to surrounding normal tissue. In contrast to these findings, however, 
some other studies by de Wazier et al (de Waziers et a l., 1991) have shown similar levels 
of DT-diaphorase activity to be present in peritumoural and tumour tissues from patients 
with colorectal adenocarcinoma when compared to normal tissue. These discrepancies 
may be real or may be explained by the possibility that in the latter case, normal tissue 
was present within the tumour biopsy sample. Other enzyme activities have been 
measured including the NADPH : cytochrome P450s. With the exception of the CYP3A 
isoform, NADPH : cytochrome P450s have been found to be lower in colorectal tumours 
compared to normal tissues (de Waziers et al., 1991; Massaad et al. , 1992). These 
findings have been supported by more recent studies in which lower levels of expression 
of several NADPH : cytochrome P450 isoforms were found using immunohistochemical 
staining in tumour tissues (Philip et a l . , 1994).
All of the aforementioned studies have increased existing knowledge as regards to 
expression of reductase enzymes within human normal and tumour tissues. One of the 
main problems in these studies, however, has been the limited quantity and range of 
biopsy material that has been available. Interestingly, several groups have recently
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reported the activity of enzymes within different tumour histiotypes using panels of 
human tumour cell lines (Patterson et al. , 1994; Plumb & Workman, 1994; Plumb et al. , 
1994a; Plumb et al. , 1994b; Robertson etal. , 1992; Smitskamp-Wilms et al. , 1994). 
While these particular studies have generally involved only small numbers of human 
tumour cell lines, they have indicated that the use of cell lines may be extremely 
important in overcoming the current problem of limited tumour biopsy material.
The US National Cancer Institute (NCI) annually screens more than 20,000 
compounds of defined chemical structure against an in vitro panel of over 60 different 
human cell lines derived from tumours with a spectrum of histologies and organs of 
origin (Boyd & Pauli, 1995). At least 42,000 compounds have been evaluated against the 
cell line panel thus far. The use of computer methods such as the COMPARE programme 
(Pauli et al. , 1992; Pauli et al., 1989), neural networks (Weinstein et al. , 1992) and 
Kohonen self-organising mapping (van Osdol et al. , 1994) has provided a unique means 
by which to identify the potential mode of action of established agents and novel 
chemical entities. The inclusion of relevant biochemical and molecular parameters, such 
as enzyme activity measurements, within the same relational data base would provide an 
additional method of identifying critical factors influencing in vitro anti tumour activity. 
For example the anthrapyrazoles DuP 937 and DuP 941, currently in clinical trial, have 
been shown to act as potent topoisomerase II inhibitors in a similar manner as that 
displayed by mitoxantrone (Leteurtre et al. , 1994). In addition, incorporation into the 
data base of wcfr-l/P-glycoprotein expression levels within the cell line panel produced 
good correlations between expression and cell resistance to a number of compounds 
(Alvarez et al. , 1995). These compounds were previously found to be substrates for P- 
glycoprotein (Lee et al. , 1994). This demonstrates the usefulness of the inclusion of 
biochemical parameters along side the more usual cytotoxicity measurements.
For this reason, an extensive collaboration between the NCI, European 
Organisation for Research and Treatment of Cancer (EORTC) and the U.K Cancer 
Research Campaign was established to study bioreductive enzyme expression in over 60 
human tumour cell lines originating from at least nine different tumour histiotypes. DT-
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diaphorase, NADPH : cytochrome P450 reductase and NADH : cytochrome b$ reductase 
were chosen to be studied. DT-diaphorase was selected because of the current degree of 
interest in its potential involvement in the activation of various bioreductive agents, 
particularly quinones (Riley & Workman, 1992a; Workman, 1994). Importantly, some of 
these quinone agents are in clinical trial, for example E09 (Schellens et al. , 1994) (see 
section 1.2.8.). NADPH : cytochrome P450 reductase has also been extensively 
investigated for its role in the metabolism of a wide range of bioreductive agents 
(Fitzsimmons etal. , 1994: Rampling et al. , 1994). NADH : cytochrome b5 reductase 
has been less extensively studied but has been shown to have the ability to bioactivate the 
clinically used agent mitomycin C (Hodnick & Sartorelli, 1993). A further, practical 
advantage of selecting these particular reductases was the similarity in the analytical 
methodology used to measure their activities, which facilitated the efficient processing of 
the limited sample size available. Enzyme activity was measured by spectrophotometric 
analysis using a modified version of the cytochrome c reduction assay described by 
Segura-Aguilar (Segura-Aguilar et al. , 1990). To help interpret the enzyme activity 
information, the amount of protein and messenger RNA (for both DT-diaphorase and 
NADPH : cytochrome P450 reductase) were also analysed by Western immunoblotting 
and reverse-transcriptase polymerase chain reaction (RT-PCR), respectively. This 
chapter, therefore, details the expression and activity of the three selected bioreductive 
enzymes within a large panel of human tumour cell lines. It was hoped that enzyme 
activities within human tumours could be predicted from known activities within the 
human tumour cell line panel. In addition, the data may be useful in predicting the 
sensitivity of known and novel compounds towards tumours with known enzyme 
activities. Furthermore, an understanding of enzyme expression within the human tumour 
cell line panel would enable the selection of cell lines for cytotoxicity studies later in this 
thesis.
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2.2 Materials and Methods
2.2.1. Chemicals and Reagents
All general chemicals were of Analar grade and supplied by Merck 
(Thomliebank, Glasgow, U.K.) or Fisons (Loughborough, U.K.) unless otherwise stated. 
NADH, NADPH, cytochrome c, bovine albumin, menadione, dicoumarol, aprotinin, 6- 
mercaptoethanol, bromophenol blue, mineral oil and ethidium bromide were all 
purchased from Sigma Chemical Company (Poole, Dorset, U.K.). The Pierce 
Bicinchoninic Acid (BCA) Protein Assay was supplied as a kit from Pierce and Warriner 
(Chester, U.K.). TEMED, Tween 20 and ammonium persulphate were obtained from 
BIORAD Laboratories (Bromley, Kent, U.K.) while the acrylamide / bis aery 1 amide 
(30% w/v) was purchased from Severn Biotech Ltd. (Kidderminster, U.K.). RNAzoi™B 
was from Biogenesis Ltd. (Bournemouth. U.K.) while the reverse-transcriptase reagents 
were all obtained from Gibco BRL (Paisley, U.K.). Hexamer primers used in the reverse 
transcriptase reaction were from Pharmacia (Milton Keynes, U.K.) and the enzyme 
primers used in the PCR reaction were made by Oswel DNA Service (University of 
Edinburgh, Edinburgh, U.K.). All other reagents used in the polymerase chain reaction 
were supplied in a kit by Boehringer Mannheim (East Sussex, U.K.) which contained Taq 
DNA polymerase.
2.2.2. Enzyme Preparations and Specific Antibodies
Highly purified preparations of rat DT-diaphorase and NADPH : cytochrome 
P450 reductase were provided by Dr. R. Knox (ICR Department of Molecular 
Pharmacology, Sutton, U.K.) and Prof. C. R. Wolf (ICRF Laboratory of Molecular 
Pharmacology, Dundee, U.K.), respectively. The enzyme preparations had previously 
been purified from rat Walker tumour cells in the case of DT-diaphorase (> 95 % pure. 
Dr. R. Knox, personal communication), and from the liver microsomal fraction of male
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Wistar rats for NADPH : cytochrome P450 reductase (> 90 % pure, Prof. C. R. Wolf, 
personal communication). In both cases, a specific polyclonal antibody raised in rabbits 
against the purified rat enzyme was provided.
2.2.3. Preparation of Human Glioma Tumour Tissue Homogenates
A series of human malignant brain tumours were provided by Dr. G. Cruikshank 
(Department of Neurosurgery, Southern General Hospital Trust, Glasgow, U.K.) for 
analysis of bioreductive enzyme activity. Resected tissue was homogenised in two 
volumes of buffer (10 mM potassium phosphate, pH 7.7; 1.15 % (w/v) potassium 
chloride; 0.1 mM diaminoethanetetra-acetic acid disodium salt (EDTA)) using a Citenco 
varicontrol homogeniser (Citenco Ltd., Hertfordshire, U.K.). Following 
ultracentrifugation at 18,000 rpm (40C, 20 mins.) using a Beckman Optima TLX 
ultracentrifuge (Beckman Ltd., High Wycombe, Bucks., U.K.), the S9 supernatant was 
aliquoted into smaller volumes (40 ql) and stored at -70°C until use.
2.2.4. Preparation of Human Tumour Cell Line Sonicates
A total of 69 tissue-specific human tumour cell lines were kindly provided by the 
NCI (Division of Cancer Treatment, Bethesda, MD, U.S.A.) for bioreductive enzyme 
profiling. The cells had been grown to confluence at the NCI laboratories, and either 
harvested using trypsin (0.25 %) / EDTA (1 mM) solution or, for suspension cell lines, by 
centrifugation. Cell pellets were then prepared and forwarded to our laboratories as 
frozen cell pellets. When required, pellets were thawed and resuspended in 0.45 ml of 
phosphate buffered saline (PBS) and 0.05 ml aprotinin (10 %). Cell suspensions were 
sonicated at 22 kHz with an amplitude of 8 |im peak for 3 x 10 s. (MSE probe sonicator, 
Fisons Instruments, Loughborough, U.K.), ensuring that vials were kept on ice as often as 
possible. Samples were then spun down using a bench top centrifuge, at 15,000 rpm for
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20 mins. at 4^0 (Heraeus Equipment Ltd., Brentwood, Essex, U.K.). Aliquots (40 |il) of 
supernatant were removed and stored at -70°C until use.
2.2.5. Measurement of Protein Content
The Pierce BCA Protein Assay (Smith et a i  , 1985) was used to determine protein 
content in each tumour cell line sonicate or tumour tissue homogenate. This assay 
allowed for the accurate measurement of protein concentration ranges of 10 - 2000 M-g/ml 
in small (10 |il) sample sizes. Essentially, a series of known albumin standards were 
prepared (0 - 2 mg/ml) and 10 ql of each added to a microtiter plate in quadruplicate 
wells. Test samples were diluted as appropriate and 10 ql of each applied to the wells in 
duplicate. BCA protein reagent was prepared by mixing Reagent A (sodium carbonate; 
BCA detection reagent; sodium tartate in 0.1 M sodium hydroxide) with Reagent B (4 % 
copper sulphate solution) in a 50:1 ratio. 200 ql of working reagent was added to all 
wells. The plate was then placed on a microtiter plate shaker (BIORAD microplate 
reader, BIORAD laboratories. Bromley, Kent, U.K.) for 30 s before being covered and 
placed at 37°C for 30 mins. Absorbence in each well at 570 nm was determined using 
Softmax Version 2.3, installed on an Emax Precision microplate reader (Molecular 
Devices Corporation, Menlo Park, CA, U.S.A.). Protein concentration was determined 
from a plot of the standard curve and expressed as mg/ml.
2.2.6. Measurement of DT-diaphorase, NADPH : Cytochrome P450
Reductase and NADH : Cytochrome b5 Reductase Activity
(a) Assay for DT-diaphorase
An indirect, coupled assay system was used to determine DT-diaphorase activity 
within the samples. Activity was assayed at 550 nm on a Lambda 2 UV/VIS 
spectrophotometer (Perkin Elmer Ltd., Beaconsfield, Bucks., U.K.) using a modification 
of the cytochrome c reduction method (Segura-Aguilar et a/., 1990). A mixture of
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cytochrome c (77 qM) and bovine albumin (0.14 %, w/v) was monitored for its reduction 
in the presence of NADH (200 qM) as cofactor and menadione (20 qM) which acts as an 
intermediate electron acceptor. The reaction was initiated by addition of a sample of 
supernatant, the volume of which was dependent upon an amount known to be in the 
linear portion of the reaction. The activity attributable to DT-diaphorase was the portion 
which was inhibited by dicoumarol (10 qM), a known inhibitor of DT-diaphorase 
(Ernster, 1967). As a positive and standardised control for the reaction conditions, a 
1:600 dilution of purified rat DT-diaphorase was assayed both in the absence, and the 
presence of dicoumarol. Inhibition of DT-diaphorase activity within the purified 
preparation was found to be between 90 - 95 %, on repeated occasions, thereby showing 
that dicoumarol was an efficient inhibitor of DT-diaphorase. Cytochrome c, bovine 
albumin and NADH were all dissolved in Tris buffer (Tris 50 mM, adjusted to pH 7.4 
with HCl) while menadione and dicoumarol were dissolved in a mixture of dimethyl 
sulphoxide (DMSO)/bovine albumin or 0.1 M sodium hydroxide/bovine albumin, 
respectively.
(b) Assay for NADPH" : Cytochrome P450 Reductase and NADH : Cytochrome b$
Reductase
NADPH : cytochrome P450 reductase and NADH : cytochrome b$ reductase 
activity were measured using a direct assay system as both enzymes were able to reduce 
cytochrome c in the presence of cofactor alone (NADPH [200 qM] and NADH [200 
qM], respectively). Appropriate controls were performed to determine background rates 
of reduction within all of the reactions.
All reactions were carried out at 37®C and initiated by the addition of the cell 
sonicate / tissue homogenate. Rates of reduction were calculated from the initial linear 
part of the reaction progress curve and were expressed as nmoles of cytochrome c 
reduced/min/mg of protein. An extinction coefficient for cytochrome c of 21.1 mMcm'^ 
was used in the calculation.
29
2.2.7. Polyacrylamide Gel Electrophoresis and Western Blot Analysis
The levels of DT-diaphorase and NADPH : cytochrome P450 reductase protein 
within each cell sonicate and tissue homogenate was determined by gel electrophoresis 
and Western blot analysis. For detection of DT-diaphorase, samples were run on a 12 % 
separating gel (1.5 M Tris base: 0.5 % sodium dodecyl sulphate (SDS) pH 8.8) while for 
NADPH : cytochrome P450 reductase, a 9 % separating gel was used. The percentage of 
separating gel used in the experiment was based upon the known molecular weights 
(MWt) of the human form of each enzyme. The stacking gel buffer was the same in all 
cases (0.5 M Tris base; 0.5 % SDS, pH 6.6). Samples were diluted to a 1 mg/ml protein 
concentration in boiling mix (10 % stacking gel buffer; 2 % SDS; 5 % b- 
mercaptoethanol; 10 % glycerol; 0.005 % bromophenol blue) and boiled for 5 mins. In 
the case of DT-diaphorase, 50 qg of protein was loaded for each sample, while for 
NADPH : cytochrome P450 reductase, 100 qg of protein was loaded. In addition, purified 
preparations of either rat DT-diaphorase or NADPH : cytochrome P450 reductase were 
used as a positive controls (0.1 qg loaded). Samples were subjected to electrophoresis 
(Pharmacia LKB-EPS 500/400 lab pack, Pharmacia, Milton Keynes, U.K.) at 50 mA for 
2 hr s., then 6 mA overnight in electrode buffer (0.05 M Tris base; 0.05 M glycine; 0.1 % 
SDS, pH 8.3). A serrii-dry graphite electroblotter (Millipore Corporation, U.S.A.) was 
used to transfer proteins from the gel onto an Immobilon-P transfer membrane (Millipore 
Corporation, U.S.A.). The transfer buffer consisted of 48 mM Tris, 39 mM glycine and 
0.037 % (v/v) SDS. Following blocking with 5 % non-fat milk (Marvel®) for 1 hr., a 
primary antibody was applied for 1 hr. (1:500 dilution for DT-diaphorase; 1:250 dilution 
for NADPH : cytochrome P450 reductase). The primary antibodies had been raised 
against the purified rat proteins and were known to crossreact with the human forms of 
the enzyme. The membrane was washed (0.05 M Tris base; 0.15 M sodium chloride, pH 
7.9; 0.01 % Tween 20) and then the membrane was washed with a 1:5000 dilution of 
Protein A linked to Horseradish Peroxidase (Amersham International pic, Amersham,
30
U.K.) for 18 mins. Following further washing, the membrane was processed using an 
Enhanced Chemiluminescence kit (Amersham International pic, Amersham, U.K.) and 
exposed to X-ray film (XR Fuji Medical film, Fuji, London, U.K.). The film was 
processed using a KODAK X-OMAT 480 RA Processor (KODAK Ltd., Hemel 
Hempstead, U.K.). The level of protein present within each cell sonicate was quantified 
by densitometric analysis using a Molecular Dynamics Laser Densitometer with Image 
Analysis Software (Protein Databases Incorporated, New York, U.S.A.).
2.2.8. Detection of DT-diaphorase and NADPH : Cytochrome P450 Reductase
Expression by Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
(a) RNA Extractions
The expression of DT-diaphorase (NQOl) and NADPH : cytochrome P450 
reductase was investigated using tumour cell lines originating from the breast and the 
CNS. RNA from individual cell pellets was isolated using the RNAzol™ B method 
described by Chomczynski & Sacchi (Chomczynski & Sacchi, 1987). This method was 
carried out as described in-the manufacture's protocol and involved several steps. Firstly, 
cells were lysed and RNA solubilised by the addition of 1 - 2 ml RNAzol™ B (0.2 ml per 
10^ cells). RNA was extracted by the addition of chloroform (0.2 ml per 2 ml of 
homogenate) and subsequent placement of the samples on ice for 15 mins., followed by 
centrifugation (12,000 rpm, 40C. 15 mins.). The aqueous phase was transferred to a clean 
eppendorf tube for the next step, RNA precipitation. An equal volume of isopropanol was 
added to the eppendorf and the sample stored at 4°C for 15 mins. before centrifugation 
(12,000 rpm, 4^C, 15 mins.). The RNA precipitate which formed was then washed by 
firstly removing the supernatant, adding 1 ml of 75 % ethanol, vortexing the sample and 
finally performing centrifugation (7,500 rpm, 4^C, 8 mins.). Ethanol was then removed 
and the pellets left to dry for 1 - 2 hrs. Pellets were then resuspended in distilled water (30 
ql) and the optical density (OD) at 260 nm and 280 nm determined. An 00260/0^280
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ratio higher than 1.9 was indicative of a pure RNA preparation with the sample 
substantially free from contaminating DNA and protein.
(b) Reverse Transcriptase Reaction
The reverse transcriptase reaction was performed in duplicate for each cell line. A 
reaction mixture consisting of hexamer primers (0.1 qg), Molony-murine leukaemia virus 
(MMLV; 10 U), nucleotides (dATP, dTTP, dCTP, dGTP; 2 mM), 5x hexamer reverse 
transcriptase (H-RT) buffer (0.25 M Tris HCl pH 8.3; 0.375 M potassium chloride; 15 
mM magnesium chloride), dithiothreitol (DTT; 10 mM) and distilled water was made. 
This was then added to RNA ( 1 qg/ql) in a ratio of 9 ql reaction mix : 1 ql RNA. Reverse 
transcriptase was carried out at 37°C for 1 hr. Following this procedure, the cDNA was 
diluted 1:5 with distilled water and stored at -70°C until the polymerase chain reaction 
was carried out.
(c) Polymerase Chain Reaction
For each cell line, several dilutions of the cDNA were used in the polymerase 
chain reaction starting at 100 ng cDNA. These dilutions had previously been found to be 
in the linear portion of the reaction for each enzyme concerned. A separate master 
reaction mix was made for each enzyme under investigation, i.e. DT-diaphorase, NADPH 
: cytochrome P450 reductase, the human ribosomal 28S protein (used as a positive 
control) and an internal standard (no cDNA) in order to ensure no cross-contamination. 
This reaction mix consisted of the appropriate primers (see below), 10 x PCR buffer (100 
mM Tris HCl, pH 8.3; 500 mM potassium chloride; 15 mM magnesium chloride), 
nucleotides (as above; 0.9 mM), Taq DNA polymerase and distilled water. DT- 
diaphorase PCR was performed using two different primers as detailed in Horikoshi et al 
(Horikoshi et al. , 1992) and consisting of (a) bases 392 - 413 of the DT-diaphorase 
coding sequence (Jaiswal et al. , 1988) and (b) bases 640 - 661 of the^DT-dia]^orase 
coding sequence (Jaiswal et a i,  1988). These primers were DT-diaphorase 1 (5'- 
A T T T G A A T T C G G G C G T C T G C T G -3) and D T -d iap h o rase  2 (5 '-
AGGCTGGTTTGAGCGAGTGTTC-3 ). For NADPH : cytochrome P450 reductase, the
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PCR primers were selected from the amino acid sequence derived from the human cDNA 
(Shephard et al. , 1992) and were NADPH : cytochrome P450 reductase 1 (5- 
GACGCCCACCGCTACGGAAT-3') and NADPH : cytochrome P450 reductase 2 (5'- 
CTGCATCCAGTCGTAGAAGT-3'). A positive control was performed alongside DT- 
diaphorase and NADPH : cytochrome P450 reductase involving the use of primers 
against the ribosomal 28S gene selected from the nucleotide sequence detailed in 
Gonzalez et al (Gonzalez et al. , 1985). Ribosomal 28S 1 consisted of (5'- 
TTACCAAAAGTGGCCCACTA-3 ) while ribosomal 28S 2 consisted of (5'- 
GAAAGATGGTGAACTATGCC-3 ). For each reaction, 20 ql of reaction mix was added 
to 5 ql of cDNA and then overlaid with 50 ql mineral oil. A negative control was 
performed in which no cDNA template was present. All reaction tubes were then spun for 
a few seconds and placed in the thermal cycler (PREM™III, LEP Scientific, Milton 
Keynes, U.K.). The programme consisted of the following steps ; denature (95°C for 45 
s), anneal (60°C for 45 s), extension (72°C for 2 mins. 15 s). This was repeated for 35 
cycles and then a final extension at 72^C for 7 mins. was performed before holding 
reactions at 4°C. Samples were mixed with DNA loading buffer (300 mM sodium 
hydroxide; 6 mM EDTA; 18 % Ficoll in water; 0.15 % bromocresol green; 0.25 % 
Xylene cyanol FF) in a ratio of 5:1 and then loaded (10 ql) into the wells of a 2 % 
agarose gel prepared in 0.5 % TBE buffer (0.89 M Tris base; 0.89 M boric acid; 0.02 M 
EDTA). A 123 bp DNA ladder (Gibco BRL, Paisley, U.K.) was run alongside the test 
samples. The gel was electrophoresed at 180 V for 4 hrs. using a Hybaid Electro-4 Gel 
Tank and then stained with ethidium bromide (1 qg/ql) before being photographed under 
UV transillumination.
2.2.9. Statistical Analysis
Tlie sensitivity data of anticancer drugs tested against the NCI cell line panel are 
routinely and conveniently displayed as COMPARE analysis plots (Pauli et al.y 1992; 
Pauli et al., 1989). For a given drug, these COMPARE plots are illustrated on a log 10 
scale with the deviation from the mean sensitivity calculated across all cell lines in the
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panel. This is known as the mean graph. The same method of analysis was used to 
display the enzyme activity data for the NCI panel.
The student's unpaired t-test was used to compare results for enzyme activity in 
groups of human tumour cell lines from different origins, and in addition, to compare 
those results for the human glioma (glioblastoma) biopsy panel with the CNS (mainly 
glioblastoma) human tumour cell lines.
3 4
2.3 Results
2.3.1 Enzyme Activity Measurements within the NCI Human Tumour Cell Line Panel
A total of 69 human tumour cell lines from nine different tissue origins were 
analysed for DT-diaphorase, NADPH : cytochrome P450 reductase and NADH : 
cytochrome b$ reductase enzyme activities using a cytochrome c reduction assay.
(a) DT-diaphorase
Figure 2.1 represents a mean graph of log DT-diaphorase activity within the cell 
line panel. This type of analysis enables cell lines with either higher or lower than 
average activities to be clearly displayed. Enzyme activity across the cell line panel 
varied approximately 2000-fold (2.6 - 5123.1 nmol/min/mg of protein ; five cell lines 
possessed activity below that which was detectable, i.e. below 2 nmol/min/mg). 
Considerable variation existed, however, patterns of high and low enzyme activity 
expressing groups were clearly seen. For example, those cell lines originating from 
tumours of the colon, CNS, non-small cell lung and melanoma histiotypes showed higher 
than average activities while the leukaemic/lymphoma, breast and, to some extent, the 
ovarian lines showed lower than average activities. Nevertheless heterogeneity of 
expression was seen within as well as between particular tumour types. Of the two 
prostate cell lines assayed, for example, one was found to express relatively high DT- 
diaphorase activity while the other expressed a much lower level.
To illustrate intra-tumour heterogeneity of expression more precisely, the enzyme 
activity measurements for each group of cell lines is shown in Table 2.1. The variation in 
DT-diaphorase activity within each group was as follows : CNS, 12-fold (Table 2.1a); 
melanoma, 19-fold (Table 2.1b); colon, 25-fold (Table 2.1c); ovarian, 10-fold (Table 
2. Id); breast, 115-fold (Table 2.le); leukaemia/lymphoma, 1.2-fold (Table 2.1f); NSCLC, 
20-fold and SCLC, 6-fold (Table 2.1g); prostate, 11-fold (Table 2.1h) and finally, kidney,
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Figure 2.1 Mean graph of log DT-diaphorase activity within the NCI human 
tumour cell line panel.
The mean activity for all of the cell lines is represented by a vertical line through 
individual plots. Horizontal bars show, on a logarithmic scale, the individual enzyme 
activities for each cell line relative to the mean value. Those cell lines with activity below 
or above the mean lie to the left and right of the vertical line, respectively. MG-MID, 
Delta and Range are defined as the calculated mean value of the panel; the number of 
logio units by which the values for the individual value of the panel differs (+ or -) from 
the MG-MID and the number of logio units by which the value for the most sensitive 
line differs from the least sensitve line, respectively.
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Table 2.1 Bioreductive enzyme activity measurements for the NCI human 
tumour cell line panel.
Units are nmol of cytochrome c reduced/min/mg of protein. Data represent a mean + SE 
(n=3), except when denoted by * (two independent values). ND represents a level of 
activity (2 nmol/min/mg of protein or less) which is undetectable in this assay system.
a) CNS
Enzyme Activities (nmol/min/mg)
Tumour Cell 
Line
DT-Diaphorase NADPH: 
Cytochrome 
P450 Reductase
NADH: 
Cytochrome 
bg Reductase
SF 268 108.3 ±13.9 20.9 ±2.8 63.4 ±  6.8
SF 295 799.1 ±27.1 15.2 ± 1.3 36.4 ±0.5
SF 539 421.9 ±18.8 19.9 ±0.4 52.8 ±2.4
SNB 19 1065.8 ±68.2 9.8 ±2.6 36.4 ±  3.9
SNB 75 1030.2 ±6.9 16.7 ± 1.6 92.8 ±5.3
SNB 78 76.2 /101.1 * 14.7 / 30.8 * 72.8 ±4.3
U251 446.8 ±11.6 13.6 ±2.1 49.6 ±3.3
XF 498 157.1 ±  2.8 9.7 /12.9* 60.3 ±  6.6
b) Melanoma
Enzyme Activities (nmol/min/mg)
Tumour Cell DT-Diaphorase NADPH : NADH:
Line Cytochrome Cytochrome
P450 Reductase bg Reductase
UACC 62 81.0/78.1* 13.2 /18.8* 63.0 ±2.7
UACC 257 355.5 ± 30.1 17.5 ± 1.3 40.6 ±0.3
MALME 740.9 ±13.1 37.7 ±2.4 121.9 ±12.9
M14 1038.6 ±  53.9 40.6 ± 1.1 87.7 ± 7.7
SK MEL 2 316.5 ± 39.0 6.6 ±  0.8 113.9 ±8.2
SK MEL 5 1515.9 ±71.7 36.7 ± 1.0 83.8 /103.0 *
SK MEL 28 692.0 ±45.0 25.4 ±2.3 77.3 ±0.5
M19 MEL 1497.1 ±  30.8 20.5 ±0.9 52.7 ±  1.9
c) Colon
Enzyme Activities (nmol/min/mg)
Tumour Cell DT-Diaphorase NADPH : NADH:
Line Cytochrome Cytochrome
P450 Reductase bg Reductase
HT-29 412.3/488.9* 20.2/21.7* 34 .6 /33 .9*
HCT-116 199.4/210.7* 21.0/21.0* 53 .3 /57 .7*
HCT-15 1396.9 /1660.2 * 21.4/41.0* 64 .1 /65 .9*
DLD-1 345.6 / 361.4 * 15.8/21.6* 15.8 /40 .3*
COLO-205 948.6 /1106.7 * 28.3/33.3* 33.3 / 43.3 *
SW 620 460.9/586.1* 22.4 / 44.7 * 35 .8 /53 .7*
KM20L2 1247.5 ±35.7 13.1 ± 1.6 31.0 ±3 .2
KM12 490.8 ±18.4 16.4 ± 1.0 29.2 ±2 .8
HCC 2998 5123.1 ±263.4 21.4 ± 1.6 104.0 ±10.8
d) Ovarian
Enzyme Activities (nmol/min/mg)
Tumour Cell 
Line
DT-Diaphorase NADPH : 
Cytochrome 
P450 Reductase
NADH: 
Cytochrome 
bg Reductase
SKOV-3 105.0 /112.8 * 10.0/10.0* 22 .1 /24 .3*
OVCAR 3 99.4 /105.3 * 18.9/18.9* 28 .8 /30 .8*
OVCAR 4 44.4/61.9* 11.9/13.5* 36.5 / 42.1 *
OVCAR 5 439.0/453.7* 19.5 / 21.5 * 27.3 / 31.2 *
OVCAR 8 37.1/52.1* 18.4/23.0* 20.7 / 29.9 *
IGROV 1 123.1 /145.9 * 16.9 /16.9* 49 .9 /53 .3*
e) Breast
Enzyme Activities (nmol/min/mg)
Tumour Cell DT-Diaphorase NADPH: NADH:
Line Cytochrome Cytochrome
P450 Reductase bg Reductase
LOX IMVI 247.9 ±16.0 16.4 ±0.8 71.6 ±  3.6
MDA-N 299.6 ± 10.6 9.0 ±1.3 17.1 ±0 .8
MDA-MB 231 2.6 13.7 ±4.0 31.9 ±5 .1
MDA-MB 435S 198.1 ± 3.6 6.3 ±1.2 34.2 ±4 .8
MCF-7 65.6 ± 2.4 11.8 ±1.2 23.0 ±1 .7
MCF-7 / ADR 127.8 ±9.2 13.4 ±2.7 43.3 ±11.0
HS 578T 213.1 ± 5.1 17.3 ±  1.5 81.1 ±4 .0
BT 549 271.9 ±17.3 5.5 ± 0.4 36.2 ± 3 .2
T 47D 61.6 ± 8.9 6.7 / 8.2 * 53.2 ± 1 .9
f) Leukaemia / Lymphoma
Enzyme Activities (nmol/min/mg)
Tumour Cell DT-Diaphorase NADPH: NADH:
Lines Cytochrome Cytochrome
P450 Reductase bg Reductase
K562 106.1 ± 7.3 29.1 ±  3.2 35 .3 /27 .0*
HL-60 ND 21.4 /17.1 * 21 .4 /17 .1*
SR (TB) 111.8/140.6* 25.8 ±5 .9 61.7 ±  2.3
MOLT 4 ND 19.9 / 27.1 * 34.3 / 37.9 *
RPM I8226 ND 11.4 /15.3 * 41.9 ±5 .8
CCRF CEM ND 7.3 / 7.3 * 13.9 ±1 .7
g) Lung
Enzyme Activities (nmol/min/mg)
Tumour Cell DT-Diaphorase NADPH : NADH:
Lines Cytochrome Cytochome
P450 Reductase bg Reductase
NSCLC
LXFL 529 135.3 ±  6.6 12.5 ±0.5 26.7 ±0.7
A549/ATCC 1952.1 ±84.6 ND 9.2 /11.4 *
NCI H522M 352.3 ± 11.4 9.3 ±1.2 19.4 ±2.1
NCI H23 666.9 ± 28.2 6.8 ±  0.8 15.2 ±2.0
NCIH322M 568.0/594.7* 4.9 ±0 .9 4 .4 /6 .3 *
HOP 92 /0 2 ND 2 .4 /4 .8 * 22.8 ±1.4
NCI H226 212.3 / 200.4 * 5.7 ± 0 13.7 ±  1.0
HOP 62 528.2 ± 13.2 2 .9 /2 .9 * 19.5 ±0.6
HOP 18 795.0 ±24.0 8.1 ±  0.6 8 .8 /8 .8 *
EKVX 93.5 ±2.4 7.2 / 6.2 * 12.4 ±2.1
SCLC
DMS 114 73.8 ± 3.8 4.4 ±  0.3 7 .9 /6 .8 *
DMS 273 495.5 ± 25.4 7.1 ±0.9 13.9 ±0.9
LARGE CELL
NCIH460 6018.4 ± 213.7 12.8/12.8* 34.3 ±5.2
h) Prostate
Enzyme Activities (nmol/min/mg)
Tumour Cell 
Line
DT-Diaphorase NADPH: 
Cytochrome 
P450 Reductase
NADH: 
Cytochrome 
bg Reductase
DV 145 2834.4 ±24.2 20.3 ±2.0 75.2 ±4.0
PC 3 251.2 ± 6.4 11.9/14.4* 50.6 / 61.9 *
i) Kidney
Enzyme Activities (nmol/min/mg)
Tumour Cell DT-Diaphorase NADPH: NADH :
Line Cytochrome Cytochrome
- P450 Reductase bg Reductase
C A K Il 492.9 ± 36.3 18.4 ±0.7 69.8 ±3.7
SN 12C 455.5 ± 38.9 24.9 ± 0 48.2 ±3.9
TK 10 466.4 ± 39.0 14.3 ± 0.8 48.0 ±6.1
RXF 393 132.5 ± 11.8 19.6 / 24.2 * 50.9 ±3.1
U 0 31 216.5 ± 20.3 18.5 ±0.6 35.5 ± 0
786.0 193.0 ±10.9 26.8/33.0* 57.0 ±6.5
A498 827.5 ± 44.7 66.9/69.0* 43.9 ±1.7
ACHN 128.8 ± 10.6 14.0 ± 1.7 127.4 ± 12.3
6-fold (Table 2.11). Interestingly, only two out of six leukaemia and lymphoma lines 
(Table 2. If) exhibited detectable levels of DT-diaphorase activity.
The inter-tumour heterogeneity in DT-diaphorase activity across the cell line 
panel can be viewed graphically in Figure 2.2. Statistical analysis revealed interesting 
differences between the groups. Clearly, statistical analysis on all nine groups of cell lines 
could be included, however, as this would involve a total of 72 separate analysis for each 
enzyme, only selected examples are shown. As expected from the figure, the mean DT- 
diaphorase activity within the leukaemia/lymphoma group was significantly lower than, 
for example, the melanoma group (20.1-fold, p<0.001) or the CNS group (13.3-fold, 
p<0.001). Perhaps more surprising from the diagram, was the significant difference 
between the leukaemia/lymphoma group and the ovarian group (3.8-fold, 0.002<p<0.01). 
Examples of other analysis reveal significant differences between colon / CNS cell lines 
(2.4-fold, 0.002<p<0.01) and, colon / NSCLC (2.3-fold, 0.001<p<0.002).
(b) NADPH : Cytochrome P450 Reductase
The activity of NADPH : cytochrome P450 reductase within the panel of cell lines 
is represented in Figure 2.3 in mean graph format. Although differences in enzyme 
activities existed both between and within the different groups of cell lines, the variation 
was less pronounced than that for DT-diaphorase (15-fold compared to 2000-fold). In 
addition, the overall level of NADPH : cytochrome P450 reductase activity was lower 
than for DT-diaphorase. Despite the lower overall range, patterns of high and low 
expressing groups did emerge. Cell lines originating from the colon, melanoma, kidney 
and, to some extent, the ovarian and leukaemic/lymphoma lines were found to have 
enzyme activities above the average level. In contrast, cell lines from the lung (both non­
small cell and small cell) and breast possessed activities which were below average.
The range of NADPH : cytochrome P450 reductase activities within individual 
selected histiotypic groups of cell lines can be seen more clearly in Table 2.1 and in 
Figure 2.4. For example in the CNS group (Table 2.1a) the level of activity varied only 2- 
3-fold, while in the melanoma group (Table 2.1b) the variation was approximately 6-fold.
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Figure 2.3 Mean graph of log NADPH : cytochrome P450 reductase activity 
within the NCI human tumour cell line panel.
The mean activity for all of the cell lines is represented by a vertical line through 
individual plots. Horizontal bars show, on a logarithmic scale, the individual enzyme 
activities for each cell line relative to the mean value. Tliose cell lines with activity below 
or above the mean lie to the left and right of the vertical line, respectively. For definition 
of MG-MID, Delta and Range see Figure 2.1 legend.
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The pattern of lower variation for NADPH : cytochrome P450 reductase compared to 
DT-diaphorase was true for all of the groups of cell lines studied. Inter-tumour 
heterogeneity can be viewed in Figure 2.4. In contrast to DT-diaphorase activity, the 
differences in mean NADPH : cytochrome P450 reductase activity between 
leukaemia/lymphoma and several other groups of cell lines, for example, melanoma 
(0.02<p<0.05) and CNS (0.02<p<0.05) were non-significant. Interestingly, however, the 
mean activity of the breast group differed significantly from those of the colon, ovarian, 
NSCLC and melanoma (p<0.001 in all cases).
(c) NADH : Cytochrome b5 Reductase
A mean graph of log NADH : cytochrome b5 reductase activity within the cell 
line panel is shown in Figure 2.5. Similar to NADPH : cytochrome P450 reductase, the 
overall level of NADH : cytochrome b$ reductase was lower than that for DT-diaphorase 
(24-fold compared to 2000-fold). As with the other two enzymes under study, patterns of 
high and low enzyme expressing groups were found. For example, cell lines from the 
CNS, melanoma and kidney expressed activities which were higher than average. In 
contrast, cell lines from the lung (both non-small cell and small cell), ovary and, to some 
extent the breast, possessed activities which, with the exception of one ovarian cell line, 
were below average.
Although the activity of NADH : cytochrome b5 reductase was generally higher 
than that of NADPH : cytochrome P450 reductase in all of the groups of cell lines 
studied, the range between the highest and lowest activity within the groups was similar. 
For example, the range in both NADH : cytochrome b5 reductase and NADPH : 
cytochrome P450 reductase activities within the CNS cell lines (Table 2.1a) was 2-3-fold. 
As with the previous two enzymes, the inter-tumour heterogeneity of NADH : 
cytochrome b5 reductase activity across the groups of cell lines is shown graphically in 
Figure 2.6. Both significant and non-significant differences were again clear from the 
graph. For example, while NADH : cytochrome b5 reductase activity was shown to be 
significantly different between melanoma / CNS (1.4-fold, p<0.001) and melanoma /
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Figure 2.5 Mean graph of log NADH : cytochrome bg reductase activity 
within the NCI human tumour cell line panel.
The mean activity for all of the cell lines is represented by a vertical line through 
individual plots. Horizontal bars show, on a logarithmic scale, the individual enzyme 
activities for each cell line relative to the mean value. Those cell lines with activity below 
or above the mean lie to the left and right of the vertical line, respectively. For definition 
of MG-MID, Delta and Range see Figure-2.1 legend.
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leukaemia/lymphoma cell lines (2.4-fold, p<0.001), it was non-significant between 
melanoma / prostate cell lines (p>0.1) and leukaemia/lymphoma / ovarian (p>0.1).
Collectively, therefore, DT-diaphorase was found to be the enzyme exhibiting 
highest activity within the cell line panel. In addition, the range in activity was also 
greatest for this enzyme (approximately 2000-fold). In contrast, the variability in NADPH 
: cytochrome P450 reductase and NADH : cytochrome b5 reductase activities was much 
lower (15- and 24-fold, respectively). Importantly for each enzyme, significant 
differences were observed between the mean enzyme activities of different groups of cell 
lines. An interesting point to note, however, was that the differences between NSCLC 
and SCLC cell lines were non-significant (DT-diaphorase - p>0.1; NADPH : cytochrome 
P450 reductase - p>0.1; NADH : cytochrome b5 reductase - 0.02<p<0.05) for each of the 
enzymes.
2.3.2 Protein Expression within the NCI Human Tumour Cell Line Panel
To complement the enzyme activity measurements, all human tumour cell lines 
within the panel were analysed for both DT-diaphorase and NADPH : cytochrome P450 
reductase protein expression. NADH : cytochrome b5 reductase was not studied as no 
antibody against the enzyme was available.
(a) DT-diaphorase
DT-diaphorase protein expression was detected in 65 out of a total of 69 cell lines. 
As with the enzyme activities, a wide range of protein expression was observed both 
within and between the different tumour types. The Western blots for each group of cell 
lines are shown in Figure 2.7. For ease of discussion, however, melanoma, CNS and 
breast groups will be taken as examples. All of the melanoma cell lines studied were 
shown to express DT-diaphorase protein with the range of levels clearly seen (Figure 
2.7b). In contrast, only 6 out of 8 CNS cell lines (Figure 2.7a) exhibited DT-diaphorase
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Figure 2.7 Western blot analysis of DT-diaphorase expression within human 
tumour cell lines.
(a) CNS : lanes 1 - 8 represent SNB 19, SNB 75, SNB 78, SF 268, SF 295, SF 539, 
U251 and XF 498 cell lines, respectively. A purified preparation of the rat form of 
DT-diaphorase (33kD) was also run as a standard.
(b) Melanoma : lanes 1 -8  represent SK MEL 2, SK MEL 5, SK MEL 28, M14,
M l9 MEL, MALME, UACC 62 and UACC 257 cell lines, respectively. A 
purified preparation of the rat form of DT-diaphorase (33kD) was also run as a 
standard.
(c) Colon : lanes 1 - 9 represent KM 12, KM 20L2, HCC 2998, HCT-116, COLO- 
205, SW 620, DLD-1, HCT-15 and HT-29 cell lines, respectively. Note that the 
samples were run on two separate gels, and hence, no DT-diaphorase standard is 
shown in this case.
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(d) Ovarian : lanes 1 -6  represent OVCAR 8, OVCAR 5, SKOV-3, OVCAR 3 and 
OVCAR 4 cell lines, respectively. A purified preparation of the rat form of DT- 
diaphorase (33kD) was also run as a standard.
(e) Breast : lanes 1 -9  represent MCF-7, MCF-7/Adr, MDA-N, MDA-MB 231, 
MDA-MB 435S, LOX IMVI, T47D, BT 549 and HS 578T cell lines, respectively. 
An HT-29 tumour cell line sample and a purified preparation of the rat form of 
DT-diaphorase (33kD) were ran as a standards.
(f) Leukaemia/Lymphoma : lanes 1 - 6 represent SR (TB), HL-60, K562, CCRF 
CEM, RPMI 8226 and MOLT 4 cell lines, respectively. A purified preparation of 
the rat form of DT-diaphorase (33kD) was also run as a standard.
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(g) Lung : lanes 1 - 1 0  represent NSCLC cell lines EKVX, LXFL 529, A549/ATCC, 
HOP 18, HOP 62, HOP 92/02, NCI H23, NCI H226, NCI H322M and NCI 
H522M, respectively. Lane 11 contains the large cell line NCI H460 and lanes 12 
- 13 contains the SCLC lines DMS 114 and DMS 273, respectively. A purified 
preparation of the rat form of DT-diaphorase (33kD) was also run as a standard.
(h) Prostate and kidney : lanes 1 -2  represent prostate cell lines DV 145 and PC 3, 
respectively. Lanes 3 - 10  represent kidney cell lines ACHN, A598, CAKI 1, 
786.0, RXF 393, UO 31, TK 10 and SN 12C, respectively. A purified preparation 
of the rat form of DT-diaphorase (33kD) was also run as a standard.
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protein, although the range in the level of expression was more notable, with some having 
relatively high levels of expression (Lanes 1, 2, 5 and 7) and others showing little or no 
detectable protein (Lanes 3, 4 and 8). In the case of the breast cell lines (Figure 2.7e), the 
overall protein expression was less than for the other two groups of cell lines. As with the 
CNS cell lines however, not all cell lines showed protein expression.
To determine whether the observed wide range of enzyme activities could be 
explained by a correlation with the DT-diaphorase protein content of the cell line, the 
results obtained with the two different endpoints were compared. Enzyme activity and 
protein expression (quantified by densitometry) were found to correlate well in the vast 
majority of cell lines studied. The comparison between DT-diaphorase activity and 
protein expression for each of the cell line groups (except the prostate group which 
contained only two cell lines) are illustrated in Figure 2.8. Correlation coefficients are 
shown in Table 2.2 and range from 0.394 - 0.938. A small number of discrepancies 
between DT-diaphorase protein expression and enzyme activity were found. These were 
mainly confined to several of the breast or ovarian cell lines which had very low levels.
(b) NADPH : Cytochrome P450 Reductase
As far as NADPH : cytochrome P450 reductase expression was concerned, no 
detectable protein was found in any of the cell lines studied (data not shown). The 
antibody used to detect the enzyme was, however, functional as the purified rat NADPH : 
cytochrome P450 reductase standard was detected on each occasion. Therefore, the lack 
of NADPH : cytochrome P450 reductase protein expression within the cell lines was 
thought to be due to protein levels being too low for detection using the antibody against 
the rat protein.
2.3.3 Detection of DT-diaphorase and NADPH : cytochrome P450 reductase by RT-PCR
To explore the reasons underlying those few instances in which weak correlations 
were seen between DT-diaphorase protein expression and enzyme activity within the
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Figure 2.8 Correlation between DT-diaphorase protein expression and enzyme 
activity in individual groups of human tumour cell lines.
(A) CNS ; (B) melanoma ; (C) colon : (D) ovarian ; (E) breast ; (F) leukaemia / 
lymphoma ; (G) lung and (H) kidney.
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ORIGIN OF CELL LINE CORRELATION COEFFICIENT
MELANOMA 0.788 (n=8)
OVARY 0.847 (n=6)
CNS 0.872 (n=8)
KIDNEY 0.938 (n=8)
BREAST 0.498 (n=9) **
LUNG 0.595 (n=13) **
COLON 0.394 (n=9)
PROSTATE _ *
LEUKAEMIA / LYMPHOMA 0.475 (n=5) **
Table 2.2 Level of correlation between two end-points, DT-diaphorase 
enzyme activity and protein expression, within each group of 
human tumour cell lines.
Values represent the correlation coefficient (r^) obtained when two different methods of 
assaying DT-diaphorase levels within the cell line panel were compared. * denotes 
insufficient numbers available; ** denotes those groups of cell lines which contained 
obvious outliers resulting in lower correlation coefficients (see Figure 2.8).
breast and ovarian cell lines, the more sensitive RT-PCR assay for DT-diaphorase was 
performed. All human tumour cell lines originating from the breast, and as a control four 
cell lines originating from the CNS, were assayed for both DT-diaphorase and NADPH : 
cytochrome P450 reductase RNA levels using RT-PCR. The breast tumour cell lines were 
selected for study in preference to the ovarian lines due to the higher number within the 
group.
In the case of the human breast tumour cell lines, all nine were found to express 
DT-diaphorase RNA although the level of expression varied. For illustration. Figure 2.9 
shows the results for two breast cell lines, MCF-7 and MCF-7/Adr. The level of NADPH 
: cytochrome P450 reductase RNA in the breast cell lines was low, although it was 
detectable in seven out of nine of the cell lines.
As a control, four CNS human tumour cell lines were analysed. The results for 
two of these cell lines, XF 498 and SF 539, are shown in Figiu*e 2.10. Once again, DT- 
diaphorase RNA was detectable in all four cell lines studied, although the levels varied. 
NADPH : cytochrome P450 reductase RNA was detected only at very low levels in the 
CNS cell lines.
2.3.4 Enzyme Activity Measurements within Human Malignant Brain Tumours
A series of human malignant brain tumours were available to study the levels of 
bioreductive enzymes such as DT-diaphorase, NADPH : cytochrome P450 reductase and 
NADH : cytochrome b5 reductase. Table 2.3 shows the enzyme activity measurements 
obtained for eight tumour biopsies using a cytochrome c reduction assay (section 2.2.6.). 
As with the cell lines, heterogeneity of expression was seen within the tumour biopsies 
for each enzyme studied. The variability in activity for DT-diaphorase, NADH : 
cytochrome b$ reductase and NADPH : cytochrome P450 reductase was approximately 
17-fold, 11-fold and 8-fold, respectively. Interestingly, DT-diaphorase activity exhibited 
within the human tumour biopsies was significantly lower than those measured in the cell 
lines, and more significantly CNS cell lines (8.9-fold, p<0.001) (Table 2.1a). The
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Enzyme Activity (nmoi/min/mg)
Tumour
Pathology
DT-diapborase NADH: 
Cytochrome 
b5 Reductase
NADPH: 
Cytochrome 
P450 Reductase
Glioblastoma 24.1 / IS2 20.8/21.4 10.2/9.6
Sarcoma 67.5146.7 85.0/90.5 22.3 /16.4
Low grade glioma 189.8 /176.1 180.4/179.7 41.1 / 38.2
Glioblastoma 25.5/25.0 16.2/16.0 7 .8 /7 .5
Glioblastoma 11.3 /10.3 25.0 / 22.1 11.8/13.8
Glioblastoma 28.9/25.1 31.2 / 30.2 5 .8 /4 .8
Glioblastoma 106.6 /121.5 33.6/30.6 41.8/44.0
Glioblastoma 24.5/24.1 21.0/19.9 17.0/13.5
Table 2.3 Bioreductive enzyme activity measurements in human malignant 
brain tumours.
Units are nmol of cytochrome c reduced/min/mg of protein. Data represent two 
independent readings.
NADPH : cytochrome P450 reductase and NADH : cytochrome b$ reductase activities 
however, were not significantly different (0.05<p<0.1 and p>0.1, respectively) between 
the tumor biopsies and CNS cell lines.
2.3.5 Protein Expression within Human Malignant Brain Tumours
As was the case with the tumour cell lines, human tumour biopsies were analysed 
for both DT-diaphorase and NADPH : cytochrome P450 reductase protein expression, the 
results of which are shown in Figure 2.11. Note that at time of determining protein 
expression levels, only six samples were available. Of the six brain tumour biopsies 
studied, 4 were shown to express DT-diaphorase protein. The level of expression was 
variable, but correlated with the enzyme activity (r^=0.876) (Figure 2.12). As previously 
demonstrated for the human tumour cell lines, NADPH : cytochrome P450 reductase 
protein was not detected in the tumour biopsies, most probably due to the low levels of 
protein present within the samples and the sensitivity of the antibody.
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Figure 2.12 Correlation between DT-diaphorase protein expression and enzyme 
activity in human malignant brain tumours (n=6) (r^=0.876)
2.4 Discussion
Several reductase enzymes have been studied for their levels of expression within 
the NCI human tumour cell line panel. Notable differences were observed within and in 
particular, between cell lines from different tissues of origins. DT-diaphorase enzyme 
activity and protein expression were generally found to be higher than those of NADPH : 
cytochrome P450 reductase and NADH : cytochrome b$ reductase, although in all cases 
heterogeneity in the expression patterns was observed.
The results described in this chapter represent one of the first in a series of 
ongoing studies to characterise selected important biochemical and molecular parameters 
across the entire NCI panel of more than 60 human tumour cell lines. The power of such 
analysis has already been demonstrated by the incorporation of topoisomerase II 
inhibition levels (Leteurtre et a i, 1994) and mdr-i/P-glycoprotein expression levels 
(Alvarez et a i,  1995) and subsequent elucidation of mechanism of action of various 
compounds. The existing relational data base on the in vitro antitumour activity of at least 
42,000 discrete chemical entities permits the assignment of a putative mechanism of 
action to both established and novel compounds (Boyd, 1993; Pauli et aL, 1992; Pauli et 
al., 1989; Weinstein et al., 1992). The addition of biochemical and molecular parameters, 
such as enzyme levels within the cell lines, allows the growing data base to be 
interrogated to determine the likely involvement of these parameters in the antitumour 
mechanism.
The selected biochemical parameters in this particular study were the activities of 
the enzymes DT-diaphorase, NADPH : cytochrome P450 reductase and NADH : 
cytochrome b5 reductase. These are among the reductases known to be involved in 
activation of bioreductive anticancer agents, including quinones, nitro compounds and N- 
oxides (Workman, 1993). Additional enzymes are also involved in bioreductive 
activation, including for example NADPH : cytochrome P450s, xanthine oxidase and 
xanthine dehydrogenase and, as a consequence, these could also be examined to 
characterise expression across the cell lines. It was felt appropriate, however, to restrict
4 2
the initial analysis to just three enzymes. The three enzymes studied were selected 
because of the extensive investigations currently underway into their role in metabolism 
of a wide range of bioreductive agents (Fitzsimmons et a i, 1994; Hodnick & Sartorelli, 
1993; Riley & Workman, 1992b; Workman, 1994). A further, practical advantage of 
selecting these particular reductases is the similarity in the analytical methodology, which 
facilitated the efficient processing of the samples. To help interpret the enzyme activity 
information and also to assess technical feasibility for future clinical studies, the amount 
of protein and messenger RNA (DT-diaphorase and NADPH : cytochrome P450 
reductase) were also analysed by Western immunoblotting and RT-PCR.
In addition to providing a valuable resource for the future analysis of mechanism 
of action of potential anticancer compounds tested in the NCI screen, the present study 
represents the most comprehensive characterisation to date of the bioreductive enzymes 
examined against human tumour cell lines in vitro (for previous studies see for example. 
Plumb & Workman, 1994; Plumb et a i, 1994a; Plumb et a i, 1994b; Robertson et al., 
1992; Robertson eta l. , 1994).
In the present study a total of 69 cell lines were examined. It is clear that the 
expression of bioreductive enzyme activities showed a considerable degree of 
heterogeneity of expression both within and between tumour cell lines of different 
origins. Moreover, quite distinct patterns of activity emerged for particular tumour types. 
Overall the level of DT-diaphorase activity (Figure 2.1) in the cell lines was higher than 
that of NADPH : cytochrome P450 reductase and NADH : cytochrome b5 reductase. This 
finding was in agreement with other studies using smaller groups of human tumour cell 
lines (Patterson et al., 1994; Plumb & Workman, 1994; Plumb et al., 1994a; Plumb et al., 
1994b). In the case of DT-diaphorase, a relatively high degree of activity was seen in 
non-small cell lung cancer, colon, CNS and melanoma cell lines. Relatively low activities 
were noted in leukaemic/lymphoma, ovarian and breast cell lines. Other studies using 
smaller panels of cell lines have also shown similar patterns of DT-diaphorase activity. 
For example, high levels of DT-diaphorase activity have been observed within human 
tumour cell lines originating from the lung and colon (Patterson et al., 1994; Plumb &
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Workman, 1994; Plumb et a i, 1994a; Plumb et al., 1994b; Robertson et al., 1992; 
Robertson et al., 1994; Smitskamp-Wilms et al., 1994) while very low levels in 
leukaemias have also been noted (Smitskamp-Wilms et al, 1994). In addition, enzyme 
activity measurements have also been previously carried out using human tumour 
samples. In this regard, Schlager and Powis (Schlager & Powis, 1990) showed that DT- 
diaphorase was enhanced (compared to paired normal tissue) in tumours of the lung, 
breast and colon. The results of this current analysis also showed higher than average 
activities in the lung and colon lines. Although tumour cell lines originating from the 
breast were shown to possess lower than average DT-diaphorase activities, the average 
activity within the group was, in fact, higher than that for the breast tumour tissue 
reported by Schlager and Powis (Schlager & Powis, 1990). It is notable that within the 
current study, the level of DT-diaphorase activity was in fact significantly higher within 
the CNS human tumour ceU lines when compared to a human glioma biopsy panel. These 
discrepancies are hard to explain. Certainly the exact site of origin of the CNS cell lines is 
important when directly comparing them to a specific glioma panel. Differences were 
noted within the glioma panel itself (Table 2.3) dependent upon the nature of the tumour. 
A further possible explanation is that depending upon the means of biopsy sampling, 
some tumour biopsies may contain what is considered to be normal tissue, and thus the 
enzyme activity measurements are influenced. Although the level of DT-diaphorase 
activity is known to increase with cell density (Plumb & Workman, 1994), this possible 
influence was ruled out by the use of cell lines grown to the same density. Differences 
can clearly exist in the patterns of enzyme activities noted between human tumour cell 
lines and human tumour biopsies and care must therefore be taken when extrapolating 
between the two.
In comparison with DT-diaphorase, the activities observed for NADPH : 
cytochrome P450 reductase and NADH : cytochrome b5 reductase were in general much 
lower. With respect to NADPH : cytochrome P450 reductase (Figure 2.3) the tumour 
types showing the highest activities were leukaemic/lymphoma, colon, melanoma and 
renal. Low levels were more characteristic of non-small and small cell lung cancer and
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breast cancer, while both high and low levels were seen in CNS, ovarian and the two 
prostate cell lines. In the case of NADH : cytochrome b5 reductase (Figure 2.5), the two 
lung cancer histiotypes were again low in activity, as were the ovarian lines. Relatively 
high activities were associated with CNS, melanoma, renal and prostate lines, while a 
mixed pattern was observed in leukaemic/lymphoma, colon and breast cell lines. In 
contrast to DT-diaphorase, the mean activity of NADPH : cytochrome P450 reductase 
and NADH : cytochrome b5 reductase across the human glioma biopsy panel was not 
significantly different to those in the CNS cell lines, although the range in activities was 
greater.
Enzyme activity was determined using a modified version of the cytochrome c 
reduction assay detailed by Segura-Aguilar et al (Segura-Aguilar et al., 1990). In many 
studies (for example, Schlager & Powis, 1990; Traver e ta l . , 1992) 2, 6-dichlorophenol- 
indophenol (DCPIP) is used as the electron acceptor when measuring DT-diaphorase 
activity. In this current study, however, menadione (2-methyl-1, 4-napthoquinone; 
vitamin Kg menadione) was used as it was previously found to be more active than 
DCPIP (Emster, 1987). According to Segura-Aguilar (Segura-Aguilar gr al., 1990), DT- 
diaphorase activity is the activity which is dicoumarol-sensitive and NADPH : 
cytochrome P450 reductase and NADH : cytochrome b5 reductase activities are those 
that are dicoumarol-insensitive in the presence of NADPH and NADH as electron donors, 
respectively. A great deal of emphasis has been placed on dicoumarol being a potent, 
specific inhibitor of DT-diaphorase (Dulhanty et al. , 1989; Keyes et al. , 1985). 
Controversially, however, it is now known that dicoumarol lacks specificity and that it 
can inhibit other enzymes such as NADH : cytochrome b5 reductase (Preusch et al. , 
1991) and some carbonyl reductases (Maser & Netter, 1989). In an attempt to overcome 
the problems associated with dicoumarol, NADPH : cytochrome P450 reductase and 
NADH : cytochrome b5 reductase activity measurements were made using a direct assay 
system, omitting the electron acceptor menadione and therefore in the absence of 
dicoumarol. In the case of DT-diaphorase, enzyme activity was determined by the activity
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which was inhibited by a low concentration of dicoumarol (lOfiM) in the presence of 
NADH as electron donor.
The Western immunoblotting studies for DT-diaphorase were useful in showing 
that protein levels associated with DT-diaphorase were generally high in those cell lines 
rich in enzyme activities and lower in those with poor enzyme activities. This suggests 
that it is the amount of protein expressed that governs the level of enzyme activity in the 
various cell lines. In breast cell lines which have very low levels of DT-diaphorase 
activity, no protein could be detected at the limits of detection of Western 
immunoblotting. For this reason the more sensitive technique of RT-PCR was carried out 
on these breast cell lines. As a control, several CNS cell lines which possessed high 
activity were also included. DT-diaphorase RNA was detected in all of the cell lines 
studied, including those with very low levels of DT-diaphorase activity. The extent of 
RNA expression was variable in a heterogeneous fashion with respect to the enzyme 
activities. It was important to note that NADPH : cytochrome P450 reductase RNA was 
detectable by RT-PCR in the cell lines. Although activity had been detectable throughout 
the cell line panel, no protein had been detected by Western immunoblotting. The reason 
for this may be due to the latter technique not being sensitive enough to detect the overall 
lower levels of enzyme activity (in comparison to DT-diaphorase).
Overall only a low number of cell lines within the NCI panel were found to lack 
DT-diaphorase activity completely. Interestingly, however, one out of ten (i.e. 10 %) non­
small cell lung cancer lines studied was found to lack DT-diaphorase activity. This 
finding was in agreement with the frequency of a point mutation in the DT-diaphorase 
gene reported by Rosvold et al (Rosvold et al. , 1993) and more recently by Ross et al 
(Ross et al. , 1994) in lung cancers. Thus it may be an indication of the presence of this 
point mutation in those cell lines lacking DT-diaphorase activity. Clearly, the presence of 
this point mutation has important implications in terms of the ability to target DT- 
diaphorase within human tumours with specific chemotherapy treatments.
In summary, the expression and more importantly, the functional activity of three 
reductase enzymes has been determined across the NCI human tumour cell line panel.
4 6
The results reveal interesting differences within and in particular between cell lines from 
different tissues of origin. Heterogeneity in the expression patterns of DT-diaphorase 
were especially noteworthy. This information could be important in the targeting of 
particular agents to certain tumour types, depending on the levels of activating and 
deactivating enzymes, as suggested by the 'enzyme-directed' approach to bioreductive 
drug development (Plumb & Workman, 1994; Plumb et al., 1994a; Plumb et a i, 1994b; 
Robertson et al., 1994; Workman, 1994; Workman & Walton, 1990). For example, 
agents which are activated by DT-diaphorase such as E09 (Walton et al. , 1991) and 
mitomycin C (Ross et al., 1994) would be best used in the treatment of colon, NSCLC 
and melanoma tumours. In contrast, agents such as tirapazamine which is activated by 
NADPH : cytochrome P450 reductase (Fitzsimmons et al., 1994) would be best used for 
the treatment of melanoma and kidney tumours. With regard to this thesis, enzyme 
activity data within the human tumour cell lines was used to determine possible 
correlations between enzyme activities and cell sensitivities towards the many 
compounds previously screened through the NCI in vitro screening programme (Chapter 
3). The potential use of such studies has been demonstrated (Plumb & Workman, 1994; 
Plumb et al., 1994a; Plumb et al., 1994b; Robertson et al., 1992; Robertson et al., 1994; 
Smitskamp-Wilms et al., 1994), although on a much smaller scale. Furthermore, the 
accumulation of enzyme activity data within human tumour cell lines enabled the 
selection of specific cell lines for cytotoxicity studies based upon enzyme activities to be 
made (Chapter 4).
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CHAPTER 3 
RELATIONSHIP BETWEEN ENZYME ACTIVITY AND CELL SENSITIVITY 
TOWARDS COMPOUNDS WITHIN THE NCI SCREENING PANEL
3.1 Introduction
Screening of novel compounds as potential anticancer agents has been ongoing 
for many years. These screens have involved a diverse array of experimental systems. 
The NCI has, for a long time, relied upon the use of the in vivo L1210 and P388 murine 
leukaemia models for their primary screening programme (Boyd, 1993). However, more 
recently they have employed an in vitro primary screening programme which involves the 
use of a diverse, disease-orientated panel of approximately 60 human tumour cell lines 
which can be arranged into distinct disease-specific subpanels (Stinson et al. , 1992). This 
new screening method allowed for the study of a greater number of different tumour 
types, the overall goal being to identify compounds with selective activity against 
particular tumour histiotypes as opposed to the more familiar broad spectrum cytotoxins.
Having fully established the new screening system, the NCI now annually screens 
approximately 20,000 novel compounds of defined chemical structure against the panel 
of in vitro human tumour cell lines (Boyd & Pauli, 1995). Use of computer methods such 
as the COMPARE program (Pauli et al. , 1989; Pauli et al. , 1992), neural networks 
(Weinstein et al. , 1992) and Kohonen self-organising mapping (van Osdol etal. , 1994) 
to search the data base of at least 42,000 compounds so far evaluated against the panel of 
human tumour cell lines, provides a unique means by which to identify the potential 
mode of action of established agents and novel chemical entities. The inclusion of 
relevant biochemical and molecular parameters into the data base is now being sought as 
an additional means of identifying mechanisms of action of particular anticancer agents 
(Boyd & Pauli, 1995). An example of such a study was the correlation of the level of 
topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941
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(Leteurtre et al. , 1994). Subsequent studies have determined the expression levels of 
wi/r-7/P-glycoprotein within each of the cell lines and correlated this to the screening 
profiles of a series of compounds (Alvarez et a l . , 1995).
A number of reports correlating enzyme activity with cell sensitivity towards 
various compounds have been published recently. These studies, while producing 
valuable data, are usually performed on a much smaller scale than those involving the 
NCI panel of cell lines. The novel indoloquinone anticancer agent E09 is known to be 
metabolised under aerobic conditions by DT-diaphorase (Walton et al. , 1991). Cell 
sensitivity towards E09 has now been correlated with DT-diaphorase activity in both 
human tumours and tumour cell line panels (Phillips et a l . , 1992; Plumb & Workman, 
1994; Plumb et al. , 1994b; Robertson etal. , 1994; Smitskamp-Wilms e t a l . , 1994; 
Walton et al. , 1992a). However, the maximum number of cell lines used in any of these 
studies was only 23. As expected, cell sensitivity towards the benzotriazine di-N-oxide, 
tirapazamine, was shown not to correlate with DT-diaphorase activity in a panel of 18 
human tumour cell lines originating from the breast, small cell and non-small cell lung 
cancers (Patterson et al. , 1994). This is not surprising as DT-diaphorase is known, if 
anything, to detoxify tirapazamine (Workman & Stratford, 1993). Some compounds such 
as the prototype alkylating agent mitomycin C have proved to be more controversial. 
Several studies have reported the correlation of DT-diaphorase activity and cell 
sensitivity towards mitomycin C under aerobic conditions (Dulhanty & Whitmore, 1991; 
Marshall et a l . , 1991; Siegel et a l . , 1990a), whereas a contrasting report by Robertson et 
al (Robertson et al. , 1992) showed a lack of correlation. The role of DT-diaphorase in 
the activation of mitomycin C is much disputed (Schlager & Powis, 1988; Workman, 
1994; Workman & Walton, 1989). However biochemical evidence suggest that under 
physiological pH (7.0 - 7.4), bioactivation can occur under aerobic conditions (Ross et al.
, 1994).
It was felt that the availability of a larger number of human tumour cell lines may 
provide more conclusive evidence of a role for reductase enzymes in drug sensitivity. In a 
collaborative project, therefore, between the NCI, the European Organisation for
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Research and Treatment of Cancer (EORTC) and the UK Cancer Research Campaign 
(CRC), the analysis of expression of three selected bioreductive enzymes, namely DT- 
diaphorase, NADPH : cytochrome P450 reductase and NADH : cytochrome b5 reductase, 
within the human tumour cell line panel has been undertaken. In addition to gaining an 
understanding of the pattern of expression of these enzymes both within and between the 
different categories of human tumour cell lines (Chapter 2), this information was 
generated in order to create a data base with which to seek correlations between the 
different enzyme activities and sensitivities to both existing and novel anti tumour agents 
which had been screened through the NCI panel. The potential use of this new data base 
is illustrated in this chapter by the correlation and COMPARE analysis of enzyme 
activity and cell sensitivity towards the compounds already screened and stored within 
the NCI data base. A total of approximately 24,000 compounds were included in this 
particular analysis. In view of the information presented earlier in this introduction, 
possible correlations between enzyme expression and antitumour activity of E09, an 
agent in Phase I / II clinical trial, and mitomycin C, a currently used clinical agent, were 
also investigated.
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3.2 Materials and Methods
3.2.1. Human Tumour Cell Lines
The NCI panel of tissue-specific human tumour cell lines (Stinson et al., 1992) 
were used in this analysis. Cell lines are in routine use at the NCI (Bethesda, MD, 
U.S.A.) as part of their drug screening programme. Details of the preparation of cell 
pellets and subsequent storage of cell sonicates for analysis of enzyme activity levels are 
described previously in Chapter 2 (Section 2.2.4.). DT-diaphorase, NADPH : cytochrome 
P450 reductase and NADH : cytochrome b5 reductase activities were determined as 
described in Chapter 2 (Section 2.2.6.) and are expressed in nmol of cytochrome c 
reduced/min/mg of protein.
3.2.2. Cytotoxicity Testing
Sensitivity of the human tumour cell lines towards approximately 24,000 
compounds within the NCI database were determined previously at the US National 
Cancer Institute using standard procedures. Adherent cell lines were detached from 
routine culture flasks using 0.05 % trypsin-EDTA. Trypsin was then inactivated by 
adding 5 % serum-containing RPMI-1640 medium and the cells counted, along with 
suspended cell lines. Cells were plated out in a volume of 100 |il per well at densities 
between 5000 - 40,000 cells per well (see Monks et al, (Monks et al. , \9 9 \)  for details of 
cell lines and their plating densities). 100 pi of complete medium was then added to cell- 
free wells as controls. Microtitre plates were then pre-incubated for 24 hrs. at 37°C 
before addition of drug. Each compound was tested at five 10-fold dilutions by adding 
100 pi of each to the appropriate plate wells. Cells were exposed to drug under aerobic 
conditions for 48 hrs. at 37°C (5 % CO2 and 100 % relative humidity).
The end-point of the assay was determined by the Sulforhodamine B (SRB) assay 
(Skehan et al. , 1990). In the case of the adherent cells, 50 pi cold 50 % (w/v)
51
trichloroacetic acid (TCA) (final concentration 10 %) was added in order to fix the cells 
in situ for 60 mins. at 40C. Supernatant was discarded and plates rinsed five times with 
deionised water before being dried. Fixed cells were stained at room temperature for 10 
mins. with 0.4 % (w/v) SRB dissolved in 1 % acetic acid. SRB was poured from the 
plates and 1 % acetic acid used to rinse the plates five times. Once plates were dry, the 
dye was solubilised using 10 mM unbuffered Tris base (pH 10 - 10.5) for 2 - 5 mins. The 
method was essentially the same for suspension cell lines (e.g. leukaemia/lymphoma 
lines), except that at the end of the drug incubation period the settled cells were fixed to 
the bottom of the plates by adding 50 pi of 80 % cold TCA (final concentration 16 %). 
Optical densities were read on an automated spectrophotometrie plate reader at 515 nm. 
Note that a measure of cell population density at time 0 (the time at which drugs were 
added) was also made by fixing two reference plates of inoculated cells prior to drug 
addition to the test plates.
Data was analysed by computer to produce three measurements ; (1) control 
optical density, (2) test optical density, and (3) optical density at time zero. These
measurements were then used to calculate growth inhibition of 50 % (GI50) [drug
relouai To
concentration causing 50"% reduction in protein control cells during the drug
incubation], total growth inhibition (TGI) [drug concentration resulting in total 
inhibition], and the LC50, [concentration of drug causing 50 % reduction in measured 
protein at end of the drug exposure compared to at the start] (Monks et al., 1991). Values 
were calculated for each of the above parameters providing the required effects were 
seen, otherwise they were expressed as greater or less than the maximum or minimum 
drug concentration tested.
3.2.3. Statistical Analysis
All of the statistical analysis was performed by Dr. K. Pauli at the NCI 
(Information Technology Branch, Division of Cancer Treatment).
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Statistical analysis in the form of the Pearson Correlation Coefficient was used to 
determine the degree of similarity and significance between cell sensitivity towards 
compounds within the NCI database and enzyme activities. For this analysis, GI50 values 
were used as an indication of cell sensitivity as this is the parameter generally employed 
by the NCI for sensitivity analysis.
The sensitivity data of anticancer drugs tested against the NCI screening panel are 
routinely and conveniently displayed as COMPARE analysis plots (Pauli et al., 1989; 
Pauli et al., 1992). For a given drug, these COMPARE plots illustrate on a loglO scale 
the deviation from the mean sensitivity calculated across all cell lines in the panel. This is 
known as the mean graph. The relationship between DT-diaphorase enzyme activity and 
cell sensitivity within the human tumour cell line panel towards both mitomycin C and 
E09 was determined in more detail using the COMPARE programme as these agents are 
known to be promising bioreductive anticancer agents.
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3.3 Results
3.3.1. Relationship between enzyme activity and cell sensitivity towards compounds
within the NCI screening panel
DT-diaphorase, NADPH : cytochrome P450 reductase and NADH : cytochrome 
b5 reductase enzyme activities were determined within a large panel of human tumour 
cell lines, as reported in Chapter 2. These data were then entered into the NCI database as 
log 10 values, and statistical analysis in the form of the Pearson Correlation was used to 
determine any possible relationship between enzyme activity and cell sensitivity 
(expressed as logiQ GI5Q values) under aerobic conditions within the NCI screening 
panel. A total of approximately 24,000 compounds were included in the analysis.
Examples of those compounds demonstrating a good correlation between DT- 
diaphorase enzyme activity and cell sensitivity are listed in Table 3.1. The highest 
correlation coefficient was obtained for the complex quinone streptonigrin. Indeed, the 
majority of compounds exhibiting the highest correlation coefficients were quinone- 
containing compounds. 'For example, cell sensitivity towards the indoloquinone 
compound E09 and DT-diaphorase enzyme activity correlated significantly across the 
cell line panel (Pearson Correlation Coefficient of 0.446; p<0.0013; n=49). A graph 
showing this correlation can be seen in Figure 3.1. It should be noted that five of the cell 
lines used in the analysis exhibited extremely low levels of DT-diaphorase activity and as 
such, lie apart from the others in Figure 3.1. In addition, a significant correlation was 
detected with the prototype bioreductive agent mitomycin C (Pearson Correlation 
Coefficient of 0.420; p<0.0005; n=64). Figure 3.2 shows the correlation between cell 
sensitivity towards mitomycin C and DT-diaphorase activity. Once again, five cell lines 
lie apart from the others due to the their extremely low DT-diaphorase activity.
Perhaps more intriguing in the analysis, was the presence of several 5- 
fluorouracil-related compounds among those compounds showing the highest correlation 
coefficients.
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CHEMICAL NAME PEARSON CORRELATION COEFFICIENT
streptonigrin 0.563 (n=42)
5-fluorouracil prodrug 0.550 (n=54)
napthoquinone D 0.550 (n=54)
n-heterocycle D 0.484 (n=54)
E 09 0.446 (n=49)
mitomycin C 0.420 (n=64)
5-fluorouracil 0.401 (n=55)
aziridinylimidazoloquinone 0.399 (n=54)
porfiromycin 0.390 (n=50)
Table 3.1 Level of correlation between DT-diaphorase activity and
sensitivity of the NCI human tumour cell line panel towards 
selected compounds within the screening program.
The degree of correlation was determined using statistical analysis in the form of the 
Pearson Correlation Coefficient (r^). n represents the number of cell lines in which 
sensitivity data towards each compound was available and hence, the number of 
comparisons made.
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Figure 3.1 Corrélation of cell sensitivity towards the indoloquinone E 09  and DT-
diaphorase enzyme activity within the NCI human tumour cell line 
panel.
Sensitivity of the cell line panel towards E09 was determined using the SRB assay and is 
represented by GI50 values, while DT-diaphorase enzyme activity was determined by the 
cytochrome c reduction assay and values are in nmol of cytochrome c reduced/min/mg of 
protein. Statistical analysis was performed in the form of the Pearson Correlation 
Coefficient (r^=0.446).
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Figure 3.2 Correlation of cell sensitivity towards the prototype alkylating agent 
mitomycin C and DT-diaphorase enzyme activity within the NCI 
human tumour cell line panel.
Sensitivity of the cell line panel towards mitomycin C was determined using the SRB 
assay and is represented by GI50 values, while DT-diaphorase enzyme activity was 
determined by the cytochrome c reduction assay and values are in nmol of cytochrome c 
reduced/min/mg of protein. Statistical analysis was performed in the form of the Pearson 
Correlation Coefficient (r^=0.420).
In contrast to DT-diaphorase, no significant correlations were detected across the 
cell line panel for either NADPH : cytochrome P450 reductase or NADH : cytochrome b5 
reductase.
3.3.2. Cell sensitivity towards the indoloquinone E09 and DT-diaphorase enzyme
activity : correlations within individual groups of cell lines
A COMPARE analysis was carried out to investigate the correlation between DT- 
diaphorase enzyme activity and cell sensitivity towards the indoloquinone compound 
E09 under aerobic conditions. Figure 3.3 shows the pattern of differential cytotoxicity 
[GI50 (A); TGI (B) and LC50 (C)] in the form of a mean graph for the compound. Each 
of the individual parameters show that on the whole, leukaemic/lymphoma and ovarian 
cell lines were most resistant, while those originating from the melanoma, colon, renal, 
CNS, small cell and non-small cell lung cancer appear to be more sensitive towards E09. 
The exact number of cell lines following this pattern within each group appears to depend 
to some extent on the parameter (i.e. GI50) used to express cell sensitivity.
3.3.3. Cell sensitivity towards the prototype alkylating agent mitomycin C and DT- 
diaphorase enzyme activity : correlations within individual groups of cell lines
As with E09, a COMPARE analysis was carried out with mitomycin C to 
investigate any correlations between DT-diaphorase activity and cell sensitivity within 
individual groups of cell lines. Figure 3.4 shows the patterns of differential cytotoxicity in 
the form of a mean graph for mitomycin C. Three different cytotoxicity parameters were 
again used in the analysis, GI50 (A), TGI (B) and LC50 (C). The results were found to be 
somewhat different to those with E09, with less clear-cut patterns arising. Even so, cell 
lines originating from the breast, ovaries and colon appeared to be relatively resistant 
while those from the CNS and melanoma were more sensitive towards mitomycin C.
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Figure 3.3 Patterns of differential cytotoxicity of the indoloquinone E09  
towards human tumour cell lines.
For each cell line, the GI50 (A), TGI (B) and the LC50 (C) are obtained. For each 
parameter, a mean log is determined and is defined as the mean of the log 10 of the 
individual values for that parameter. The difference between the logio of each cell line 
and the mean log is then determined, to yield positive values for cell lines more sensitive 
than average (bars projecting to the right) and negative values for cell lines less sensitive 
than average (bars projecting to the left). MG-MID, Delta and Range are defined as the 
calculated mean value of the panel; the number of logio units by which the values for the 
individual value of the panel differs (+ or -) from the MG-MID and the number of logio 
units by which the value for the most sensitive line differs from the least sensitve line, 
respectively.
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Figure 3.4 Patterns of differential cytotoxicity of quinone alkylating agent 
mitomycin C towards human tumour cell lines.
For each cell line, the GI50 (A), TGI (B) and the LC50 (C) are obtained. For each 
parameter, a mean log is determined and is defined as the mean of the log 10 of the 
individual values for that parameter. The difference between the log 10 of each cell line 
and the mean log is then determined, to yield positive values for cell lines more sensitive 
than average (bars projecting to the right) and negative values for cell lines less sensitive 
than average (bars projecting to the left). See Figure 3.3 for definition of MG-MID, Delta 
and Range.
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3.4 Discussion
The potential benefits of incorporating biochemical and molecular parameters into 
the existing relational data base on the in vitro antitumour activity of approximately
42,000 chemical entities are considerable (Boyd, 1993; Pauli et a i,  1989; Pauli et ai, 
1992; Weinstein et a i, 1992). Clearly, it would increase the valuable information which 
can be obtained by facilitating the determination of the possible involvement of these 
parameters in the antitumour mechanism. In this chapter, the effectiveness of this type of 
analysis has been put to the test by searching the data base for correlations between 
bioreductive enzyme activity (detailed in Chapter 2) and cell sensitivity within the large 
panel of approximately 60 human tumour cell lines. The normal procedure at the NCI is 
to use GI50 values in the correlation analysis as an indication of cell sensitivity (i.e. the 
concentration of drug that caused 50% inhibition in protein increase in drug-treated cells 
compared to control cells). This is in fact equivalent to the IC50 value more frequently 
used within our laboratory.
As an initial test of the ability to use enzyme activity measurements to investigate 
involvement in in vitro antitumour activity, the data base was searched for any 
correlations between DT-diaphorase activity and cell sensitivity towards compounds 
within the NCI screen. Certain quinones are well documented as being bioactivated by 
DT-diaphorase (Cadenas & Hochstein, 1992; Ross et al., 1994 and references therein) 
and therefore it was not surprising to find that several quinone-containing compounds, 
such as the indoloquinone E09 and the prototype alkylating agent mitomycin C, were 
common among the top 40 compounds (based on the Pearson Correlation Coefficient). 
Interestingly, the quinone-containing compound streptonigrin was found to exhibit the 
highest correlation between cell sensitivity and DT-diaphorase activity. Streptonigrin has 
been reported to be an excellent substrate for both rat and human recombinant DT- 
diaphorase (Beall et al. , 1994a). Additional studies by this group (Ross et al., 1994) have 
shown that compared to other compounds, streptonigrin displayed the greatest selective 
cytotoxicity to cell lines containing high DT-diaphorase activity. These latter findings.
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although based on a smaller study, are in direct agreement with those in the current study 
and provide an explanation for the finding that cell sensitivity towards streptonigrin 
showed the best correlation with DT-diaphorase activity out of a total of approximately
24,000 compounds included in this analysis. Perhaps more surprising was the fact that 10 
fluorouracil derivatives, including 5-fluorouracil (5-FU) itself, were present within the 
top 40 compounds. 5-FU is the most effective single agent used in the treatment of 
colorectal carcinoma (Pinedo & Peters, 1988). It was interesting to note therefore that 
human tumour cell lines originating from colon cancers appeared to be more sensitive to 
5-FU (data not shown). These particular cell lines were shown in Chapter 2 (2.3.1.) to 
have higher than average DT-diaphorase enzyme activities. Although there have been no 
previous reports available concerning a link between 5-FU and DT-diaphorase, it may be 
that the high levels of DT-diaphorase present in colon cancers (Schlager & Powis, 1990) 
play a role in the antitumour activity of this agent. An alternative, and perhaps more 
likely, explanation is that co-ordinate regulation of enzymes such as DT-diaphorase and 
dihydropyrimidine dehydrogenase (known to regulate 5-FU metabolism and hence, 
sensitivity (Pinedo & Peters, 1988)) occurs, such that in colon tumour cell lines several 
enzymes are in fact co-ordinately up-regulated. This unexpected finding may therefore 
have important implications in understanding 5-FU activity and also for future 
therapeutic applications.
Although positive and highly significant Pearson Coefficient Correlations were 
obtained in this study, the degree of correlation could be described as only moderate (see 
correlation coefficients in Table 3.1). A possible explanation for this is that enzyme 
activity measurements were performed in the laboratories in Glasgow while the cell 
sensitivity data was carried out at the NCI laboratories. Perhaps greater correlation 
coefficients would have been obtained had both studies taken place within the same 
laboratory environments. For example, a recent study by Plumb et al (Plumb et a i,  
1994a) produced a much higher correlation coefficient of 0.87 when comparing DT- 
diaphorase activity and cell sensitivity towards E09, both of which were measured in the 
same laboratory (Plumb et al. , 1989). This collaboration was established in this manner.
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however, as the NCI possessed a large panel of human tumour cell lines in which the 
aerobic cell sensitivity towards compounds within their data base had been determined. 
This would therefore be the first study of its kind to use such a large panel of human 
tumour cell lines. A great deal of variability exists across the panel of cell lines (i.e. 
origins of the cell lines) and this may contribute to lower correlations being obtained.
A protein-binding dye, SRB is used as an end-point to the cell sensitivity assay at 
the NCI laboratories (see Section 3.2.2.). In contrast, other studies (Plumb & Workman, 
1994; Plumb etal., 1994a; Plumb e ta l,  1994b; ; Robertson et a i, 1992) have used MTT- 
dye reduction as the end-point to the assay. The NCI elected to use the SRB method 
following a pilot study (Monks et al., 1991) in which two different types of tétrazolium 
assays (one of which was MTT) and an assay using the protein-binding dye SRB were 
compared for their ability to measure cell viability and cell growth. Comparisons of the 
MTT and SRB assays suggested that the results were similar in each case (Rubinstein et 
al. , 1990). However, the MTT assay was found to be both time-consuming and also 
dictated by time restrictions (i.e. critical time period at the plate reading stage). As the 
NCI required an extremely efficient and least-time consuming assay for their future 
annual screening of approximately 20,000 agents in potentially 100 different cell lines, 
they concluded that the SRB assay presented the most efficient assaying system for their 
purpose.
In addition to DT-diaphorase activity, the data base was searched for any 
correlations between either NADPH : cytochrome P450 reductase or NADH : 
cytochrome b5 reductase activity and cell sensitivity towards compounds within the NCI 
screen. In both cases, no significant correlations were detected between enzyme activity 
and cell sensitivity. It is important to remember, however, that cell sensitivity studies 
have been performed under aerobic conditions and that the results may be quite different 
under hypoxic conditions.
As a further test of the ability to use enzyme activity measurements to investigate 
involvement in in vitro antitumour activity, the data base was interrogated in more detail 
with respect to two selected compounds, namely the clinically used mitomycin C and the
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structurally-related compound E09 which has been undergoing recent Phase I clinical 
trial (Verweij et a i  , 1994). The former was selected as an established agent for which a 
number of enzymes are known biochemically to activate the drug (Gustafson & Pritsos, 
1992; Gustafson & Pritsos, 1993; Hoban etal. , 1990; Hodnick & Sartorelli, 1993; Siegel 
et al. , 1990a). Moreover, whereas DT-diaphorase is thought to be one of these, a 
previous study in a panel of 15 human tumour cell lines found no correlation between 
DT-diaphorase expression and cytotoxicity (Robertson et al., 1992). E09 was selected as 
a developmental drug in which a strong correlation between DT-diaphorase expression 
and cytotoxicity has been seen in several smaller studies but for which information on the 
role of additional reductases is lacking (for review see Workman, 1994). The results of 
the current study show that in this much larger cell line panel covering a wider range of 
tumour histiotypes, a highly significant correlation was seen between DT-diaphorase 
expression and sensitivity to both E09 (Figure 3.1) and mitomycin C (Figure 3.2) under 
aerobic conditions. These results are in direct agreement with several other reports 
suggesting a role for DT-diaphorase in the activation of these two compounds (Plumb & 
Workman, 1994; Robertson et al., 1994; Ross et al., 1994; Walton et al., 1992a and 
references therein). As mentioned above, Robertson and colleagues (Robertson et al., 
1992) found contrasting results in that no correlation between mitomycin C cell 
sensitivity and DT-diaphorase activity. The reasons for this finding are unclear. A very 
small number of human tumour cell lines were used in the study (Robertson et al., 1992) 
and the analysis may have been influenced by outliers thereby giving no correlation. 
Mitomycin C is known to be activated by DT-diaphorase at physiological pH, i.e. in the 
range of 7 - 7.4 (Siegel et al. , 1992), but at pH 7.8 it is an effective inhibitor of the 
enzyme (Siegel et al. , 1993). It may be possible that the culture conditions could affect 
the interaction of mitomycin C and DT-diaphorase.
When looking at the sensitivity of individual tumour types to E09 (Figure 3.3), 
leukaemic/lymphoma and ovarian lines tended to be more resistant whereas small-cell 
and non-small ceU lung cancer, colon, CNS and melanoma were generally more sensitive. 
The results corresponded with those tumour types expressing above average DT-
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diaphorase activity. In contrast, there was no significant relationship between cell 
sensitivity and activities of either NADPH : cytochrome P450 reductase or NADH : 
cytochrome b5 reductase. These results would suggest therefore that DT-diaphorase is an 
important enzyme in the activation of the bioreductive quinone E09 in intact cells under 
aerobic conditions whereas the other enzymes are much less important or not involved at 
all.
The correlation between mitomycin C cell sensitivity and DT-diaphorase activity, 
although still highly significant, was lower than with E09. Hence, it was not surprising 
that the situation was less clear cut as far as sensitivity of individual tumour types to 
mitomycin C was concerned. Patterns of resistance and sensitivity, however, were still 
detectable across the panel of cell lines. For example, breast and ovarian lines tended to 
be more resistant whereas melanoma, CNS and non-small cell lung cancer lines were 
more sensitive. As mentioned previously, no relationship between the other two enzyme 
activities and cell sensitivity towards mitomycin C were detected. As is the case with 
E09, the results suggested that DT-diaphorase is an important enzyme in the activation of 
mitomycin C in intact cells under aerobic.
The correlations shown in Figure 3.1 and 3.2, which are supported by the 
statistical analysis, nevertheless demonstrate that although DT-diaphorase is a major 
determinant of cellular sensitivity to E09 and mitomycin C it is clearly not the only 
factor. This is not surprising. Not only may other activating and detoxifying systems play 
a role, but factors such as intrinsic sensitivity to DNA alkylation and DNA repair capacity 
will also play a role.
It should be emphasised that the correlations reported above concern the 
cytotoxicity of E09 and mitomycin C under aerobic conditions. The sensitivity of the 
NCI human tumour cell line panel to these drugs has not been determined under hypoxic 
conditions, and the present configuration of the screen would not permit this. Very recent 
studies have shown that different results can be obtained under aerobic versus hypoxic 
environments (Plumb & Workman, 1994; Plumb et al., 1994a; ; Robertson et al., 1994) 
but the significance of these differences for the in vivo situation remains unclear.
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In summary, the ability to use enzyme activity measurements as an additional 
parameter in establishing possible correlations with in vitro antitumour activity has been 
investigated. The correlations observed between enzyme activity and tumour cell line 
sensitivity to various quinones including the indoloquinone E09 and mitomycin C, 
suggests that the inclusion of the enzyme activity measurements within the relational data 
base should allow similar questions to be asked across the 42,000 or more discrete 
chemical entities that have been screened to date. It should be possible to determine not 
only where compounds are activated by the reductases concerned, but also where 
reductive metabolism leads to deactivation in intact cells. Moreover, new agents under 
study in the panel can also be analysed in this way. This could lead to the targeting of 
particular agents to certain tumour types, depending on the levels of activating and 
deactivating enzymes, as suggested by the 'enzyme-directed' approach to bioreductive 
drug development (Plumb & Workman, 1994; Plumb et al., 1994a; Robertson et a i, 
1994; Workman, 1992; Workman, 1994; Workman & Walton, 1990). This study has 
therefore confirmed the feasibility and value of measuring biochemical and molecular 
parameters as potential aids to the diagnostic power of the NCI human tumour panel to 
investigate potential mechanism of action.
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CHAPTER 4 
CYTOTOXICITY OF POTENTIAL BIOREDUCTIVE ANTICANCER AGENTS 
IN A PANEL OF HUMAN BREAST TUMOUR CELL LINES
4.1 Introduction
Early studies of potential bioreductive anticancer agents involved the electron- 
affinic radiosensitisers which, during the course of study, were shown to demonstrate 
preferential toxicity towards hypoxic cells in vitro (Stratford et al. , 1980) and in vivo 
(Rauth et al. , 1978). Perhaps the most promising compounds of this group were the 
nitroimidazole class which included the 2-nitroimidazole misonidazole and, at a later 
stage, the 'dual-function' radiosensitiser RSU 1069 (see Chapter 1, Figure 1.2). During 
clinical trials, however, several of the compounds were shown to possess dose-limiting 
toxicities such as neurotoxicity and gastrointestinal toxicity (Workman, 1993) and as 
such proved unsuccessful. Furthermore, the level of potency of the compounds under 
hypoxic conditions was reported to be low (Wilson et al. , 1984). In an attempt to develop 
more potent radiosensitisers, Denny and colleagues have studied the potential of a second 
group of nitro-containing compounds to act as bioreductive anticancer agents. The 
nitroacridines, as they are known, are grouped within the acridine class and are large 
heterocyclic compounds (Ferguson & Denny, 1991). In addition to their intercalative 
DNA binding ability (Roberts et al. , 1990), it was hoped that they would act as more 
potent agents than the nitroimidazoles. The antitumour agent nitracrine (1-NC; l-nitro-9- 
(dimethylaminoporopylamino)-acridine) has, in fact, been shown to be approximately
100,000 times more potent than misonidazole under hypoxic conditions (Wilson et al., 
1984). This is thought to be due in part to the ability of the agent to intercalate with DNA 
and cause DNA alkylation, but also due to reductive metabolism of the compound under 
hypoxic conditions (Wilson et al., 1984). Subsequent studies, however, have shown that
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while this is the case, the cytotoxic activity was not completely inactivated by the 
presence of oxygen (Wilson et al. , 1986). Cytotoxicity in this situation was believed to 
arise from DNA adduct formation (Konopa et al. , 1983; Pawlak et al. , 1983). As a 
consequence, further studies are under way to further develop new nitroacridines as 
potentially useful clinical bioreductive agents (Roberts et a i, 1990). In addition, the same 
group have also been investigating compounds such as the quinoline analog of 1-NC, 5- 
nitraquine (Wilson et a l . , 1992) and the 4-alklyamino-5-nitroquinoline derivative (8Me- 
5NQ) (Siim et al. , 1994) as potential bioreductive anticancer agents. To date, however, 
these studies have revealed problems of lower potency (Wilson et al., 1992) and oxygen 
sensitivity {Siim etal., 1994).
One of the most promising areas of bioreductive anticancer agents has been the 
recent development of a series of benzotriazine di-N-oxides, the lead compound being 
tirapazamine (SR 4233; WIN 59075). Although tirapazamine has now progressed to 
Phase n  clinical trial, minor problems such as muscle cramping and solubility (Doherty et 
a l . , 1994) were observed during the Phase I clinical trial. As discussed previously for the 
nitroheterocyclic compounds, further developmental studies are underway to produce a 
potentially better compound than tirapazamine for use in the clinic. For example, 
structure-activity relationship studies revealed that the analogue SR 4482 was more toxic 
to hypoxic cells in vitro and less toxic in vivo than tirapazamine (Zeman et al. , 1989). In 
addition, the analogue SR 4895 has been shown to be as effective as tirapazamine itself in 
causing DNA damage in vitro (Morecroft et a l . , 1994). Further studies will determine 
whether results such as these lead to better agent for use in the clinic.
In an attempt to discover more potent and selective bioreductive anticancer 
agents, three novel compounds were selected for study as potential bioreductive 
anticancer agents based upon their structural similarities with some of the more active 
agents currently studied. These compounds, provided by ZENECA Pharmaceuticals, 
consisted of a nitroacridine compound (ZM 33191), a large nitroheterocyclic compound 
(ZM 29362) and a quinoxaline (ZM 81853) (Figure 4.1a). The former was selected due to 
its structural similarity to nitracrine (1-NC) (Wilson gf al., 1984; Wilson et al., 1986).
63
ZM 33191
ZM 29362
O
t CN
N NO2
O
ZM 81853
Figure 4.1a Structures of novel compounds from ZENECA Pharmaceuticals.
However, it was hoped that it would prove to be less toxic under oxic conditions. 
Although both ZM 33191 and ZM 29362 would be classed as nitroheteocyclic 
compounds, an additional interesting feature of ZM 29362 was the presence of a quinone 
moiety in the structure. This would create two possible reduction sites within the 
compound and as such make it an intriguing compound to study. The final compound, 
ZM 81853, was selected due to its structural similarity with tirapazamine and could be 
directly compared to that compound. The main aim of the study was to determine the 
ability of each of the compounds to be preferentially activated under hypoxic conditions 
and to compare this ability to known bioreductive anticancer agents.
Previous studies, for example with tirapazamine (Minchinton et al. , 1992; 
Morecroft et a i, 1994) and with the indoloquinone E09 (Bailey et al. , 1992), have 
shown that small stmctural changes can alter the activity of compounds considerably. The 
structure-activity relationship of the quinoxaline ZM 81853 was therefore investigated by 
comparing the ability of a small series of the quinoxalines to act as bioreductive 
anticancer agents. The specific structures chosen are displayed in Figure 4.1b.
An in vitro cell cytotoxicity assay was used to establish the ability of these novel 
compounds to act as bioreductive anticancer agents and to determine the potential one- 
and / or two-electron reducing enzymes involved in their activation. A small panel of 
human breast tumour cell lines was selected for the study, based upon the varying levels 
of enzyme activity displayed previously in the NCI cell line panel (Chapter 2). 
Furthermore, as hypoxic regions have previously been demonstrated within breast 
tumours (Vaupel e ta l . , 1991), it was of interest to study the effects of these agents in cell 
lines originating from such tumours. In addition, two Chinese Hamster Ovary cell lines 
were used in the study, one of which had been transfected with the active gene for 
NADPH : cytochrome P450 reductase and as such should possess significantly higher 
enzyme levels compared to other cell lines. A modified version of the 3-(4, 5- 
dimethylthiazol-2-yl)-2, 5-diphenyl-tetrazolium bromide (MTT) assay (Plumb et al. , 
1989) was used as a measure of the potential ability of the novel compounds to act as 
bioreductive anticancer agents. This assay measures the ability of live cells to reduce a
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QUINOXALINE SERIES
NH?
TIRAPAZAMINE 
(SR 4233; WIN 59075)
Analogue R l R2 R3 R4
ZM 8173 - - - -
ZM 10309 - - NH2 -
ZM 65086 - - - NH2
ZM 81853 CN NH2 - -
ZM 12557 CH3 CONHOH - -
Figure 4.1b Structural differences between the quinoxaline series and 
tirapazamine.
tétrazolium dye, and hence produces an estimate of cell numbers in a simple 
chemosensitivity assay. Such an assay system has been shown previously to produce 
similar results to those determined by clonogenic assay (Plumb et a i ,  1989). The MTT 
assay system was selected for use in preference to the more widely used clonogenic assay 
for several reasons. First and foremost, not all of the human breast tumour cell lines 
selected for study were colony-forming cells, for example, T47D cells. Secondly, the 
clonogenic assay procedure is considerably more time-consuming (only 2 - 3  can be 
performed at the one time) and is unsuitable for comparing larger numbers of cell lines 
and drugs as more variables are introduced into the system. In addition, the possibility 
that the drugs interfere with the ability of the cells to reduce MTT is overcome by 
removal of drugs after a 3.5 hr. exposure, followed by a 3 day drug-free period. Perhaps 
the main advantage of the clonogenic assay system is that both cytotoxic (colony number) 
and cytostatic (colony size) effects can be studied. Early results, however, indicated that 
any effects were most likely cytotoxic as all cells in the top drug concentration and some 
in the other concentrations are dead within 24 hr. after drug treatment. A final factor was 
the limited availability of compounds.
Thus the present chapter describes the ability of structurally distinct compounds to 
act as bioreductive anticancer agents, and discusses possible differences between the 
current results and those obtained with previously studied bioreductive compounds.
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4.2 Materials and Methods
4.2.1. Chemicals and Reagents
Seven novel compounds including quinoxalines, a nitroacridine and a heterocyclic 
compound were kindly provided by ZENECA Pharmaceuticals (Macclesfield, Cheshire, 
U.K.). Generous donations of tirapazamine (SR 4233; WIN 59075) and E09 were 
received from Drs. M. Tracy and W. W. Lee of SRI International (Menlo Park, CA, 
U.S.A.) and by the New Drug Development Office of the EGRTC, respectively. All 
tissue culture media components were purchased from Life Technologies (Paisley, 
Scotland). Tissue culture flasks and 96-well microtitration plates were purchased from 
Bibby Sterilin (Stone, Staffordshire, U.K.) and the PETG Tulip 96-well plastic plates 
were from Alpha Laboratories (Eastleigh, Hampshire, U.K.). 3-(4, 5-dimethylthiazol-2- 
yl)-2, 5-diphenyltetrazolium bromide (MTT) was purchased from Sigma Chemical 
Company (Poole, Dorset, U.K.).
4.2.2. Cell Lines
The source and doubling time of the cell lines used in this study are shown in 
Table 4.1. T47D and MDA-MB 231 cell lines were from the American Type Tissue 
Collection (ATCC). MCF-7 cells were originally from Dr. K. Cowan (NCI, Bethesda, 
MD, U.S.A.). Chinese Hamster Ovary cells transfected with either vector and human 
NADPH : cytochrome P450 reductase gene (CHO-P450R) or with vector and gene in 
opposite orientation (control cell line) (CHO-Kl-WT) were kindly provided by Prof. C.R. 
Wolf (ICRF Laboratory of Molecular Pharmacology, Dundee, U.K.).
4.2.3. Routine Cell Maintenance
All epithelial cell lines were maintained in RPMI 1640 supplemented by sodium 
bicarbonate (0.075 %), L-glutamine (2 mM), foetal calf serum (10 %, v/v). Penicillin (50
66
Cell Line Doubling
Time
(days)
Characteristics Source Reference
MCF-7 1.2 Human Breast 
Adenocarcinoma
Dr. K. Cowan, 
NCI, Bethesda, 
U.S.A.
(Soule et al. , 
1973)
T47D 2.1 Human Breast 
Carcinoma
ATCC HTB 
133
(Sher et a l , 
1981)
MDA-MB 231 1.5 Human Breast 
Adenocarcinoma
ATCC HTB 26 (Cailleau et 
a l , 1974)
CHO-Kl-WT 0.6 Chinese Hamster 
Ovary (transfected 
with non functional 
NADPH : 
cytochrome P450 
reductase gene)
Prof. C. R. 
Wolf
CHO-P450R 0.8 Chinese Hamster 
Ovary (transfected 
with functional 
NADPH: 
cytochrome P450 
reductase gene)
Prof. C. R. 
Wolf
Table 4.1 Source, characteristics and cell doubling times of the cell lines used in 
these studies.
U/ml) and Streptomycin (50 |ig/mi). In the case of T47D and MDA-MB 231, cells were 
passaged at weekly intervals at a 1:10 dilution. MCF-7 cells were passaged at weekly 
intervals but at a 1:25 dilution. The CHO-Kl-WT and CHO-P450R cell lines were grown 
in Dulbecco's modified Eagle's Medium (DMEM) containing L-glutamine (2 mM), 
sodium bicarbonate (0.075 %), foetal calf serum (10 %, v/v). Penicillin (50 U/ml) and 
Streptomycin (50 |ig/ml). CHO-Kl-WT cells were passaged twice weekly at a dilution of 
1:25. In contrast, the CHO-P450R cell line was passaged at weekly intervals at a 1:10 
dilution. Following passaging of this latter cell line, cells were maintained in media as 
detailed above for 2 - 3 dys. before being replaced by selective media containing 
puromycine (2.5 |ig/ml). All cell lines were incubated at 37°C in an atmosphere of 2 % 
CO 2 in air.
Cells were passaged by removal of all medium from the flask then adding 2.5 mis 
of phosphate buffered saline (PBS) containing EDTA (1 mM) and trypsin (0.25 %) to the 
flask. This solution was left on the cells for 5 - 15 mins., depending on the cell line, to 
allow the cells to detach from the surface of the flask. Cells were resuspended by the 
addition of 7.5 mis of the relevant medium and diluted into fresh medium in sterile tissue 
culture flasks.
4.2.4. Mycoplasma Testing
All cell lines were free of mycoplasma as confirmed by monthly screening. Cells 
were fixed with ice-cold glacial acetic acid (25 %, v/v) in methanol and then stained with 
the fluorescent DNA stain Hoescht 3328 (Sigma Chemical Company, Poole, Dorset, 
U.K.) at a concentration of 100 ng/ml for 15 mins. at room temperature (Chen, 1977). 
Plates were then examined under a fluorescent microscope (Polyvar Microscope, 
Reichert, Leica Ltd., Milton Keynes, U.K.) for visible evidence of infection, i.e. 
characterised by non-nuclear staining.
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4.2.5. Enzyme Activities within Cell Lines
DT-diaphorase, NADPH : cytochrome P450 reductase and NADH : cytochrome 
b5 reductase enzyme activities were determined in each of the five cell lines using the 
method described in Chapter 2 (Section 2.2.6.). At the time of passaging cells, three 
additional flasks were set up for each cell line. Having reached confluence, the cells from 
each flask were harvested separately as described in Section 4.2.3., pelleted by 
centrifugation at 200 g for 5 mins. at 4°C (Centra-7R centrifuge. International Equipment 
Company, U.S.A.) and the cells washed twice with PBS. The final cell pellet was 
resuspended in 0.5 mis PBS containing 10 % aprotinin. Cells were then sonicated, 
centrifuged in an Eppendorf centrifuge at 4°C to remove debris, and aliquoted as 
described previously (Section 2.2.4.). Protein content of each set of aliquots was 
determined using the Pierce BCA Protein Assay (detailed in Section 2.2.5.).
4.2.6. Drugs
ZM 33191 and E09 were prepared as 5 mM stock solutions in 
dimethylsulphoxide (DMSO), while tirapazamine was made as a 200 mM stock solution. 
All other compounds were prepared as 50 mM stock solutions. In the case of the novel 
quinoxaline compounds, the range of concentration used for each drug was based on 
preliminary studies performed at ZENECA Pharmaceuticals. Dilutions were made from 
the stock solution into culture medium. The range of concentrations used for ZM 81853, 
ZM 10309, ZM 12557, ZM 65086 and ZM 8173 under oxic conditions was 19.5 - 2500 
|iM. For all of these compounds except ZM 81853, a range of 7.8 - 1000 jiM was used 
under hypoxic conditions. In the case of ZM 81853, the range was 2.0 - 250 |iM. Both the 
nitroacridine ZM 33191 and the heterocyclic compound ZM 29362 were used at the 
wider concentration ranges of 6.4 x 10"'  ^- 50 |iM and 0.032 - 2500 |iM under both oxic 
and hypoxic conditions as neither compound had been used before. Several of the 
compounds required high concentrations of stock solution to be made and as a result, the
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level of DMSO on the cells was as high as 5 %. For this reason, solvent controls (2 % and 
5 %) were used in the assays.
4.2.7. Cytotoxicity Assays
Cytotoxicity was determined using an adaptation of the tetrazolium-based 
microtitration assay described previously (Plumb et al., 1989). When measuring cell 
cytotoxicity under oxic conditions, this assay is normally performed using 96-well plastic 
microtitre plates (for example, Co star. High Wycombe, Bucks., U.K.). However, general 
tissue culture plastic is known to be soluble to oxygen (Chapman et al. , 1970), and as 
such is unsuitable for studies involving hypoxic conditions. This problem is avoided by 
the use of glass dishes for drug exposure and cell survival determined by colony 
formation. Glass 96-well plates are not available, however. In an attempt to overcome this 
problem, Mr. M. Fennell (ZENECA Pharmaceuticals, Macclesfield, Cheshire) tested the 
ability of PETG (polyethylene terephthalate glycol) Tulip' 12-well plastic plates to 
absorb oxygen, and compared the findings to those of general tissue culture plastic 12- 
well plates (Costar, High- Wycombe, Bucks., U.K.) and 12-well glass plates. The 
procedure employed was to measure oxygen levels using an oxygen electrode immersed 
in approximately 8 mm of saline at the bottom of the well over a period of time (3 hrs.) 
during which a constant flow of nitrogen (0.6 1/min) was maintained. The electrode was 
calibrated at the start in fully aerated saline (the top value) and with saline gassed for 18 
hrs. with 0.4 % oxygen in nitrogen (horizontal line across graph). The electrode current 
was measured on a nanometer at regular intervals. Results of the study are shown in 
Figure 4.2, and clearly show that the level of oxygen in the PETG plates decreases over 
time in a similar manner to that in the glass wells. In contrast, the level of oxygen within 
the Costar plastic plates, whilst decreasing with time, is consistently higher than the other 
two. It is important to note that the level of oxygen falls below that generally considered 
to be present in hypoxic tumour regions (p02 5 mm mercury) following equilibration for 
2 hrs. with nitrogen. Dr J. Plumb (Plumb & Workman, 1994) has also performed a small
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scale validation study comparing the differential cytotoxicity of tirapazamine in HT29 
cells under oxic and hypoxic conditions. This was determined using either the clonogenic 
assay or the MTT assay (with PETG plates). Results (Table 4.2) indicated that cells are 
less sensitive to tirapazamine under both oxic and hypoxic conditions when exposed to 
drug in PETG plates (MTT) compared to glass (clonogenic). However, the hypoxic 
cytotoxicity ratio (HCR) values obtained by the two methods were comparable. As a 
consequence, the MTT cytotoxicity assay was adapted for use with the PETG Tulip 
plastic 96-well plates.
For the human breast lines, cells were seeded (750 cells/well) into 96-well PETG 
plates in 150 ql of medium. In contrast, studies involving the CHO-Kl-WT and CHO- 
P450R cells required seeding levels of 525 and 775 cells/well respectively. The first and 
last row (8 wells in each) of each plate contained medium only. Plates were incubated for 
72 hr s. at 37°C in an atmosphere of 2 % CO2 in air to allow the cells to attach and grow. 
Medium from the wells was then replaced with medium containing a range of drug 
concentrations. A total of eight concentrations were used for each drug and four wells per 
concentration. In addition, medium containing 2 % DMSG or 5 % DMSG was added to 
two rows of wells as a solvent control. Plates were then exposed to the drugs for 3.5 hrs. 
in an atmosphere of 2 % CG2 in either air (oxic) or nitrogen (hypoxic). Following drug 
exposure, the drug-containing medium was removed and replaced by fresh medium. 
Plates were then left under normal incubation conditions for a further 3 dys. At the end of 
the growth period, 30 |il of medium was carefully removed from the wells and replaced 
by MTT (30 |il; 5 mg/ml PBS). Plates were then wrapped in aluminium foil and 
incubated for a further 4 hrs. Medium and MTT were removed from the wells and the 
formazan crystals dissolved in 150 \i\ DMSG which was added via a dispenser (Welltech 
Wellfill 3; Denley, Sussex, U.K.). The dissolved crystals were immediately transferred to 
a rigid plastic 96-well plate, and glycine buffer added (16.7 ql; glycine (0.1 M); sodium 
chloride (0.1 M), adjusted to pH 10.5 by sodium hydroxide (1 M)) to adjust the final pH. 
The absorbance was then recorded at a wavelength of 570 nm using Softmax Version 2.3 
installed on an Emax Precision microplate reader (details in Section 2.2.5.). The first and
7 0
Assay Conditions IC50 (|iM) HCR
Clonogenic Oxic 577 ±  88 74
Hypoxic 7.8 ±0.9
MTT (PETG) Oxic 3550 ±275 50.0
Hypoxic 71 ±19
Table 4.2 Comparison of two assay techniques for determining cytotoxicity 
of tirapazamine in HT-29 cells.
[Reproduced by permission of Dr J. Plumb (Plumb & Workman, 1994)]
last rows which contained only medium were used to blank the plate reader. Results were 
expressed as the IC50 concentration which was determined as the drug concentration 
required to reduce the absorbance to half that in the control untreated cells.
4.2.8. Statistical Analysis
The student's unpaired t-test was used to compare results for enzyme activity in 
the different cell lines.
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4.3 Results
4.3.1. Enzyme Activity Measurements within the Panel of Cell Lines
The human breast tumour cell lines were selected for use in the cytotoxicity assay 
based upon enzyme activity measurements across the NCI cell line panel. However, as 
differences do exist between batches of the same cell line, the activities of DT- 
diaphorase, NADPH : cytochrome P450 reductase and NADH : cytochrome b5 reductase 
were determined using the cytochrome c reduction assay described previously (Chapter 
2). The levels of enzyme activities are shown in Table 4.3. MCF-7 cells were found to 
possess the highest DT-diaphorase and NADH : cytochrome b5 reductase activities 
amongst the breast lines. In contrast, the highest NADPH : cytochrome P450 reductase 
activity was found within T47D cells. These results were different from those determined 
for the same cell lines within the NCI panel (Chapter 2) as the highest NADH : 
cytochrome b$ reductase and NADPH : cytochrome P450 reductase were obtained within 
T47D cells and MDA-MB 231 cells, respectively. This result is not surprising, however, 
as the cells used in this current study were from a different source. Importantly, clear 
differences were still present between the three cell lines.
In an attempt to obtain cell lines expressing greater differences in one-electron 
reducing enzymes, two Chinese Hamster Ovary cell lines transfected with either the 
active or inactive gene for human NADPH : cytochrome P450 reductase, were studied. 
As the table shows, however, little variation in NADPH : cytochrome P450 reductase was 
observed. In fact, the activity was not significantly different (p>0.1). In addition NADH : 
cytochrome b5 reductase, although showing 3.6-fold higher activity in the CHO-P450R 
cells, was not significantly different (0.05>p>0.02). The level of DT-diaphorase was, 
however, 2.9-fold higher in the CHO-P450R cell line (significant; 0.01>p>0.002).
4.3.2. Cytotoxicity of the Compounds in the Human Breast Tumour Cell Lines
The cytotoxicity of the compounds, determined under both oxic and hypoxic 
conditions for the three human breast tumour cell lines is shown in Tables 4.4 - 4.6. Also
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Enzyme Activities (nmol/min/mg)
Tumour Cell Line DT-diaphorase NADPH ; 
Cytochrome P450 
Reductase
NADH: 
Cytochrome bg 
Reductase
MCF-7 568.4 ±  55.6 19.0 ±4.3 85.4 ±13.4
T47D 108.5 ±8.0 82.8 ±17.6 24.5 ±3 .7
MDA-MB 231 24.7 ± 13.7 14.8 ±1.0 55.1 ±13.1
CHO-Kl-WT 113.3 ±32.0 13.1 ±1.2 276.7 ±45.3
CHO-P450R 325.4 ± 39.2 15.8 ±4.8 993.8 ±277.1
Table 4.3 Activities of DT-diaphorase, NADPH : cytochrome P450 reductase 
and NADH : cytochrome bg reductase within the panel of cell lines 
used in the cytotoxicity studies.
Units are nmol of cytochrome c reduced/min/mg of protein. Data represent a mean ± SE 
(n=3). ND represents a level of activity (2 nmol/min/mg of protein or less) which is 
undetectable in this assay system.
IC50 (pM)
Compound Air N2 HCR
E09 0.67,0.79 0.29,0.23 2.31,3.43
Tirapazamine 1150,1300 40,20 28.8,65.0
ZM 81853 1700 ±190 40 ±10 42.5
ZM 10309 > 2 5 0 0 ± 0 > 1 0 0 0 ± 0 -
ZM 8173 > 2 5 0 0 ± 0 > 10 0 0 ± 0 -
ZM 65086 > 2500 ± 0 > 1 0 0 0 ± 0 -
ZM 12557 > 2 5 0 0 ± 0 > 1 0 0 0 ± 0 -
ZM 33191 1.8 ±0.12 2.1 ±0.99 0.9
ZM 29362 520 ±160 1690,1250 0.4
Table 4.4 Sensitivity of the human breast tumour cell line, MCF-7, to E 09, 
tirapazamine and seven novel compounds.
Sensitivity was determined using the MTT-based cytotoxicity assay. Cells were exposed
to drug for 3.5 hr. and sensitivity was expressed as IC50 values. Results represent the
mean + SE of triplicate estimations, and are one of three repeated experiments.
IC50 (|iM)
Compound Air N2 HCR
E 09 2.11,2.05 0.39,0.12 5.41,17.1
Tirapazamine 600,450 10,10 60,45
ZM 81853 970 ±40 2 0 ± 3 48.5
ZM 10309 740 ±150 840 ±440 0.9
ZM 8173 > 2500 ± 0 > 10 0 0 ± 0 -
ZM 65086 > 2 500± 0 > 1 0 0 0 ± 0 -
ZM 12557 > 2 500± 0 > 10 0 0 ± 0 -
ZM 33191 1.06 ±0.21 0.36 ±  0.17 2.9
ZM 29362 > 2500 ± 0 560 ±420 > 4.5
Table 4.5 Sensitivity of the human breast tumour cell line, T47D, to E 09, 
tirapazamine and seven novel compounds.
Sensitivity was determined using the MTT-based cytotoxicity assay. Cells were exposed
to drug for 3.5 hr. and sensitivity was expressed as IC50 values. Results represent the
mean + SE of triplicate estimations, and are one of three repeated experiments.
IC50 (|lM)
Compound Air N2 HCR
E09 6.22,6.56 1.55,3.22 4.01,2.04
Tirapazamine 1300,1940 40,60 32.5,3 2 3
ZM 81853 1520 ±30 100 ±20 15.2
ZM 10309 910 ±70 580 ±40 1.6
ZM 8173 2300 ± 40 > 1000 ± 0 -
ZM 65086 1800 ±250 >1000 ± 0 -
ZM 12557 > 2500 ± 0 >1000 ± 0 -
ZM 33191 0.55 ± 0.04 0.22 ±0.04 2.5
ZM 29362 420 ±60 540 ±90 0.8
Table 4.6 Sensitivity of the human breast tumour cell line, MDA-MB 231, to 
E09, tirapazamine and seven novel compounds.
Sensitivity was determined using the MTT-based cytotoxicity assay. Cells were exposed
to drug for 3.5 hr. and sensitivity was expressed as IC50 values. Results represent the
mean ±  SE of triplicate estimations, and are one of three repeated experiments.
shown is the hypoxic cytotoxicity ratio (HCR) which is the ratio of the sensitivity under 
oxic conditions to that under hypoxic conditions. Considering first the quinoxaline series. 
None of the ceil lines were sensitive to ZM 12557, ZM 65086 or the unsubstituted parent 
compound ZM 8173, suggesting that all of these compounds are inactive under both oxic 
(air) and hypoxic (N2) conditions. ZM 10309 showed little cytotoxic effects under either 
oxic or hypoxic conditions in the high DT-diaphorase containing cell line MCF-7 (Table 
4.4). Furthermore, although both T47D and MDA-MB 231 cells (Tables 4.5 and 4.6, 
respectively) were more sensitive to ZM 10309 under oxic conditions, no significant 
enhancement of this sensitivity occured under hypoxic conditions. In contrast, all three 
cell lines exhibited enhanced sensitivity to the quinoxaline ZM 81853 under hypoxic 
conditions (Tables 4.4 - 4.6 and Figure 4.3). Interestingly, ZM 81853 showed similar 
characteristics to those of tirapazamine in each of the three cell lines (Table 4.4 - 4.6) 
both in terms of HCR and IC50 values. In particular, T47D cells (Table 4.5) which 
contained the highest level of NADPH : cytochrome P450 reductase activity were 
approximately 48-fold (ZM 81853) and 52-fold (tirapazamine) more sensitive towards 
these agents under hypoxic conditions. The enhanced cytotoxic effects of tirapazamine 
can be viewed graphically in Figure 4.4. As expected, MCF-7 cells showed only a small 
shift (2 to 3-fold) in sensitivity towards the control compound E09 under hypoxic 
conditions (Table 4.3) while in the case of T47D and MDA-MB 231 cells (Tables 4.5 and 
4.6) this shift was greater (5 to 17-fold and 2 to 4-fold, respectively). Typical cytotoxicity 
curves for each of the cell lines are shown in Figure 4.4.
In addition to the quinoxaline series, two further novel compounds were studied 
for their selectivity towards hypoxic conditions. The results for both compounds are 
shown in Tables 4.4 - 4.6. The nitroheterocyclic compound, ZM 29362, exhibited a very 
low level of cytotoxicity towards the cell lines under oxic conditions. Incubation under 
hypoxic conditions resulted in no significant enhancement of this cytotoxicity, suggesting 
that this compound did not possess the ability to act as a particularly good hypoxia- 
selective anticancer agent. A similar low level of enhancement in cytotoxicity occured 
with ZM 33191 under hypoxic conditions. However, it was interesting to note that the
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Figure 4.3 Sensitivity of Human Breast Tumour Cell Lines MCF-7 (A), T47D 
(B) and MDA-MB 231 (C) to ZM 81853.
Cells were exposed to drug for 3.5 hr. under oxic (2 % CO2 in air; closed circle) or 
hypoxic (2 % CO2 in N2; open circle) conditions, and cell survival determined by an 
MTT-based assay. Points on the graphs represent a mean + SE of triplicate readings and 
are from one of three repeat experiments.
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Figure 4.4 Sensitivity of Human Breast Tumour Cell Lines MCF-7 (A), T47D 
(B) and MDA-MB 231 (C) to E09 and Tirapazamine.
Cells were exposed to drug (E09 solid line; Tirapazamine dashed line) for 3.5 hr. under 
oxic (2 % CO2 in air; closed circle) or hypoxic (2 % CO2 in N2; open circle) conditions, 
and cell survival determined by an MTT-based assay. Points on the graphs represent a 
mean of two estimations. This experiment was repeated three times.
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IC50 under oxic conditions for ZM 33191 was, in fact, similar to that for E09 (Tables 4.4 
- 4.5).
4.3.3. Cytotoxicity of the Compounds in the CHO-Kl-WT and CHO-P450R Cell Lines
Due to the similarities in cell cytotoxicity data between ZM 81853 and 
tirapazamine, and the known involvement of one-electron reducing enzymes such as 
NADPH : cytochrome P450 reductase in the activation of tirapazamine under hypoxic 
conditions, further cytotoxicity studies were undertaken using two CHO cell lines, one of 
which had been transfected with the active gene for human NADPH : cytochrome P450 
reductase and the other with the inactive gene (control cell line). However, as the results 
show in Table 4.3, the level of activity of the enzymes was not as expected.
Table 4.7 shows the cytotoxicity of compounds, determined under oxic and 
hypoxic conditions, for both of the CHO-transfected cell lines. In addition, the HCR is 
also shown. As in the human breast tumour cell lines, quinoxalines ZM 10309, ZM 8173, 
ZM 65086 and ZM 12557, along with the nitroheterocyclic compound ZM 29362 showed 
little, if any, increased sensitivity under hypoxic conditions in either of the cell lines. 
Although IC50 values for the nitroacridine, ZM 33191, were similar to those of E09 
under oxic conditions, they were not altered significantly under hypoxic conditions. In 
contrast to the other quinoxalines, ZM 81853 exhibited increased cytotoxic effects under 
hypoxic conditions (Table 4.7, Figure 4.5B). Interestingly, however, the level of 
enhanced sensitivity under hypoxic conditions was similar in each cell line (75-fold, 
CHO-Kl-WT; 73-fold, CHO-P450R). Whilst both cell lines experienced increased 
sensitivity towards E09 and tirapazamine (Table 4.7) under hypoxic conditions, neither 
drug was as selective as ZM 81853 (with the exception of those results marked by *, 
which appear to be ambiguous results). Interestingly, in the case for ZM 81853, the 
degree of enhancement was similar for each of the two cell lines.
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Figure 4.5 Sensitivity of CHO-Kl-WT (circles) and CHO-P450R (squares) 
towards Tirapazamine (A) and ZM 81853 (B).
Cells were exposed to drug for 3.5hrs under oxic (2% CO2 in air; open symbols) or 
hypoxic (2% C0% in N2; closed symbols) conditions, and cell survival determined by an 
MTT assay. Points on the graph represent a mean of duplicate (tirapazamine) and 
triplicate (ZM 81853) estimations and are from one of two separate experiments.
4.4 Discussion
Based upon enzyme activity measurements within the NCI cell line panel 
(Chapter 2), three human breast tumour cell lines were selected to study the cytotoxic 
effects of seven novel compounds under both oxic and hypoxic conditions. Enzyme 
activities were shown to be slightly higher than those in the NCI panel. However, similar 
differences in each of the three enzymes were noted within each cell line. Sensitivity to 
the reference compounds E09 and tirapazamine were demonstrated. Of the seven novel 
compounds investigated, only the quinoxaline ZM 81853 showed significant 
enhancement under hypoxic conditions. This compound was, in fact, structurally similar 
to tirapazamine.
The potency of potential anticancer agents has previously been measured using 
either the clonagenic assay or the MTT cell growth assay. More recent studies have 
involved large numbers of both cell lines, and potential anticancer agents (for example, 
the NCI screening programme (Boyd, 1993; Boyd & Pauli, 1995)). As a result, the MTT- 
based microtitration assay described by Plumb et al, (Plumb et al., 1989) has proved to be 
a valuable assay system for rapidly and efficiently measuring the cell cytotoxicity of large 
numbers of compounds and thereby determining their potential as anticancer agents. 
Problems arise, however, when investigating the cytotoxic potential of anticancer agents 
under hypoxic conditions, since normal tissue culture plastics absorb oxygen (Chapman 
et al., 1970) and hence prevent the attainment of a hypoxic environment. Previous studies 
investigating the differential cytotoxicity of bioreductive compounds under oxic and 
hypoxic conditions have exposed cells to the gassing conditions in glass dishes and 
determined cell survival by colony formation (Plumb & Workman, 1994; Plumb et al. , 
1994a). The MTT assay has been used successfully when modified for 24-well plates 
with glass inserts (Stratford & Stephens, 1989). However, neither of these assays would 
enable a large scale study to be carried out rapidly. As a result, the MTT assay (Plumb et 
al., 1989) has been adapted for oxic and hypoxic conditions by the use of Tulip PETG- 
plastic 96-well tissue culture plates which act in a similar manner as glass as far as
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absorption of oxygen is concerned. Although the assay system appeared to be slightly 
less sensitive than the conventional clonogenic assay, the HCR values were comparable 
(Table 4.2, Section 4.2.7. and also Plumb and Workman, (Plumb & Workman, 1994)), 
suggesting that this system was efficient for use in such a study. Furthermore, the HCR 
results obtained in this thesis for the reference compounds, tirapazamine and E09, were 
comparable with those reported in other human tumoiu* cell lines (for example MCF-7 
and HT-29 cells, (Plumb & Workman, 1994); T47D cells, (Adams & Stratford, 1994)). 
One exception, however, was the low HCR values obtained in low DT-diaphorase 
containing cell lines such as MDA-MB 231 (Table 4.6). This result was in sharp contrast 
to published results in similar cell lines (Plumb et a i, 1994a). However, more recent 
studies by Dr. Plumb have also shown significant HCR values for E09 in low DT- 
diaphorase containing cell lines using the PETG MTT assay (personal communication). 
The assay system therefore appeared to be working efficiently. An interesting point, 
however, is that the activity of NADPH : cytochrome P450 reductase in MDA-MB 231 
cells appeared to be lower in this current study compared to that reported by Plumb et al 
(Plumb et a i,  1994a) and as such may account for the lack of enhancement under 
hypoxic conditions.
In the first instance, human breast tumour cell lines were used to assess the 
cellular potency of the novel compounds under study. The selection of human breast 
tumour cell lines was based upon two factors. Firstly, the prior analysis of the NCI human 
tumour cell line panel (Chapter 2) had indicated that several enzymes expressed variable 
activity between different cell lines originating from breast tumours. This factor in itself 
however did not separate breast cell lines from any other group. The second influential 
factor was that hypoxic regions have been measured previously within human breast 
tumours (Vaupel et a i, 1991) and this particular tumour type would therefore have the 
potential to act as a good target for bioreductive therapy. The highest average HCR 
(hypoxic cytotoxicity ratio) was obtained for tirapazamine within the cell line T47D. This 
observation was consistent with the fact that NADPH : cytochrome P450 reductase is 
known to be the enzyme responsible for activation of the drug to a DNA damaging
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species under hypoxic conditions (Fitzsimmons et al. , 1994). Interestingly, the novel 
quinoxaline compound ZM 81853 showed similar results, with T47D cells proving to be 
the most sensitive under hypoxic conditions. Collectively, these results suggest therefore 
that ZM 81853 possesses the ability to be selectively activated under hypoxic conditions, 
and that under these conditions the drug may in fact be activated within the cells in a 
similar manner to tirapazamine. As a means of addressing this possibility, further 
cytotoxicity studies were performed in the presence of two CHO cell lines. One of the 
cell lines (CHO-P450R) had been transfected with the active gene for human NADPH : 
cytochrome P450 reductase while the other (CHO-Kl-WT) was transfected with the gene 
in the reverse orientation, and hence, the enzyme was inactive. Unfortunately the 
expected increase in activity of human NADPH : cytochrome P450 reductase within the 
CHO-P450R cell line was not present and as a result, although HCR values were obtained 
for both ZM 81853 and tirapazamine, no difference in sensitivity of the two cell lines was 
detected. Original Western immunoblot data provided by colleagues at the ICRF in 
Dundee showed that the human NADPH : cytochrome P450 reductase protein was 
present within the CHO-P450R cell line; however, no comparison to the CHO-Kl-WT 
cell line was provided. It may be possible that although the protein was detectable, the 
vector may not be expressing the enzyme sufficiently within the cell line to result in 
increased activity. As successful transfection of NADPH : cytochrome P450 reductase 
into human tumour cells is known to be difficult, the results of this particular study 
suggest that the selection of human tumour cells with defined enzyme activities may in 
fact be more reliable as an in vitro screen of novel compounds.
A further four novel quinoxaline compounds were studied for cellular potency 
towards the human breast tumour cell lines and the two CHO cell lines. ZM 10309, 
although more cytotoxic than ZM 81853 in two out of three breast cell lines under oxic 
conditions, showed only a small increase in cytotoxicity under hypoxic conditions. This 
suggested therefore that ZM 10309 may not act as an efficient hypoxia-selective 
bioreductive anticancer agent. All three other quinoxaline compounds, namely ZM 
12557, ZM 65086 and the unsubstituted parent compound ZM 8173, showed no cytotoxic
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effects towards any of the cell lines. In addition, ZM 10309 was the only one of the four 
compounds to exhibit any degree of cytotoxicity towards the CHO cell lines, and this was 
observed under oxic conditions.
These studies therefore show that small structural changes within a series of novel 
quinoxaline compounds greatly influence the cytotoxic nature of the compounds. Similar 
studies by Naylor (Naylor, 1994) demonstrated that structural changes within a series of 
new imidazo [l,2-a] quinoxaline mono-N-oxides influenced the ability of the compounds 
to act as bioreductive cytotoxins. There are several possible explanations for the current 
finding including lack of solubility of the compounds, instability of the parent compound 
and/or metabolites, inability of reductase enzymes to interact with the active site of the 
compound, lack of appropriate enzymes in the cells, inability of the compounds to 
penetrate into the cell and also inappropriate reduction potentials to allow efficient 
reduction of the compounds under hypoxic conditions. In an extended study of the 
quinoxaline series (Monge et a i  , 1995), electrochemical studies suggested that the 
cytotoxic potential of these compounds, and hence the HCR, could be influenced by 
changes in the one-electron reduction potential. Such changes were brought about by the 
addition of either electron donating (CHg) or electron withdrawing (Cl, F, CFg) groups 
into the compounds. Links between hypoxic cytotoxicity / DNA damaging capacity and 
reduction potentials of nitro-containing compounds have been reported previously 
(Adams et a i  , 1980; Morecroft et al., 1994). The reduction potentials of quinoxalines 
used in this thesis are not available, however, and therefore the role of this factor in 
determining cytotoxic effects of the compounds cannot be determined. In addition to the 
possible influence of reduction potentials, Monge et al (Monge et al., 1995) also showed 
that substitution of an amine in the Rg position of the 7-chloroquinoxalines led to 
decreased potency, but a 7-fold increase in HCR. Interestingly, ZM 81853 possesses an 
amine in this position (see Figure 4.1b). A further explanation of lack of cytotoxicity was 
that those enzymes possibly required for activation of the quinoxalines (with the 
exception of ZM 81853) were not present at all, or at high enough activities, to cause
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activation. Clearly, therefore, several factors were involved in influencing the potency 
and HCR of the larger quinoxaline series.
In addition to a small series of quinoxaline di-N-oxides, two further structurally 
independent compounds were studied. The nitroacridine compound, ZM 33191, was 
selected for study due to the presence of the potentially active nitre group and its 
structural similarity to the nitroacridine, nitracrine (1-NC), extensively by Wilson and 
colleagues (Wilson et al., 1984; Wilson etal., 1986; Wilson et al., 1992). As with 1-NC, 
ZM 33191 exhibited the ability to be cytotoxic under oxic conditions suggesting that it 
may act in a similar manner to that of 1-NC, i.e. by intercalation with DNA and 
subsequent DNA alkylation. In contrast, however, further enhanced cytotoxicity was not 
observed with ZM 33191 under hypoxic conditions. As with the quinoxaline series, the 
lack of hypoxic cytotoxicity may well be due to a lack of appropriate activating enzymes 
within the cells and / or the reduction potential of ZM 33191, however, in the latter case, 
no conclusions can be made. These results certainly suggest that the potential of ZM 
33191 as a selective bioreductive anticancer agent is limited. Interestingly, however, 
cytotoxicity under oxic conditions was similar to that of E09. ZM 33191 may be useful, 
therefore, as an anticancer agent in oxic tumour cells.
ZM 29362, a large nitroheterocyclic compound, was also investigated for its 
potential as a selective bioreductive agent. This compound was interesting due to the 
presence of both a quinone moiety and a nitro group within the structure. As with the 
nitroacridine ZM 33191, however, it displayed only very small HCR in each of the cell 
lines. Unlike ZM 33191, however, the compound was inactive under oxic conditions. A 
lack of activity may result from an inability of the compound to penetrate into the cells 
due to its large size. As previously mentioned, however, it may be due to a lack of 
activating enzyme, or perhaps more likely, the reduction potential of the compound. The 
size of the compound does not usually restrict access of the reductases to the active site, 
therefore, this was probably not a reason for the lack of cytotoxicity.
In summary, a group of novel compounds has been investigated for their ability to 
act as hypoxia-selective anticancer agents. Three structurally distinct compounds were
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analysed, based upon their structural similarities to known active compounds. The results 
suggested that quinoxaline compounds such as ZM 81853, in contrast to the nitroacridine 
and the nitroheterocyclic compounds, can be preferentially activated under hypoxic 
conditions to form potent cytotoxins. Activation of ZM 81853 appeared to take place in a 
similar manner to that of the benzotriazine di-N-oxide, tirapazamine. Further studies 
involving a small series of quinoxaline di-N-oxides suggested that small structural 
differences were important for determining the cytotoxic activity of the quinoxaline 
compounds. Results from a more detailed study by Monge et al (Monge et al., 1995) 
suggested that activity of the 2-cyano-3-aminoquinoxaline di-N-oxides was enhanced by 
the presence of an electron withdrawing group (such as Cl, CFg or F) in the R7 position. 
Of interest, substitution of the amino by a dialkylaminoalkylamino group further 
enhanced potency and the HCR of the quinoxalines, especially in the presence of a CF3 
group at R7.
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CHAPTER 5 
DEVELOPMENT OF A HIGH PERFORMANCE LIQUID 
CHROMATOGRAPHY ASSAY FOR THE DETECTION OF NOVEL 
QUINOXALINE COMPOUNDS
5.1 Introduction
In the previous chapter, a small series of structurally-related quinoxaline di-N- 
oxide compounds was studied for the ability to act as bioreductive cytotoxins in a panel 
of human breast tumour cell lines. It was evident that even small changes in their 
structure resulted in vast differences in the ability of the compounds to be cytotoxic under 
hypoxic conditions. This may have been a reflection on the actual reduction potentials of 
the compounds not being appropriate for reduction under hypoxic conditions (as 
discussed in Section 4.4). A further requirement for successful reduction is the presence 
of reductase enzymes within the human tumour cell lines which are involved in 
metabolism of the compounds. For example, the reduction potentials of the quinoxaline 
compounds may have been suitable for reduction, however, enzymes involved in their 
reduction may not have been sufficiently active within the cell lines to cause metabolism. 
To study further the potential of these compounds to be reduced under hypoxic 
conditions, in vitro metabolism studies were performed. Carried out under both oxic and 
hypoxic conditions in the presence of drug, cofactor (for example, NADH and / or 
NADPH) and various enzyme sources, these studies were designed to indicate whether 
the compounds possessed the ability to be metabolised. In order to undertake such 
studies, however, a sensitive and reproducible assay was required for the quantification of 
parent compound loss and possible metabolite compound formation.
Several methods are currently available to study the metabolism of anticancer 
agents to possible metabolites. One such method is that of high performance liquid 
chromatography (HPLC). This method allows for the quantification of both parent loss
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and metabolite formation following in vitro metabolism in the presence of various 
enzyme preparations. To date, extensive studies have been performed to investigate the 
reductive metabolism of other bioreductive agents such as tirapazamine using isocratic 
reverse-phase chromatography and ultra-violet (UV) detection (Fitzsimmons et al. , 1994 
and references therein). As this benzotriazine di-A-oxide compound is structurally similar 
to the quinoxaline compounds used in this current study, the development of an HPLC 
assay for the latter compounds will be based initially on that which has been used 
successfully for tirapazamine.
This chapter, therefore, describes the development of an HPLC assay for the 
detection of each of the five novel quinoxaline compounds used in this study. In addition, 
the reproducibility of the assays was tested by performing a small validation study using 
the lead compound ZM 81853.
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5.2 Materials and Methods
5.2.1. Chemicals and Reagents
All general chemicals and solvents (of the highest grade commercially available) 
were purchased from Sigma Chemical Company (Poole, Dorset, U.K.) or Fisons pic. 
(Loughborough, U.K.) unless otherwise stated. Zero grade nitrogen (< 5 vpm oxygen) 
was obtained from the British Oxygen Company (London, U.K.)
5.2.2. Development of HPLC Conditions for the Quinoxaline Compounds
Due to the similarities in structure, conditions for separating and subsequently 
quantifying the quinoxaline compounds by HPLC were based upon those previously used 
for tirapazamine (Fitzsimmons et al., 1994). In order to achieve optimal conditions for 
each compound, however, changes were made to the original protocol used for 
tirapazamine separation.
Chromatography was carried out using modular HPLC equipment and columns 
obtained from Waters Chromatography (Millipore U.K. Ltd., Watford, U.K.). Injections 
were made using a 712 WISP injector, controlled by a 600E System Controller. 
Separations were performed using a jiBondapak Phenyl steel column (3.9 x 300 mm), 
protected by a Phenyl pre-column cartridge. Detection was made by ultra-violet (UV) 
using a 991 Photodiode Array Detector. All quinoxalines were analysed by gradient 
reverse-phase HPLC. The details of mobile phases, flow rate and run time for each 
individual compound are noted in Table 5.1. All mobile phases were degassed with 
helium (Air products pic., Walton on Thames, U.K.) before use.
5.2.3. Validation of HPLC Assay for ZM 81853
In order to validate the HPLC assay for its reproducibility in measuring drug 
levels, a range of different drug concentrations were tested. Stocks (15 mM) of ZM 81853
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Quinoxaline Mobile 
Phase A
Mobile 
Phase B
Flow
Rate
(ml/min)
Nature of Run 
Run Time Mobile 
(mins) Phase
Gradient
ZM 81853 18% 45% 1.5 0 -15.0 A -
MeOH MeOH 15.01 - 30 A - > B Linear
ZM 10309 15% 45% 1.5 0-7.0 A -
MeOH MeOH 7.01 -14 A -> B Linear
ZM 12557 15% 45% 1.5 0-7.0 A -
MeOH MeOH 7.01 -14 A - > B Linear
ZM 8173 15% 45% 1.5 0-7.0 A -
MeOH MeOH 7.01 -14 A -> B Linear
ZM 65086 15% 45% 1.5 0-7. 0 A -
MeOH MeOH 7.01 -14 A - > B Linear
Table 5.1 Optimal conditions for analysis of each compound by HPLC.
MeOH = methanol in water; each mobile phase was adjusted to pH 3.2 using 
concentrated HCl.
were made up in dimethyl sulphoxide (DMSO) and diluted to the appropriate 
concentration (15 - 1920 |iM) in a total volume of 1 ml buffer (50 mM Tris HCl, pH 7.4). 
In addition to the drug, the sample mixture also contained cofactor NADPH (1 mM final 
concentration) as this would be present within metabolism reactions. Three separate 100 
|il aliquots of each concentration were set up for injection onto HPLC and the amount of 
drug that was injected in each case, determined by the area of the peak.
5.2.4. Stability of Quinoxaline ZM 81853 under Varying Incubation Conditions
The stability of ZM 81853 under several different conditions was investigated. 
Two different concentrations (100 and 300 |iM) of ZM 81853 were analysed for their 
stability at 37°C in both light and dark conditions. These concentrations were selected 
based upon those conditions used for reductive metabolism studies of tirapazamine (Riley 
& Workman, 1992b; Walton & Workman, 1990). A 5 mM stock concentration of ZM 
81853 was made in dimethyl sulphoxide (DMSO) and diluted to 100 |iM or 300 |iM in 50 
mM Tris HCl, pH 7.4 (buffer to be used at a later stage in metabolism studies). Samples 
were kept under the appropriate incubation conditions and aliquots removed at 0, 2.5, 5,
7.5, 10 & 20 mins. In the case of the 300 |iM sample, a 1:3 dilution of the aliquot was 
made into 100 % methanol, samples were spun down and then loaded onto HPLC (details 
in Section 5.2.2.). To determine whether the drug was unstable when diluted into the 
methanol, aliquots from the 100 |iM samples were removed and injected directly onto 
HPLC. The level of ZM 81853 present at each time point was determined by the area of 
the drug peak.
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5.3 Results
5.3.1. Development of HPLC conditions for Quinoxaline Compounds
General conditions for detection of each of the quinoxaline compounds are shown 
in Table 5.1. Having established these conditions, compounds (100 qM) were then 
injected onto HPLC and the retention time and optimal absorption wavelength 
determined. Table 5.2 shows these parameters for each quinoxaline compound. The 
chromatograms obtained in these studies are shown in Figure 5.1 and illustrate that the 
assays allow for sensitive detection of each of the compounds.
5.3.2. Validation of the HPLC Assay for ZM 81853 Quantification Purposes
To ensure the reproducibility of the HPLC assay for future quantification studies, 
a validation study was undertaken with ZM 81853. The results are shown in Table 5.3 
and Figure 5.2. The amount of drug present within a sample is quantified using the peak 
area, therefore, this parameter was used in the validation study. Importantly, the peak area 
was shown correlate well with increasing drug concentration (r^ = 1.0) (Figure 5.2). In 
addition, repeated injections of the drug were shown to produce little variability in the 
peak area i.e. the largest SE observed was 1.4 % of the mean peak area (240 qM; Table 
5.3).
5.3.3. Stability of ZM 81853
Two different concentrations (100 qM and 300 qM) of ZM 81853 were analysed 
for stability at 37°C under light and dark conditions. These particular conditions were 
selected as it was felt that they were the most likely to be used in subsequent metabolism 
studies. In addition the stability of a concentrated stock (15 mM) of ZM 81853 was tested 
at -20°C as this would be the storage conditions for the drug. In all cases, the drug was
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Quinoxaline Retention Time 
(mins.)
Optimum Absorbence 
(nm)
ZM 81853 11.0 265
ZM 10309 5.5 260
ZM 12557 4.7 260
ZM 8173 6.8 240
ZM 65086 8.3 250
Table 5.2 Detection conditions for each quinoxaline compound.
Compounds were run under the conditions detailed in Table 5.1 and their retention times 
determined. Optimum absorbence of each compound was determined by performing 
chromatogram analysis to indicate the wavelength at which absorbence was greatest.
Figure 5.1 Representative HPLC chromatograms of ZM 81853 (A), ZM 8173 
(B), ZM 12557 (C), ZM 10309 (D) and ZM 65086 (E).
Compounds (100 qM) were injected onto HPLC and analysed for retention time and 
optimum absorbence (as displayed in Table 5.2).
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ZM 81853 Concentration
(liM)
Mean Peak Area 
(Peak Height x time)
Standard Error
15 8.1 X 10-3 4.8 X 10-5
30 1.4 X 10-2 7.5 X 10-5
60 2.6 X 10-2 2 .8  X 10-4
120 5.4 X 10-2 3.3 X 10-4
240 9.9 X 10-2 1.4 X 10-3
480 18.8 X 10-2 9.2 X 10-5
960 37.5 X 10-2 3.1 X 10-4
1920 76.2 X 10-2 5.4 X 10-3
Table 5.3 Validation of HPLC assay for detection of ZM 81853.
Triplicate samples for each drug concentration were injected onto HPLC and a mean peak 
area determined. Table shows the mean peak area + SE, n=3.
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Figure 5.2 Validation of HPLC assay for detection of ZM 81853.
Triplicate samples for each drug concentration were injected onto HPLC and a mean peak 
area determined. Graph represents the mean ± SE (n=3) for each drug concentration.
found to be stable and hence exhibit no notable loss when analysed by HPLC (data not 
shown).
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5.4 Discussion
In order to study the reductive metabolism of a small series of structurally-related 
quinoxaline compounds, a sensitive and reproducible HPLC assay technique is required. 
This chapter described the development of such an assay for the quinoxaline ZM 81853, 
and the subsequent minor alterations that were required for the successful detection of 
four structurally-related quinoxalines.
Several methods of investigating the metabolism of anticancer agents are 
available. These include, among others, spectrophotometric studies which directly 
monitor the loss of parent compound (change in absorbence) in the presence of enzyme 
and cofactor. Perhaps more useful and informative, however, is the technique of HPLC 
analysis involving reverse phase chromatography and either ultra-violet (UV) or 
radioisotope detection. The latter form of detection involves the use of radiolabelled 
compounds (for example ^^C labelled) to monitor both parent loss and metabolite 
formation. In this particular study, however, UV detection was selected for use due to the 
fact that, in the first place, no radiolabelled compounds were available for use, and 
secondly, an HPLC method involving UV detection had already been developed for the 
structurally similar compound, tirapazamine (Walton & Workman, 1988). Initial analysis 
of the lead compound ZM 81853 showed that although detection could be made under 
those conditions used for tirapazamine, a more sensitive assay was produced following a 
number of adjustments to the protocol. These changes included the use of steel 
qBondapak phenyl column, the use of a gradient mobile phase system, and adjustments to 
the MeOH : water ratios of the mobile phase. These changes improved the separation of 
the quinoxaline compounds by HPLC. Importantly, the new assay conditions were shown 
to be reproducible for ZM 81853. Having established the assay conditions for the lead 
compound ZM 81853, further minor adjustments were made to the mobile phase 
constituents and the gradient flow system to enable the successful detection of the four 
structurally-related quinoxalines.
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Following the successful development of both sensitive and reproducible HPLC 
assays for the detection of quinoxaline compounds, the stability of the lead compound 
ZM 81853 was investigated under conditions which would be used in subsequent 
metabolism studies. ZM 81853 was selected as this compound has been shown to be the 
most cytotoxic compound (Chapter 4) of the group studied, and as such would be used 
for more detailed metabolic analysis (see Chapter 6 and 7). In addition, due to a limited 
supply of the four other quinoxaline compounds, care had to be taken in the use of each 
compound. ZM 81853 was shown to be stable as a diluted sample at 37^C for at least 20 
mins. and also as a concentrated sample at - 20°C over a number of weeks. Unfortunately 
only ZM 81853 could be studied due to only a small quantity of the other quinoxalines 
being made available.
In summary, therefore, a sensitive and reproducible HPLC assay has been 
developed for the lead quinoxaline ZM 81853. This has been used to show that the 
compound is stable under the conditions required for future metabolism studies. In 
addition, the assay has been adapted for the detection of four structurally-related 
quinoxahne compounds.
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CHAPTER 6 
METABOLISM OF A SERIES OF QUINOXALINE DI-V-OXIDES BY MOUSE 
LIVER ENZYMES
6.1 Introduction
Cytotoxicity studies using a panel of human breast tumour cell lines indicated that 
the quinoxaline di-V-oxide ZM 81853 exhibited the potential to act as an effective 
hypoxia-selective bioreductive cytotoxin (Chapter 4). In addition, results indicated that 
one-electron reducing enzymes such as NADPH : cytochrome P450 reductase may play a 
role in this action. Further investigations using a small series of quinoxaline di-N-oxide 
compounds (shown in Chapter 4, Figure 4.1b) indicated that structural changes altered 
the ability of the compounds to act as hypoxia-selective cytotoxins. To further investigate 
the activation of the quinoxaline di-V-oxide ZM 81853 under hypoxic conditions, and to 
establish those enzymes responsible for its activation, metabolism studies using various 
enzyme preparations were performed. In addition, the lack of hypoxia-selective 
cytotoxicity displayed by the structurally-related quinoxaline series was investigated by 
determining their ability to be metabolised under hypoxic conditions.
The importance of reductase enzymes in the metabolism of bioreductive 
anticancer agents, and hence determination of their expression in human tissues, has been 
demonstrated and described in detail earlier in this thesis (Chapters 1 and 2). An 
understanding of the both the metabolic pathway and those enzymes involved for 
different bioreductive agents may allow the targeting of particular agents to a specific 
tumour type depending upon the levels of activating and deactivating enzymes present 
within that tumour. This concept has been suggested by the 'enzyme-directed' 
bioreductive drug development approach described by Workman and colleagues 
(Workman & Walton, 1990; Workman, 1994). In this regard, the enzymology of many 
bioreductive agents has been studied in detail (for examples, see reviews by Workman
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(Workman, 1992; Workman, 1993)). Of particular interest to this thesis, however, is the 
benzotriazine di-V-oxide bioreductive agent tirapazamine as it is structurally similar to 
the quinoxaline diW-oxides (Chapter 4, Figure 4.1b). This bioreductive agent is thought 
to be metabolised by one-electron reducing enzymes to a nitroxide radical (Fitzsimmons 
et al. , 1994; Lloyd et a l., 1991; Riley et al. , 1993) while two-electron reducing enzymes 
metabolise the drug to the inactive products, SR 4317 and SR 4330 (Cahill et al. , 1993; 
Riley & Workman, 1992b) (see Chapter 1, Section 1.2.3.). Data such as this has been 
gained by performing metabolism studies in the presence of an enzyme source such as 
crude tissue extracts, cell lysates, subcellular fractions or even purified enzymes. The use 
of crude tissue extracts or cell lysates provides a means of studying enzymes in an 
environment similar to the cell as many enzymes are present. The use of subcellular 
fractions such as liver microsomal or cytosolic fractions in combination with chemical 
and immunoinhibition, however, gives a cleaner enzyme system for studying specific 
roles of individual enzymes in metabolism of a bioreductive agent. This is further 
enhanced by the use of purified enzymes although such enzymes are always hard to 
obtain and are in short supply. It is important to remember, however, that purified 
enzymes act in complete isolation of other enzymes and may therefore produce different 
results than in a true cell system.
The liver is frequently used as an enzyme source as its morphological integrity 
can be disrupted by physical means to yield subcellular fractions following differential 
centrifugation. The two most important subcellular fractions for drug metabolism studies 
are the endoplasmic reticulum (or microsomal fraction) and the cytosolic fraction. In 
general. Phase I metabolising enzymes are present within the microsomal fraction (e.g. 
NADPH : cytochrome P450s and NADPH : cytochrome P450 reductase) while Phase II 
enzymes are present within the cytosolic fraction (e.g. DT-diaphorase). Although 
cytotoxicity studies indicated a similar activation of ZM 81853 as tirapazamine, and 
hence, a possible involvement of one-electron reducing enzymes, initial metabolism 
studies were performed in the presence of both microsomal and cytosolic subcellular 
enzyme preparations. As mentioned above, chemical inhibitors and epitope-specific
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inhibitory antibodies have been used in combination with subcellular enzyme fractions to 
determine the role of different enzymes in metabolism (for example Riley et al.y 1993; 
Walton et al. , 1992b). In this thesis, therefore, chemical inhibitors were used to 
investigate those enzymes responsible for activation of ZM 81853. The chemical 
inhibitors used are shown in Table 6.1. Hepatic enzyme induction can also be used as a 
further means of addressing the possible involvement of NADPH : cytochrome P450 
enzymes in metabolism (Meehan et al. , 1988; Riley et al., 1993). For this reason, both 
control (mice administered with the carrier solution only) and dexamethasone (DEX) 
induced subcellular fractions were prepared. DEX had been previously shown to induce 
NADPH : cytochrome P450 Cyp2b, Cyp2c and Cyp 3a isoenzymes (Meehan et al., 1988; 
RÜQy et a i, 1993).
Collectively, therefore, it was hoped that these investigations would indicate 
which enzymes were involved in the activation of ZM 81853 under hypoxic conditions. 
In addition, investigations into the ability of the structurally-related quinoxalines to be 
metabolised by the subcellular fractions were performed in an attempt to determine the 
reasons behind the lack of cytotoxicity shown by these compounds (Chapter 4).
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Inhibitor / Substrate Enzymes Reference
Carbon Monoxide (CO) NADPH : cytochrome 
P450s
(Omura & Sato, 1964)
SKF 525A NADPH : cytochrome 
P450s
(Schenkman et a l , 1972)
Erythromycin NADPH : cytochrome 
P450 CYP 3A *
(Wrighton et a l , 1985)
Metyrapone NADPH : cytochrome 
P450 Cyp 2a, Cyp 2b, Cyp 
2c and Cyp 3a *
(Riley et a l , 1993)
Thallium Chloride NADPH : cytochrome 
P450 reductase
(Woods & Fowler, 1984)
Diphenyliodonium NADPH : cytochrome (Tew, 1993)
Chloride (DIPC) P450 reductase
Dicoumarol DT-diaphorase, NADH : (Maser & Netter, 1989;
cytochrome b5 reductase. Preusch et a l , 1991;
carbonyl reductase Segura-Aguilar et a l , 
1990)
Rutin Carbonyl reductase (Wermuth, 1981)
Table 6.1 Inhibitors / substrates of reductase enzymes known to be involved 
in bioreductive drug metabolism.
[* Note that NADPH : Cytochrome P450 nomenclature recommended by Nebert et al 
(Nebert et a l . , 1991) was used throughout the thesis.]
6.2 Materials and Methods
6.2.1. Chemicals and Reagents
All general chemicals and solvents (of the highest grade commercially available) 
were purchased from Sigma Chemical Company (Poole, Dorset, U.K.) or Fisons pic. 
(Loughborough, U.K.). SKF 525A (proadifen hydrochloride) was provided by 
SmithKline and French Research Ltd. (Welyn, Hertfordshire, U.K.) while 
diphenyliodonium chloride (DIPC) and thallium (III) chloride tetrahydrate were from 
Aldrich Chemical Company (Gillingham, U.K.). Zero grade nitrogen (< 5 vpm oxygen) 
was obtained from the British Oxygen Company (London, U.K.) and research grade 
carbon monoxide (CO) from BDH Ltd. (Poole, Dorset, U.K.). Sodium dithionate was 
also purchased from BDH Ltd. (Poole, Dorset, U.K.).
6.2.2. Isolation of Hepatic Microsomes
Male BALB/c mice (18 - 21 g) were purchased from (Harlam Olac, Glasgow, 
U.K.) and were administered with dexamethasone (DEX) (100 mg/kg) by intraperitoneal 
injection in com oil daily for 3 dys. A control group of animals received the equivalent 
dose volume of vehicle (com oil; 10 ml/kg) once a day for 3 dys. Following the final 
injection, mice were fasted for 24 hrs. The animals were killed by cervical dislocation and 
their livers excised, washed in ice-cold buffer (buffer A : 50 mM Tris HCl, pH 7.4; 150 
mM potassium chloride), weighed and an equivalent volume of buffer A was added. 
Livers were then homogenised (Citenco Varilab, Citenco Ltd., Borhamwood, Herts., 
U.K.) with a loose fitting pestle. The homogenate was spun down in a high speed 
centrifuge (Beckman U2-21 centrifuge with JA 20 fixed-angle rotor, Beckman Ltd., High 
Wycombe, Bucks., U.K.) at 10,000 g for 30 mins. at 4^C. Cell pellets were discarded and 
the supernatant respun (10,000 g; Ihr; 4°C) in an ultracentrifuge (Beckman L60 
Ultracentrifuge with SW 40 swing out rotor, Beckman Ltd., High Wycombe, Bucks.,
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U.K.). Following completion of the spin, the supernatant (cytosolic fraction) was 
removed and stored at -70°C until use. The remaining pellet was resuspended in buffer A 
and respun (as indicated above). The resulting supernatant was discarded and the 
microsomal pellets were stored either as intact pellets or concentrated suspensions (in 
buffer B : 0.1 M Tris/HCl, pH 7.4) at -70^C until required.
Protein content of both the microsomal and cytosolic fractions were determined 
using the Pierce BCA protein assay previously described (Chapter 2, Section 2.2.5.). 
Total NADPH : cytochrome P450 content was measured by the standard method of 
Omura and Sato (Omura & Sato, 1964). Briefly, 1 ml of microsomal or cytosolic protein 
was placed in each of two cuvettes. A few grains of sodium dithionate were added to both 
cuvettes, and the contents mixed. Samples were then scanned for absorbance (400 - 500 
nm) using a Lambda 2 UV/VIS spectrophotometer (Perkin Elmer Ltd., Beaconsfield, 
Bucks., U.K.). The sample cuvette was then removed and the contents bubbled with CO 
for 30 s. A second scan was then performed. Total NADPH : cytochrome P450 content 
(nmol/mg) was determined by using an extinction coefficient of 91 mM'^cm’ l and the 
absorbance change at 450 nm).
6.2.3. Establishment of Optimal Conditions for Metabolism of ZM 81853 in the
Presence of Control or DEX-induced Mouse Liver Microsomes or Cytosol
Reductive metabohsm of ZM 81853 was carried out at 37°C in specially modified 
Erhlenmeyer flasks, the contents of which were shaken throughout the reaction. The 
incubation mixtures were pregassed for 7 mins. with zero grade N%, which was further 
deoxygenated by passage through an oxytrap (Alltech, Camforth, U.K.). Oxic incubations 
were performed in flasks open to the air. Incubations contained 1 mM NADPH, 1 mM 
NADH, 0.1 - 1.0 mg/ml microsomal protein or 0.5 - 15 mg/ml cytosolic protein in a total 
volume of 1 ml 50 mM Tris HCl, pH 7.4. Reactions were initiated by the addition of the 
substrate in DMSO (ZM 81853; 75 - 600 |iM final concentration) through air-tight seals. 
Aliquots (100 |il) of the reaction mixture were removed at 4 - 5 consecutive time-points
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and added to 2 volumes of ice-cold methanol. Samples were then centrifuged at 4®C 
(15,000 g for 15 mins.) and the supernatants analysed by HPLC (as described in Chapter 
5; Section 5.2.2.). Having established the optimal conditions for metabolism of ZM 
81853 by microsomal or cytosolic protein preparations, several control incubations were 
performed including, among others, cofactor dependence reactions.
6.2.4. Metabolism of ZM 81853 and Four Structurally-related Quinoxalines by
DEX-induced Mouse Liver Microsomes and Cytosol
The ability of the four structurally-related quinoxalines to be metabolised by 
either cytosolic or microsomal protein preparations was investigated, and the rate of 
metabolism for each compound determined. The incubation conditions used were those 
which had previously been optimised for ZM 81853 (Section 6.2.3.), i.e. a set protein (0.3 
mg/ml microsomal or 1 mg/ml cytosolic protein) and drug (300 p-M) concentration. 
Unfortunately, limited availability of each structurally-related quinoxaline compound 
prevented a more detailed study being performed to establish optimal metabolism 
conditions. Incubations were carried out as detailed above (Section 6.2.3.) following 
which, samples were analysed by HPLC under the conditions detailed previously in 
Chapter 5 (Section 5.2.2.).
6.2.5. Chemical Inhibition of ZM 81853 Metabolism by DEX-induced Mouse Liver
Microsomes and Cytosol
Incubations and analysis of samples were performed as detailed above except that 
various diagnostic substrates / inhibitors (Table 6.1) were added at concentrations of 20 - 
2500 pM. In each case control experiments were performed with the same amount of 
buffer or vehicle (DMSO or methanol) required for solubilisation of the inhibitor. As far 
as possible, the concentrations used were based upon previous studies performed in this 
laboratory.
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6.2.6. Identification by Mass Spectroscopy of Predominant Product Following
Metabolism of ZM 81853 by DEX-induced Mouse Liver Microsomes
Metabolism of ZM 81853 by DEX-induced mouse liver microsomes was 
performed essentially as described in Section 6.2.3.. To ensure a large enough 
concentration of the predominant product for subsequent mass spectroscopy 
(approximately 100 pg), reaction constituents were used at a higher concentration : ZM 
81853 (495 pM), NADPH (5 mM) and protein (2.5 mg/ml). Furthermore, the incubation 
was performed for 45 mins. before removing all of the sample and centrifuging for 15 
mins. (15,000 rpm, 4°C). The sample was then injected (50 pi at a time) onto HPLC (as 
detailed in Chapter 5, Section 5.2.2.) and the predominant peak collected and stored on 
ice. The final fraction was dried down using an Alpha freeze drier (Christ, V. A. Howe 
Ltd., Banbury, U.K.).
Mass spectroscopy was performed in collaboration with Dr. D. G. Watson at the 
Department of Pharmaceutical Sciences, University of Strathclyde, Glasgow. The dried 
sample was dissolved in 100 pi of glycerol as fast atom bombardment (FAB) matrix. An 
FAB spectrum was obtained using a JEOL JMS-AX505HA double focusing mass 
spectrometer (JEOL Ltd., Tokyo, Japan) with xenon gas as the source of fast atoms. 
Spectra were obtained with a resolution of 3000. Calibration for accurate mass 
measurement was carried out against the peaks (MWt. 185, 277 and 369) of glycerol 
matrix.
6.2.7. Statistics
The Student's unpaired t-test was used to compare the rates of metabolism for 
each compound and also the significance of the level of inhibition observed with various 
inhibitors.
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6.3 Results
6.3.1. Establishment of Optimal Conditions for Metabolism of ZM 81853 by Mouse
Liver Microsomes and Cytosol
To determine whether DEX-induction of the mouse liver microsomes had been 
successful, the total NADPH : cytochrome P450 content was measured in both control 
and DEX-induced microsomal preparations. DEX-induction resulted in approximately 2- 
fold higher levels of NADPH : cytochrome P450 content within the microsomes (data not 
shown).
The ability of ZM 81853 to be metabolised, under hypoxic conditions, in the 
presence of either control or DEX-induced mouse liver microsomes and cytosol, was 
investigated. Metabohsm was measured as the loss of ZM 81853 over time. In the case of 
the mouse liver microsomes, DEX-induction appeared to cause increased loss of ZM 
81853 by 10 mins. when compared to control microsomes (Figure 6.1). The level of loss 
was shown to become non-linear between 0.25 and 0.5 mg/ml of protein (Figure 6.1 A) 
and above 300 pM drug concentration (Figure 6. IB).
A similar situation was observed in the presence of mouse liver cytosol, with ZM 
81853 loss shown to be greater in the presence of the DEX-induced cytosol. In this case, 
however, protein concentrations above 1 mg/ml and drug concentrations between 200 and 
400 pM resulted in non-linear loss of ZM 81853 (Figure 6.2A and 6.2B, respectively).
Collectively these results suggest that optimal metabolism of ZM 81853 would 
occur in the presence of DEX-induced microsomes and cytosol, and that the ideal protein 
and drug concentrations were 0.3 mg/ml and 300 pM, and 1.0 mg/ml and 300pM, 
respectively.
6.3.2. Metabolism of ZM 81853 by DEX-induced Mouse Liver Microsomes
Having established optimal conditions for the metabolism of ZM 81853 in the 
presence of DEX-induced mouse liver microsomes, a series of control incubations were
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Figure 6.1 ZM 81853 metabolism in the presence of control (closed circles) or 
DEX-induced (open circles) mouse liver microsomes. Effect of 
increasing protein (A) and drug (B) concentration on ZM 81853 
metabolism.
Incubations contained 0.1 - 1.0 mg/ml microsomal protein, 1 mM NADH and NADPH 
and 75 - 600 fiM ZM 81853 in a total volume of 1 ml 50 mM Tris HCl, pH 7.4. Results 
represent one of two repeat experiments. Graphs show amount of ZM 81853 lost after a 
10 mins. incubation. In (A), 300|iM of ZM 81853 was used, while in (B), 0.3 mg/ml of 
protein was used.
300
250-
200-
150-
QO 100 -
s
N -
60 2 3 4 51
Protein Concentration (mg/ml)
200
5  150-
W)
0 u
m 100-iTiQO
00
1  50-
600 8000 200 400
Drug Concentration (jiM)
Figure 6.2 ZM 81853 metabolism in the presence of control (closed circles) or 
DEX-induced (open circles) mouse liver cytosol. Effect of increasing 
protein (A) and drug (B) concentration on ZM 81853 metabolism.
Incubations contained 0.5 - 5.0 mg/ml cytosolic protein, 1 mM NADH and NADPH and 
75 - 600 |iM ZM 81853 in a total volume of 1 ml 50 mM Tris HCl, pH 7.4. Graphs show 
the amount of ZM 81853 lost after a 10 mins. incubation. In (A), 300 |iM of ZM 81853 
was used while in (B), 1 mg/ml of protein was used.
performed. The results in Table 6.2 show that metabolism of ZM 81853 was 
predominantly dependent upon the presence of NADPH as cofactor, and to a lesser extent 
on NADH. In addition the reaction was completely inhibited in the presence of air and 
boiled microsomes. Importantly, metabolism of ZM 81853 in the presence of 300 )iM 
drug and 0.3 mg/ml protein can be seen to be linear with time up to at least 15 mins. 
(Figure 6.3).
A representative HPLC chromatogram of ZM 81853 metabolism under control 
(N2) conditions is shown in Figure 6.4. At 0 mins., ZM 81853 formed the predominant 
peak (no. 1) with a retention time of approximately 11 mins. Following a 15 mins. 
incubation under hypoxic conditions, ZM 81853 was significantly reduced in size (no. 1) 
and several potential metabolites had formed. The predominant new peak eluted at 16 
mins. (no. 2).
6.3.3. Metabolism of ZM 81853 by DEX-induced Mouse Liver Cytosol
As with the mouse liver microsomes, a series of control incubations were 
performed in the presence of DEX-induced cytosolic protein. The results in Table 6.3 
show that metabolism of ZM 81853 by cytosolic protein was fully dependent upon 
hypoxic conditions, active enzyme and the presence of NADPH as a cofactor. The rate of 
loss of ZM 81853 was significantly lower (3.5-fold; p<0.001) than in the presence of 
microsomal protein. Metabolism was shown to be linear with time up to at least 15 mins. 
(Figure 6.5). A similar HPLC chromatogram was obtained to that which was seen in the 
presence of microsomal protein (see Figure 6.4). However as previously noted, the level 
of ZM 81853 loss was lower (data not shown).
6.3.4. Metabolism of Four Structurally-related Quinoxaline Compounds
Using the conditions found to be optimal for ZM 81853, metabolism of the 
structurally-related quinoxaline compounds in the presence of both microsomal and
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Incubation Rate of Metabolism Range in Rate of % Inhibition in
(nmol of ZM 81853 Metabolism Metabolism
lost/min/mg of (nmol of ZM 81853 (compared to
protein) * lost/min/mg of 
protein)
control incubation)
Control (N2) ** 59.5 ± 17.9 (n=ll) 33.8 - 91.7 -
Air 0 (n=3) 0 100
Boiled Microsomes 0 (n=3) 0 100
minus NADH 46.4 ±  6.4 (n=4) 38.0 - 53.7 22
minus NADPH 0 (n=3) 0 100
Table 6.2 Effect on metabolism of ZM 81853 by DEX-induced mouse liver 
microsomes in the presence of various controls.
* Figures represent the mean + SD; n value is noted in brackets
** Control incubations were carried out under and contained 0.3 mg/ml microsomal 
protein, 1 mM NADH and NADPH and 300 pM ZM 81853.
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Figure 6.3 Typical progress curve for the metabolism of ZM 81853 by DEX- 
induced mouse liver microsomes under nitrogen.
Incubations contained 0.3 mg/ml microsomal protein, 1 mM NADH and NADPH and 
300 |iM ZM 81853 in a final volume of 1 ml 50 mM Tris HCl, pH 7.4.
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Incubation Rate of Metabolism Range in Rate of % Inhibition in
(nmol of ZM 81853 Metabolism Metabolism
lost/min/mg of (nmol of ZM 81853 (compared to
protein) * lost/min/mg of 
protein)
control incubation)
Control (N2) ** 17.2 ±9.3 (n=6) 10.7 - 36.2 -
Air 0 (n=2) 0 100
Boiled Cytosol 0 (n=2) 0 100
minus NADH 20.0 ±13.7 (n=3) 11.4 - 35.8 0
minus NADPH 0 (n=2) 0 100
Table 6.3 Effect on metabolism of ZM 81853 by DEX-induced mouse liver 
cytosol in the presence of various controls.
* Figures represent the mean + SD; n value is noted in brackets
** Control incubations were carried out under and contained 1.0 mg/ml cytosolic 
protein, 1 mM NADH and NADPH and 300 pM ZM 81853.
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Figure 6.5 Typical progress curve for metabolism of ZM 81853 by DEX-induced 
mouse liver cytosol.
Incubations contained 1.0 mg/ml cytosolic protein , 1 mM NADH and NADPH and 300 
|liM ZM 81853 in a final volume 1 ml 50 mM Tris HCl, pH 7.4.
cytosolic protein was performed. Only ZM 10309 was shown to be metabolised by both 
microsomal and cytosolic enzyme preparations (Table 6.4). The rates of loss in the 
presence of both cytosolic and microsomal protein, however, were significantly lower 
than that of ZM 81853 (2.7-fold; 0.002>p>0.001, and 3.6-fold; p<0.001, respectively). 
The resulting chromatograms were similar to ZM 81853 (Figure 6.4) and indicated that in 
both cases, the ZM 10309 peak had reduced in size, following a 15 mins. incubation, and 
a new peak had formed with a retention time of approximately 9 mins. With the 
exception of one particular experiment (ZM 8173 incubated with cytosolic protein), all 
the three other quinoxalines were found not to act as substrates for either enzyme 
preparation. The very low level loss of ZM 8173 detected in the presence of cytosolic 
protein was believed to a spurious result as loss was non-hnear over the incubation period 
and was not reproduced in a subsequent experiment.
6.3.5. Chemical Inhibition of ZM 81853 Metabolism by DEX-induced
Mouse Liver Microsomes
The effects of various chemical inhibitors on the metabolism of ZM 81853 by 
DEX-induced mouse liver microsomes are shown in Table 6.5. In addition, the effect of 
CO on the reaction is shown. Metabolism of ZM 81853 was significantly reduced (26.6 
%) in the presence of CO (0.01>p>0.002). Subsequent reactions in the presence of SKF 
525A, an established cytochrome P450 inhibitor, showed an even higher level of 
inhibition (43.7 %; p<0.001). Collectively these results, along with those which show an 
increased level of metabolism in the presence of DEX-induced enzyme preparations, 
suggest a possible role for NADPH : cytochrome P450 enzymes in the metabolism of ZM 
81853 under hypoxic conditions. This is supported further by the inhibition, although at a 
lower rate, caused by metyrapone (an inhibitor of NADPH : cytochrome P450 Cyp 2b, 
Cyp 2c and Cyp 3a in mice). Interestingly, no inhibition was observed in the presence of 
erythromycin (an inhibitor of NADPH : cytochrome P450 CYP3A in the rat) suggesting 
no role for the Cyp 3a isoenzyme of NADPH : cytochrome P450. Furthermore, no
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Drug
Rate of loss 
(nmol of compound lost/min/mg of protein)
Microsomes Cytosol
ZM 81853 59.5 ±17 .9* 17.4 ±  10.6 *
ZM 10309 19.1,13.9 7.5,5.3
ZM 8173 0,0 1.0,0
ZM 12557 0,0 0 ,0
ZM 65086 0,0 0 ,0
Table 6.4 Rate of loss of compound in the presence of either DEX-induced 
mouse liver microsomes or cytosol.
Figures represent two independent experiments except where denoted by*, in which case 
figures are the mean ± SD (n=l 1 and 5, repectively). Incubations contained 300 |lM drug, 
0.3 mg/ml microsomal or 1.0 mg/ml cytosolic protein, 1 mM NADH and 1 mM NADPH.
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inhibition was observed in the presence of rutin (an inhibitor of carbonyl reductase). The 
highest, and most significant level of inhibition, however, was obtained in the presence of 
either thallium chloride or DIPC (94.6 % and 93.1 %, respectively), both of which are 
known to inhibit NADPH : cytochrome P450 reductase.
6.3.6. Chemical Inhibition of ZM 81853 Metabolism by DEX-induced
Mouse Liver Cytosol
Metabolism of ZM 81853 by cytosolic proteins has been demonstrated earlier, 
although at a lower level than in the presence of microsomal protein. The effects of two 
inhibitors on this metabolism are shown in Table 6.6. Only in the presence of rutin was 
the level of inhibition seen to be significant (58 %; 0.01>p>0.002). This chemical is 
known to be an inhibitor of carbonyl reductase; therefore this enzyme may be involved in 
the metabolism of ZM 81853 by cytosolic protein under hypoxic conditions. Although 
the level of inhibition by dicoumarol (primarily used as a DT-diaphorase inhibitor) 
appeared to be similar, this was shown to be non-significant (0.05>p>0.02). Interestingly, 
in the presence of both inhibitors the level of inhibition was reduced to only 27 %.
6.3.7. Identification by Mass Spectroscopy of Predominant Product Following
ZM 81853 Metabolism by DEX-induced Mouse Liver Microsomes
As shown in Figure 6.4, metabolism of ZM 81853 by DEX-induced mouse liver 
microsomes resulted in one predominant peak. To identify this product, mass 
spectroscopy was performed. The resulting FAB spectrum is shown in Figure 6.6, and 
indicates a major ion in the spectrum at 207 with an elemental formula of C9H 11O2N4. 
As FAB spectra usually indicate the MWt. of the compound (4- H), the result indicated 
that a four-electron reduction product with a MWt. of 206 may be produced following 
reduction of ZM 81853 in the presence of DEX-induced mouse liver microsomes.
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6.4 Discussion
The novel quinoxaline di-A-oxide ZM 81853 was shown in earlier studies in this 
thesis (Chapter 4) to exhibit similar hypoxia-selective cytotoxicity to that of the 
benzotriazine di-N-oxide, tirapazamine and as such, may undergo similar metabolic 
activation as tirapazamine. Further analysis of a series of structurally-related quinoxalines 
suggested that small changes in the structure of ZM 81853 resulted in loss of the 
observed hypoxia-selective cytotoxicity. It was of interest, therefore, to investigate this 
further by studying the metabolic properties of all of the quinoxaline compounds under 
hypoxic conditions. Furthermore, the role of particular reductase enzymes in metabolism 
was investigated as it is known that the action of particular enzymes can influence the 
selective toxicity of bioreductive cytotoxins (discussed in Chapter 1). ZM 81853 was 
metabolised by enzymes within the cytosolic and the microsomal fractions, although the 
rate of ZM 81853 loss was greater in the latter case. Interestingly, chemical inhibition 
studies suggested that NADPH : cytochrome P450 reductase was the enzyme 
predominantly responsible for metabolism in the presence of microsomes. ZM 10309 was 
the only other quinoxaline from the series to undergo metabolism. However, the rate of 
loss of the compound was significantly lower in the presence of both cytosolic and 
microsomal fractions than was the case for ZM 81853.
Enzymes such as the NADPH : cytochrome P450 family, DT-diaphorase and 
xanthine oxidase have been implicated in the reductive metabolism of many drugs, 
including various nitro and A-oxide compounds (McLane et al. , 1983; Workman & 
Walton, 1990). Their role can either be one of activation or detoxification of the drug 
(Workman & Walton, 1990). For example in the case of tirapazamine, the one-electron 
reducing enzymes NADPH : cytochrome P450 (CYP 2B6) and NADPH : cytochrome 
P450 reductase (Fitzsimmons et al., 1994; Lewis et al. , 1995; Riley et al., 1993) are 
known to be involved in activation whilst the two-electron reducing enzyme DT- 
diaphorase was shown to be involved in detoxification (Riley & Workman, 1992b). 
Information of this nature has generally been accumulated by performing metabolism
100
studies in the presence of subcellular fractions from mouse livers. The role of reductases 
can be investigated with the use of various chemical enzyme inhibitors and, more 
specifically, confirmed with the use of highly purified enzyme preparations. In addition, 
hepatic enzyme induction has also been incorporated to investigate the role of different 
enzymes. For example, significant induction by DEX of total NADPH : cytochrome P450 
Cyp 2b, Cyp 2c and Cyp 3a isoenzyme content and of DT-diaphorase activity in the 
microsomal fraction of mouse livers have been demonstrated (Meehan et al., 1988; Riley 
et a i ,  1993). Such techniques have been used to predict those reductase enzymes 
involved in metabolism of a large number of bioreductive compounds (reviewed in 
Workman, 1993).
Due to the similarities between ZM 81853 and tirapazamine, in both structure and 
hypoxic-selectivity in human breast tumour cell lines (Chapter 4), it was felt that an 
appropriate starting point for determination of enzymes involved in reductive metabolism 
of ZM 81853, and indeed the other quinoxalines, would be to use subcellular fractions 
from mouse liver (both control and DEX-induced preparations). To further address the 
role of specific enzymes in metabolism, various chemical inhibitors (Table 6.1) were 
included in the analysis. Whilst it was realised that a more detailed investigation could be 
performed by combining the use of chemical inhibitors and antibodies, the latter were in 
limited supply and therefore were not included at this stage. Investigations involving 
diagnostic inducers, inhibitors and /  or antibodies are extremely complex, not least 
because of inherent problems of species variation (Boobis et al. , 1990). Nevertheless, it 
was believed that this initial study would provide valuable information regarding the 
potential role of different enzymes in ZM 81853 metabolism.
ZM 81853 was shown to be metabolised by microsomal protein, but only in the 
presence of active enzyme and cofactors. Interestingly, although both NADH and 
NADPH played a role as cofactors in the metabolism of the compound, the latter cofactor 
was shown to be the most important. Similar results were reported by Sugiura and 
colleagues (Sugiura et al. , 1976) using the tertiary amine N-oxides of iiiiipramine, 
tiarimide and N, A-dimethylanaline; however, in contrast to these findings, reduction of
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tirapazamine showed a complete dependence upon NADPH (Walton & Workman, 1990). 
Interestingly, however, the rate of loss of ZM 81853 was found to be approximately 4- 
fold lower than that for tirapazamine under similar conditions (Walton & Workman, 
1990). Metabolism of ZM 81853 was shown to be completely inhibited by the presence 
of oxygen, a finding which is in agreement with previous studies involving tirapazamine 
(Riley et a i,  1993) and the tertiary amine A-oxides (Sugiura et al., 1976). Therefore, 
metabolism of ZM 81853 was shown to occur preferentially under hypoxic conditions, as 
indicated by the cytotoxicity studies (Chapter 4).
As mentioned above, DEX is known to induce total NADPH : cytochrome P450 
content within mouse liver microsomes approximately 2-fold, with the emphasis on the 
Cyp 2b, Cyp 2c and Cyp 3a isoenzymes (Meehan et al., 1988; Riley et al., 1993). 
Metabolism of ZM 81853 was shown to be higher in the presence of DEX-induced 
mouse liver microsomes, thereby suggesting a possible involvement of NADPH : 
cytochrome P450 enzymes in the reaction. This possibility was further supported by the 
observation that metabolism of ZM 81853 in the presence of the established NADPH : 
cytochrome P450 inhibitors, CO and SKF 525A, was reduced by approximately 26 % and 
44 %, respectively. Similar roles for NADPH : cytochrome P450 enzymes have been 
reported for other A-oxides such as tirapazamine (Riley et a i,  1993), and the tertiary 
amine A-oxides (Sugiura et al., 1976). In contrast, however, some studies (Walton et al., 
1992b) have previously reported an increase in the level of metabolism in the presence of 
the type I ligand, SKF 525A. Proposed mechanisms for this effect, have suggested that an 
increase in NADPH : cytochrome P450 reduction occurs in the presence of the ligand 
(Gigon et al. , 1969), or that the presence of the ligand causes shunting of electrons 
towards a more efficient NADPH : cytochrome P450 enzyme and hence causes an 
increase in metabolism (Walton et al., 1992b). It is important to note, however, that an 
aerobic preincubation step has been reported as a requirement for inhibition of drug 
metabolism by SKF 525A (Gillette & Sasame, 1964) and those studies performed 
previously by Walton and colleagues, did not involve such a step. Subsequent studies 
involving tirapazamine and SKF 525A inhibition have shown that in the presence of an
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aerobic preincubation step, approximately 58 % inhibition of metabolism occurs (Riley et 
al., 1993). Further analysis using chemical inhibitors suggested that the NADPH : 
cytochrome P450 Cyp 3a isoenzyme did not play a role in metabolism of ZM 81853, as 
no inhibition occurred in the presence of the macrolide antibiotic erythromycin (a 
substrate and competitive inhibitor of rat CYP3A subfamily (Wrighton et a l . , 1985)). In 
contrast, a low level of inhibition occurred in the presence of metyrapone (a type II ligand 
and inhibitor of NADPH : cytochrome P450 Cyp 2a, Cyp 2b, Cyp 2c and Cyp 3a 
isoenzymes (Riley et al., 1993 and references therein) suggesting the possible 
involvement of one or more of the aforementioned NADPH : cytochrome P450 
isoenzymes, other than Cyp 3a, in the metabolism of ZM 81853.
Previous studies have demonstrated an important role for rodent liver NADPH : 
cytochrome P450 reductase in the metabolism of tirapazamine (Fitzsimmons et al., 1994; 
Riley et al., 1993). In contrast, no direct role for NADPH : cytochrome P450 reductase 
has been reported for the tertiary amine A-oxides (Sugiura et al., 1976), although these 
studies were with rat rather than mouse liver microsomes. As for total NADPH : 
cytochrome P450 content, NADPH : cytochrome P450 reductase activity has been shown 
to be increased in DEX-induced mouse liver microsomes (Riley et al., 1993). In this 
present study, metabolism of ZM 81853 by DEX-induced microsomes was inhibited by 
approximately 94 % in the presence of thallium chloride, a known inhibitor of NADPH : 
cytochrome P450 reductase (Woods & Fowler, 1984). This result was further supported 
by the extensive inhibition which occurred in the presence of DIPC, an alternative 
inhibitor of NADPH : cytochrome P450 reductase (Tew, 1993). These results strongly 
suggest that NADPH : cytochrome P450 reductase was the enzyme predominantly 
responsible for metabolism of ZM 81853 in the presence of DEX-induced mouse liver 
microsomes. This is in agreement with the possible role of NADPH : cytochrome P450 
reductase in the hypoxic-selective cytotoxicity of ZM 81853, as demonstrated in Chapter 
4 of this thesis. Therefore, the results of the metabolism studies further support the view 
that NADPH : cytochrome P450 reductase may play an important role in the hypoxia- 
selective activity of ZM 81853. A secondary role for NADPH : cytochrome P450
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enzymes was also suggested by the inhibition of metabolism in the presence of CO or 
SKF 525A. Whilst the specificity of CO for haem-containing enzymes such as NADPH : 
cytochrome P450 enzymes is known to be due to the irreversible binding to the haem 
group within the enzyme structure, the specifity of SKF 525A is less clearly understood. 
In the presence of SKF 525A, inhibition of metabolism was approximately 17% greater 
than CO suggesting that inhibition of enzymes other than the NADPH : cytochrome P450 
family may have occurred. SKF 525A was in fact shown to cause almost complete 
inhibition of ZM 81853 metabolism in the presence of a purified, recombinant form of 
human NADPH : cytochrome P450 reductase (data not shown), thereby helping to 
explain the higher level of inhibition obtained in the presence of the ligand.
Metabolism of ZM 81853 in the presence of cytosolic protein was also studied. 
The rate was again shown to be greater in the presence of the DEX-induced enzyme 
preparation. However, the actual rate of metabolism was significantly lower (3.5-fold) 
than that in the presence of microsomal proteins. Interestingly, the observed rate of ZM 
81853 loss (17.4 nmol ZM 81853 lost/min/mg of protein) in the presence of mouse liver 
cytosol was approximately 3-fold greater than that of the di-A-oxide, tirapazamine (5 
nmol/min/mg) (Walton &lAorkman, 1990). However, in the latter case metabolism was 
performed in the presence of a non-induced cytosolic preparation. The fact that 
metabolism of ZM 81853 was higher in the presence of the DEX-induced cytosol was 
interesting as DEX treatment has been previously shown by Riley et al (Riley et al., 
1993) to significantly increase the activity of the 2-electron reducing enzyme DT- 
diaphorase within the microsomal fraction of mouse livers. It may therefore be possible 
that induction within the mouse liver cytosol also occurs. Importantly, however, 
metabolism was shown to be fully dependent upon NADPH as a cofactor indicating that 
the enzyme(s) involved in metabolism would utilise only NADPH. This finding, 
therefore, ruled out a role for DT-diaphorase in the metabolism of ZM 81853 as this 
enzyme has the ability to utilise both NADH and NADPH equally (Emster et a l . , 1962). 
These results are in sharp contrast to those of tirapazamine for which reduction displayed 
an equal dependence upon both NADH and NADPH for metabolism in the presence of
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cytosolic protein, and for which metabolism was shown to involve DT-diaphorase 
(Walton & Workman, 1990). These results with tirapazamine were confirmed by the use 
of a purified human preparation of DT-diaphorase in which equal dependence for NADH 
and NADPH was displayed (Walker et al. , 1994). Further analysis using either 
dicoumarol, an known inhibitor of DT-diaphorase (Segura-Aguilar et al. , 1990), or rutin, 
a potent inhibitor of carbonyl reductase (Wermuth, 1981), revealed that both inhibitors 
caused approximately 58 % inhibition of ZM 81853 metabolism. Inhibition in the 
presence of dicoumarol alone was shown to be statistically non-significant. However, it 
was clear that a reasonable level of inhibition could be obtained. Dicoumarol, once 
considered to be a very specific inhibitor of DT-diaphorase (Dulhanty et al. , 1989; Keyes 
et al. , 1985), is now known to inhibit a large number of enzymes including NADH : 
cytochrome b5 reductase (Hodnick & Sartorelli, 1993; Preusch et al. , 1991) and some 
forms of carbonyl reductase (Maser & Netter, 1989). Therefore, due to the similar levels 
of inhibition and the possible cross reactivity for carbonyl reductase, it was felt that 
metabolism of ZM 81853 in the presence of DEX-induced mouse liver cytosol may be 
due to a NADPH-utilising carbonyl reductase enzyme, most likely via 2-electron 
reduction of the compound. A possible complication in this hypothesis is that in the 
presence of both inhibitors, the percentage inhibition is reduced to only 27 %. However, 
the reasons for this observation are unclear at this stage.
The novel quinoxaline di-A-oxide ZM 81853 appears, therefore, to be reduced by 
carbonyl reductase and, more predominantly, by NADPH : cytochrome P450 reductase 
from mouse liver under hypoxic conditions. Mass spectroscopy following reduction of 
ZM 81853 by DEX-induced mouse liver microsomes suggested that the predominant 
reduction product may have a MWt of 206 (see Section 6.3.7 for explanation). This 
information indicated, therefore, that the reduction product may result from four-electron 
reduction of ZM 81853 (MWt. 202). Although these studies were not performed 
following DEX-induced cytosolic metabolism, results from HPLC analysis suggested that 
the predominant product was, in fact, the same species, as retention time and wavelength 
spectra were identical (data not shown). Collectively, therefore, these results suggest that
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ZM 81853 can undergo a series of one-electron reductions by NADPH : cytochrome 
P450 reductase to yield a four electron reduced product. In addition, they suggest that ZM 
81853 may also undergo a two-electron reduction pathway by carbonyl reductase to form 
the same four-electron reduced product. Certainly in the case of NADPH : cytochrome 
P450 reductase these results are in agreement with the proposed role of this enzyme in the 
metabolism of ZM 81853 to a cytotoxic species under hypoxic conditions.
Metabolism of the structurally-related quinoxalines to cytotoxic species was 
investigated to determine possible reasons as to why these compounds were not active in 
the human tumour cell lines (Chapter 4). The parent unsubstituted quinoxaline ZM 8173, 
and two other substituted quinoxalines ZM 12557 and ZM 65086 were found to be 
inactive as substrates for both microsomal and cytosolic enzyme preparations under 
hypoxic conditions. Although these latter studies were performed in the presence of 
mouse enzymes (as opposed to human), the results do support earlier suggestions that the 
compounds lacked the ability to be metabolised to active species under hypoxic 
conditions. As discussed previously in Chapter 4 (Section 4.4), this may be due to the fact 
that the compounds possess inappropriate reduction potentials for reduction by enzymes 
present within the human cells or the mouse liver fractions. The influence of reduction 
potentials (one-electron) of a range of nitro-compounds on cytotoxicity towards Chinese 
hamster V79 cells was clearly demonstrated by Adams and colleagues (Adams et a i  , 
1980). More recently, a direct correlation between reduction potential and rate of 
reduction by NADPH : cytochrome P450 reductase has been demonstrated (Butler & 
Hoey, 1993). Morecroft and colleagues (Morecroft et al. , 1994) also demonstrated a 
correlation between reduction potentials of a series of tirapazamine analogues and their 
ability to be metabolised by NADPH : cytochrome P450 reductase. Therefore this aspect 
is clearly important when analysing the ability of compounds to act as bioreductive 
cytotoxins.
In contrast to the other quinoxalines, ZM 10309 exhibited some degree of 
reduction by both mouse liver microsomes and cytosol, although the rate of loss of the 
compound was significantly lower than that of ZM 81853. The cytotoxicity studies had
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previously revealed that although ZM 10309 showed no notable HCR, the IC50 values 
for this compound under both oxic and hypoxic conditions were the lowest, and therefore 
most potent, for all of the four structurally-related compounds in question. It appears, 
therefore, that ZM 10309 was metabolised but at only a low level under both oxic and 
hypoxic conditions and hence exhibited no hypoxic-selectivity.
In summary, the preferential metabolic activation of ZM 81853 under hypoxic 
conditions was confirmed with the use of mouse liver enzyme preparations. In addition, 
chemical inhibition studies revealed that the one-electron reducing enzyme NADPH : 
cytochrome P450 reductase may be the principal enzyme responsible for activation of 
ZM 81853 under hypoxic conditions. This was certainly suggested in the cytotoxicity 
studies, as the highest HCR value was obtained in the human tumour cell line with the 
greatest NADPH : cytochrome P450 reductase activity (Chapter 4). Roles for one or more 
of the NADPH : cytochrome P450 isoenzymes Cyp 2a, Cyp 2b or Cyp 2c, and also 
carbonyl reductase were also indicated in this study. Furthermore, mass spectroscopy 
suggested that the predominant product was a four-electron reduced product. 
Interestingly, three out of four structurally-related quinoxaline compounds did not act as 
substrates for mouse liver enzymes, thereby suggesting that the lack of cytotoxicity 
observed (Chapter 4) was due to a lack of metabolic activation of the compounds. 
Although ZM 10309 did undergo metabolism under hypoxic conditions, it was to a much 
lesser degree than for ZM 81853. Collectively this study supports the cytotoxicity data by 
indicating that small changes in the quinoxaline structure clearly affect the ability of the 
compound to be metabolised, and hence exert its activity under hypoxic conditions. 
Although strongly implicated, the present results do not provide direct evidence for a role 
of NADPH : cytochrome P450 reductase in the cytotoxic effects of ZM 81853. Purified 
enzyme preparations can be extremely valuable in establishing such roles. Chapter 7 
describes an investigation to establish the ability of a purified, recombinant preparation of 
human NADPH : cytochrome P450 reductase to reduce ZM 81853 to a DNA damaging 
species.
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CHAPTER 7 
ZM 81853 METABOLISM : KINETIC ANALYSIS AND ABILITY TO CAUSE 
DNA DAMAGE
7.1 Introduction
ZM 81853 has been shown to be metabolised under hypoxic conditions by both DEX- 
induced mouse liver microsomes and cytosol (Chapter 6). Furthermore, chemical 
inhibition studies in the presence of DEX-induced mouse liver microsomes and cytosol 
indicated a predominant role for NADPH : cytochrome P450 reductase in the metabolism 
of ZM 81853 under hypoxic conditions. In this current chapter, the kinetics of ZM 81853 
metabolism in the presence of DEX-induced mouse liver microsomes and cytosol were 
investigated as a means of comparing ZM 81853 to other established bioreductive agents. 
The potential role of NADPH : cytochrome P450 reductase was examined more 
specifically by studying the kinetics of ZM 81853 metabolism in the presence of a 
purified, recombinant human form of the enzyme. In order to establish a direct role for 
the NADPH : cytochrome P450 reductase in the selective toxicity observed within 
tumour cell lines, the ability of this enzyme to metabolise ZM 81853 to a DNA damaging 
species under hypoxic conditions was also examined. Although chemical inhibition 
studies indicated a role for carbonyl reductase in the metabolism of ZM 81853 by 
cytosolic proteins, no purified enzyme preparation was available to study such a role. 
Since dicoumarol had been shown to inhibit metabolism and a purified, recombinant form 
of human DT-diaphorase was available, this was used to determine the possible role of 
this enzyme in ZM 81853 metabolism.
The enzymology of bioreductive anticancer agents has been proposed as an 
important factor in future drug development programmes (Workman & Walton, 1990). 
To date, a number of potential bioreductive anticancer agents have been studied in detail 
to determine which enzymes are involved in metabolism. For example, the benzotriazine
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di-A-oxide tirapazamine is known to be metabolised by one-electron reducing enzymes 
such as NADPH : cytochrome P450s and NADPH : cytochrome P450 reductase (Riley et 
al. , 1993; Walton et al. , 1992b), and by two-electron reducing enzymes such as DT- 
diaphorase (Riley & Workman, 1992b). Furthermore, DT-diaphorase has been shown to 
be involved in metabolism of the novel indoloquinone, E09 (Walton et al. , 1991) and 
also the dinitrobenzamide, CB 1954 (Boland et al. , 1991). It would be reasonable, 
therefore, to predict that tumours rich in enzymes such as NADPH : cytochrome P450 
reductase and DT-diaphorase would be susceptible to the actions of these bioreductive 
agents.
In addition to determining those enzymes involved in the metabolism of 
bioreductive agents, it is also important to establish the level of efficiency with which 
metabolism occurs. This can be achieved by performing kinetic analysis to determine the 
Wmax (maximum rate of reaction) and YJn (substrate concentration at which Vmax is half 
its maximum rate) of the enzyme-catalysed reaction (Henderson, 1978). By establishing 
such parameters for individual bioreductive agents, comparisons between the efficiency 
of metabolism of such agents could then be made. In the previous chapter, mouse liver 
enzymes were shown to metabolise ZM 81853 under hypoxic conditions. Here kinetic 
analysis of these reactions were performed in the presence of both DEX-induced mouse 
liver microsomes and cytosol in order to allow comparisons between ZM 81853 and other 
A-oxides such as tirapazamine and the tertiary A-oxides (Sugiura et al. , 1976; Walton & 
Workman, 1990). Studies of this nature can also be performed in the presence of purified 
enzyme preparations to establish more conclusively a direct role for specific enzymes in 
the metabolism of bioreductive agents. Chemical inhibition studies (Chapter 6) 
previously indicated that NADPH : cytochrome P450 reductase played a predominant 
role in metabolism of ZM 81853 by DEX-induced microsomal proteins under hypoxic 
conditions. For this reason, the ability of a purified, recombinant human form of the 
enzyme to metabolise ZM 81853 was investigated and kinetic parameters of metabolism 
determined. Similar studies were undertaken in the presence of a purified, recombinant
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form of human DT-diaphorase since no such preparations were available for carbonyl 
reductase. The results of the kinetic analysis are described in this chapter.
Both the cytotoxicity (Chapter 4) and chemical inhibition (Chapter 6) studies 
indicated that ZM 81853 may undergo a similar pathway of activation to that of 
tirapazamine. Tirapazamine has previously been shown to be metabolised under hypoxic 
conditions by purified rat (Fitzsimmons et al. , 1994) and human (Walker et a l . , 1994) 
NADPH : cytochrome P450 reductase to a DNA damaging species, believed to be a 
nitroxide radical (Lloyd et al. , 1991). Similar studies were performed, therefore, to 
investigate the ability of ZM 81853 to be metabolised to a DNA damaging species by a 
purified, recombinant form of human NADPH : cytochrome P450 reductase. The results 
of this investigation are also described here.
110
7.2 Materials and Methods
7.2.1. Chemicals and Reagents
All general chemicals and solvents (of the highest grade commercially available) 
were purchased from Sigma Chemical Company (Poole, Dorset, U.K.) or Fisons pic. 
(Loughborough, U.K.) unless otherwise stated. Zero grade nitrogen (< 5 vpm O2) was
obtained from the British Oxygen Company (London, U.K.).
7.2.2. Enzyme Sources
DEX-induced microsomal and cytosolic fractions were prepared as previously 
detailed in Section 6.2.2. A highly purified, recombinant form of human NADPH : 
cytochrome P450 reductase was kindly provided by Prof. C. R. Wolf (ICRF Department 
of Molecular Pharmacology, Dundee, U.K.). Purified, recombinant human DT-diaphorase 
was also kindly provided by Dr. S. Chen (City of Hope, Duarte, CA, U.S.A.) (Chen et a i  
, 1995). In all four cases, total protein content was determined using the Pierce Microtiter 
Plate BCA assay (detailed in Section 2.2.5.). Activity of the purified, recombinant forms 
of the human enzymes were determined spectrophotometrically using the cytochrome c 
reduction assay detailed in Section 2.2.6.
7.2.3. ZM 81853 Metabolism Under Hypoxic Conditions
Reductive metabolism of ZM 81853 and analysis of samples were carried out 
essentially as detailed in previous chapters (Sections 5.2.2. 6.2.3. and 6.2.4.). All 
reactions were performed under conditions in which the rate of loss of ZM 81853 was 
shown to be linear with respect to protein / activity level and time. A control reaction in 
the absence of cofactor was performed during each experiment. Reactions were pre­
incubated for 7 mins. under the flow of N% before initiation. In the case of DEX-induced
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mouse liver cytosol and microsomes, standard incubations contained 1.0 mg/ml or 0.3 
mg/ml protein, respectively, and 1 mM NADPH in a total volume of 1 ml 50 mM Tris 
HCl buffer, pH 7.4. Reactions were initiated by the addition of ZM 81853 in DMSO to 
give final substrate concentrations of 15 - 540 |iM. Aliquots (100 jil) were removed at 0 
and 7.5 mins. and added to 200 |il ice-cold methanol. Samples were then processed as 
described before (Section 6.2.3.).
For analysis in the presence of purified recombinant human enzyme, standard 
incubations contained 40 mU of NADPH : cytochrome P450 reductase activity (where 
lU  = Ijimol cytochrome c reduced/min/mg protein measured at 37®C) and 1 mM 
NADPH in a total volume of 1 ml 50 mM Tris HCl buffer, pH 7.4. This level of activity 
had been shown to metabolise ZM 81853 successfully (data not shown). Reactions were 
initiated by the addition of ZM 81853 in DMSO to give final substrate concentrations of 
30 - 800 |liM. Aliquots (100 |il) were removed at 0 and 10 mins. in this case, and were 
added to 200 p-l ice-cold methanol. Samples were processed as described before (Section
6.2.3.). Similar studies were performed in the presence of the structurally-related 
quinoxaline ZM 10309 as it was the only other compound to be metabolised in the 
presence of mouse liver enzymes (Chapter 6).
Reductive metabolism of ZM 81853 in the presence of a purified, recombinant 
form of human DT-diaphorase was performed using a range of enzyme activities (up to 
1400 mU (lU  = l|imol cytochrome c reduced/min/mg protein measured at 37°C)). In this 
case, incubations contained 1 mM NADH as cofactor. Aliquots of the reaction mixture 
were processed as above.
7.2.4. Kinetic Analysis
Michaelis-Menten enzyme kinetics were defined under optimal conditions for ZM 
81853 using the criteria described by Henderson (Henderson, 1978). Apparent YJn, Wmax 
and Kcat were determined by computer graphics analysis (Enzyme Kinetics, Trinity 
Software, Campton, NH, U.S.A.) using a total of nine different substrate concentrations.
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Y^cat is defined as the catalytic constant of the enzyme and describes the capacity of the 
enzyme-substrate complex to form the product under saturating substrate conditions. As 
these conditions are unlikely to be achieved intracellularly, however, Yicat/Km  can be a 
more useful parameter as this takes into consideration non-saturable conditions. The ratio 
Vmax ! Km was also determined to enable comparisons of overall activity of different 
substrates.
7.2.5. DNA Damage Assays
The ability of purified, recombinant human NADPH : cytochrome P450 reductase 
to activate ZM 81853 to a DNA damaging species under both oxic and hypoxic 
conditions was investigated in vitro by measuring the level of conversion of a supercoiled 
preparation (form I) of plasmid pBR322 DNA (Boehringer Mannheim, East Sussex, 
U.K.) to the relaxed, circular configuration (form II) or the linearised conformation (form 
III). Incubation mixtures contained ZM 81853 (9.4 - 600 jJ.M) with NADPH (1 mM), 
pBR322 DNA (1000 ng) and purified, recombinant NADPH : cytochrome P450 
reductase (0.039 - 60 mU) in a total volume of 60 pi of 100 mM sodium phosphate 
buffer, pH 7.4. Superoxide dismutase (SOD) (150 - 600 pg/ml) and catalase (150 - 600 
pg/ml) were also added to some of the reactions. NADPH : cytochrome P450 reductase 
(40 mU) was added to all reactions (except those investigating effect of enzyme 
concentration) at the equivalent activity to that used in the previous metabolism studies 
(Section 7.2.3.). Control incubations omitted various reagents, while boiled enzyme 
preparations were used as an inactive enzyme control. Hypoxic reaction mixtures were 
pre-incubated in sealed vials under N% at 37°C for 2 mins. before the addition of ZM
81853 through air-tight seals to initiate the reaction. The reactions were then incubated 
for a further 30 mins. before being stopped by the addition of 15 pi of stop buffer (5 mM 
EDTA, 0.5 % SDS, 60 % (v/v) glycerol and 0.1 % (v/v) bromophenol blue). Oxic 
reaction mixtures were incubated in vials open to the air for 30 mins. at 37®C following
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initiation of the reaction by the addition of ZM 81853. Reactions were stopped as 
described above.
Aliquots (25 pi) of stopped reaction mixtures were added to a horizontal 1 % 
(w/v) agarose gel (20 x 24 cm) and electrophoresed at 40 Volts for 15 - 20 hrs. at room 
temperature. DNA in gels was stained with ethidium bromide (0.5 pg/ml) and 
photographed under UV transillumination (TF 35M UV box, Vilber Lourmat, Marne La 
Vallee, France). Densitometric analysis was performed using a Molecular Dynamics 
Laser Densitometer with Image Analysis Software (Protein Databases Incorporated, NY, 
U.S.A.). Correction factors were employed to account for differential staining of DNA 
forms by ethidium bromide.
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7.3 Results
7.3.1 Kinetics of ZM 81853 Metabolism by Mouse Liver Enzymes
ZM 81853 has previously been shown to be metabolised in the presence of both 
DEX-induced mouse liver microsomes and cytosol, although in the latter case, 
metabolism was demonstrated to be significantly lower (Chapter 6).
Metabolism of ZM 81853 by cytosolic protein was shown to conform to 
Michaelis-Menten kinetics. This was indicated by the plots of V versus S (Figure 7.1 A), 
which gave rectangular hyperbolae, and by the linear nature of the Hanes-Woolf plots 
(Figures 7. IB). Values of apparent Kwi and Wmax (mean + SD, n=3) were obtained using 
five different kinetics plots and were in the range 56 - 198 pM for Km and 11-21  nmol 
of ZM 81853 lost/min/mg protein for Wmax. The kinetic parameters for non-linear 
regression and Hanes-Woolf analysis are shown in Table 7.1. In addition Wmax / Km 
ratios were calculated and found to be 0.13 and 0.12, depending upon the type of analysis 
employed.
Similar studies to investigate the kinetics of ZM 81853 metabolism by 
microsomal protein also indicated that metabolism conformed to Michaelis-Menten 
kinetics. Plots of V versus S (Figure 7.2A) and Hanes-Woolf plots (Figure 7.2B) are 
shown. As before, values of apparent Km and Wmax (mean + SD, n=3) were obtained 
using five different kinetics plots and were in the range 208 - 518 pM for Km and 131 - 
238 nmol of ZM 81853 lost/min/mg protein for Wmax. The kinetic parameters for non­
linear regression and Hanes-Woolf analysis are shown in Table 7.2, including ratios for 
W max/Km  of 0.51 and 0.46.
7.3.2. Kinetics of ZM 81853 and ZM 10309 Metabolism by Purified,
Recombinant Human Enzymes
Purified, recombinant human NADPH : cytochrome P450 reductase was found to 
catalyse the reduction of ZM 81853. Chromatogram analysis indicated that one
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Figure 7.1 Typical plot of V versus 5 (A) and corresponding Hanes-Woolf linear 
transformation plot (B) for ZM 81853 metabolism by DEX-induced 
mouse liver cytosol.
Units of S and V are pM and nmol of ZM 81853 lost/min/mg protein, respectively.
Parameter Non-linear regression Hanes-Woolf
Km (pM) 121.3 ±  35.9 130.4 ±30.7
\m a x  (nmol/min/mg) 15.6 ±3.0 15.2 ±3 .0
\m a x lY im  ratio 0.13 0.12
Table 7.1 Michaelis-Menten parameters for ZM 81853 loss following 
metabolism by DEX-induced mouse liver cytosol in vitro.
Values were obtained from three independent experiments, each with nine substrate 
concentrations. Km and Vmax values represent a mean + SD, n=3.
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Figure 7.2 Typical plot of V versus 5 (A) and corresponding Hanes-Woolf
linear transformation plot (B) for ZM 81853 metabolism by DEX- 
induced mouse liver microsomes.
Units of S and V are fiM and nmol of ZM 81853 lost/min/mg protein respectively.
Parameter Non-linear regression Hanes-Woolf
Km (pM) 319.2 ±82.9 374.3 ±  51.1
Wmax (nmol/min/mg) 162.5 ±27.6 170.9 ±22.2
\m a x  1 Km ratio 0.51 0.46
Table 7.2 Michaelis-Menten parameters for ZM 81853 loss following
metabolism by DEX-induced mouse liver microsomes in vitro.
Values were obtained from three independent experiments, each with nine substrate 
concentrations. Km and Nrhax values represent a mean + SD, n=3.
predominant new peak eluted at approximately 16 mins., closely similar to previous 
studies involving DEX-induced mouse liver microsomes (Chapter 6, Figure 6.4). 
Reduction was shown to be dependent upon NADPH as cofactor. Furthermore, progress 
curves for ZM 81853 loss were linear with time up to at least 10 mins. at all substrate 
concentrations used.
Loss of ZM 81853 in the presence of NADPH : cytochrome P450 reductase was 
shown to conform to Michaelis-Menten kinetics, with plots of V versus S (Figure 7.3A) 
showing the expected rectangular hyperbolae, and Hanes-Woolf plots being linear in 
nature (Figure 7.3B). As with those studies detailed above, kinetic parameters were 
determined using five different plots and were in the range of 59 - 327 |iM for Km and 
3075 - 6800 nmol of ZM 81853 lost/min/mg protein for Wmax. The parameters for non­
linear regression and Hanes-Woolf analysis are shown in Table 7.3. The additional 
parameters of Kcat and Kcat/Km were also determined, as was the ratio Wmax /  Km. 
Interestingly, studies with purified, recombinant human DT-diaphorase produced no 
metabolism of ZM 81853, even at enzyme concentrations as high as 1400 mU.
The structurally-related quinoxaline ZM 10309 had been shown to be metabolised 
by DEX-induced mouse liver enzymes, although at a lower rate than ZM 81853 (Chapter 
6). Kinetic analysis of ZM 10309 metabolism by NADPH : cytochrome P450 reductase 
was performed in order to compare the two quinoxaline compounds. Although 
metabolism of ZM 10309 by purified, recombinant NADPH : cytochrome P450 reductase 
was detected (data not shown), loss of ZM 10309 was not linear and did not conform to 
Michaelis-Menten kinetics.
7.3.3. DNA damage in the presence of ZM 81853 and NADPH : cytochrome
P450 reductase
From chemical inhibition studies (Chapter 6) and those detailed above, ZM 81853 
appears to be metabolised predominantly by the one-electron reducing enzyme NADPH : 
cytochrome P450 reductase under hypoxic conditions. In addition, ZM 81853 was shown
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Figure 7.3 Typical plot of V versus S (A) and corresponding Hanes-Woolf linear 
transformation plot (B) for ZM 81853 metabolism by purified, 
recombinant human NADPH : cytochrome P450 reductase.
Units of 5 and V are pM and nmol of ZM 81853 lost/min/mg protein, respectively.
Parameter Non-linear regression Hanes-Woolf
Km (|iM) 289.8 ±61.8 241.8 ±42.8
y  max (nmol/min/mg) 5825.4 ±397.0 5264.4 ±708.7
Kcat (/s) 7.6 ± 0.5 6.8 ±0.9
Kcat I Km (/|aM s) 0.03 ± 0.01 0.03 ± 0
Vma%/ Km ratio 20.1 21.8
Table 7.3 Michaelis-Menten parameters for ZM 81853 loss following
metabolism by purified, recombinant human NADPH : cytochrome 
P450 reductase in vitro.
Values were obtained from three independent experiments, each with nine substrate 
concentrations. Km and Nmax values represent a mean + SD, n=3.
to exhibit similar cytotoxic characteristics as tirapazamine in each of the cell lines studied 
(Chapter 4). In particular, this was the case in the cell line possessing the highest 
NADPH : cytochrome P450 reductase activity. Tirapazamine has been shown previously 
to cause DNA damage when activated by purified rat and human preparations of NADPH 
: cytochrome P450 reductase (Fitzsimmons et al., 1994; Walker et al., 1994). Similar 
studies were undertaken with ZM 81853 to determine whether this compound could also 
be activated by human NADPH : cytochrome P450 reductase to a DNA damaging species 
under hypoxic conditions.
Initially, the extent of DNA damage in the presence of increasing concentrations 
of ZM 81853 (0 - 600 fiM) was investigated. These concentrations were selected as they 
were in the range used for kinetic analysis. Figure 7.4 demonstrates the results of such an 
experiment. With the exception of one result (Figure 7.4, lane 10), DNA damage was 
seen to become more extensive with increasing ZM 81853 concentration (Figure 7.4, 
lanes 4 - 11). No sample was detected in the case of 300 |iM ZM 81853 (Figure 7.4, lane 
10), possibly due to lack of movement from the loading well. DNA damage was seen, 
however, in a repeat experiment. Interestingly, DNA damage was not complete even at 
the highest concentration x)f ZM 81853 (600 pM).
Although NADPH : cytochrome P450 reductase had been used above at an 
activity of 40 mU (the concentration used in kinetic analysis), the ability of ZM 81853 to 
be metabolised to a DNA damaging species in the presence of a range of enzyme 
concentrations was investigated. Figure 7.5 shows the ability of NADPH : cytochrome 
P450 reductase to cause conversion of ZM 81853 to a DNA damaging species at a variety 
of different concentrations (0.039 - 2.5 mU per assay). Considerable damage was 
observed at enzyme concentrations as low as 0.3 mil. A repeat experiment which further 
extended the range of enzyme concentrations used to 60 mU (not shown) confirmed that 
at concentrations of 1.25 mU and above, DNA damage was considerable, i.e. 
approximately 80% conversion.
Finally, the possible influence of oxygen on the ability of ZM 81853 to be 
metabolised to a DNA damaging species was investigated. Conditions used for the assay.
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Figure 7.4 (A) Dose-dependent effect of increasing ZM 81853 concentration on
DNA damage induced in plasmid pBR322 DNA by purified, 
recombinant human NADPH : cytochrome P450 reductase and (B) 
the corresponding densitometric analysis [open bar, supercoiled 
plasmid DNA (form I); hatched bar, relaxed, circular plasmid DNA 
(form II)].
Lanes 1 - 3 are controls: (1) plasmid DNA (1000 ng) alone, (2) DNA with enzyme (40 
mU) and 600 |iM ZM 81853 (no cofactor), (3) DNA with 600 jiM ZM 81853 and 
NADPH (no enzyme). Lanes 4 - 1 1  show the effect of increasing concentrations of ZM 
81853 (0, 9.4, 18.8, 37.5, 75, 150, 300 and 600 p.M) in the complete system. Molecular 
weight markers are present on the extreme left and right of the gel. Results represent one 
of two repeat experiments.
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Figure 7.5 (A) Effect of increasing enzyme concentration on DNA damage
induced in plasmid pBR322 DNA by purified, recombinant human 
NADPH : cytochrome P450 reductase and (B) the corresponding 
densitometric analysis [open bar, supercoiled plasmid DNA (form I); 
hatched bar, relaxed, circular plasmid DNA (form II)].
Lanes 1 - 3 are controls: (1) plasmid DNA (1000 ng) alone, (2) DNA with enzyme (2.5 
mU) and 300 |iM ZM 81853 (no cofactor), (3) DNA with ZM 81853 and NADPH (no 
enzyme). Lanes 4 - 1 1  show the effect of increasing concentrations of NADPH : 
cytochrome P450 reductase (0.039, 0.078, 0.156, 0.3125, 0.625, 1.25 and 2.5 mU) in the 
complete system. Molecular weight markers are present on the extreme left and right of 
the gel. Results represent one of two repeat experiments.
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i.e. ZM 81853 concentration and NADPH : cytochrome P450 reductase concentration, 
were those used previously in the kinetic studies, and shown to produce DNA damage 
(experiments above). Figure 7.6 shows the effect of hypoxic and oxic conditions, 
respectively, on the damage induced in plasmid DNA following metabolism of ZM 
81853. Various control incubations were performed under hypoxic (Figure 7.6, Lanes 1 - 
8, see figure legend) and oxic conditions (not shown). The effect of increasing 
concentrations of SOD and catalase on the level of DNA damage under hypoxic 
conditions is shown in lanes 9 - 11 ,  while damage in the absence of SOD and catalase is 
shown in lane 12. The same incubations performed under oxic conditions are shown in 
lanes 13 - 16. Both the gel (Figure 7.6A) and the densitometry data (Figure 7.6B) 
indicated that the background level of relaxed, circular DNA (Form II) was not 
significantly altered under different control conditions (lanes 1 - 8). This background 
level did not rise above approximately 35% of total DNA. Similar observations were 
made under oxic conditions. Clearly, this basal level of relaxed, circular DNA was 
present in the original preparation of plasmid DNA.
DNA damage occurred under both hypoxic and oxic conditions (lanes 12 and 16, 
respectively). In both cases, metabolism of ZM 81853 by NADPH : cytochrome P450 
reductase resulted in conversion of the supercoiled plasmid DNA (Form I) to the relaxed, 
circular form (Form II), indicative of single strand breaks (Figiu*e 7.6, lanes 12 and 16). 
No evidence for the occurrence of double strand breaks was seen. Importantly, however, 
the level of conversion under hypoxic conditions was approximately 60% higher than 
under oxic conditions (Figure 7.6B, lanes 12 and 16). DNA damage in the presence of 
SOD and catalase was reduced by approximately 20 - 30% under hypoxic conditions 
(Figure 7.6, lanes 9 -11). In contrast, however, the presence of SOD and catalase under 
oxic conditions reduced the level of DNA damage observed by approximately 50% 
(Figure 7.6A and B, lanes 13 - 16).
Although ZM 10309 had been demonstrated to be metabolised by mouse liver 
enzymes (Chapter 6), the level of metabolism was significantly lower than for ZM 81853.
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Figure 7.6 (A) Effect of hypoxic versus oxic conditions on the damage induced in
plasmid pBR322 DNA by the reduction of ZM 81853 by purified, 
recombinant human NADPH : cytochrome P450 reductase and (B) 
the corresponding densitometric analysis [open bar, supercoiled 
plasmid DNA (form I); hatched bar, relaxed, circular plasmid DNA 
(form II)].
Lanes 1 - 1 2  represent hypoxic incubations. Lanes 1 - 8 are controls: (1) plasmid DNA 
(1000 ng) alone, (2) DNA with enzyme (40 mU), (3) DNA with ZM 81853 (300 |iM), (4) 
DNA with NADPH (1 mM), (5) DNA with enzyme and ZM 81853 (no cofactor), (6) 
DNA with ZM 81853 and NADPH (no enzyme), (7) DNA with enzyme and NADPH (no 
ZM 81853) and (8) DNA with boiled enzyme, ZM 81853 and cofactor. Lanes 9 - 1 1  
show the effect of increasing concentrations of SOD and catalase (150 - 600 M-g/ml) on 
the DNA damage in the complete system. Lane 12 shows the complete incubation 
reaction in he absence of SOD and catalase. Lanes 13 - 1 6  represent oxic incubations 
performed within the same experiment but samples were run on a separate gel. The effect 
of increasing SOD and catalase concentrations on DNA damage in the complete system 
are shown in lanes 13 - 15. Lane 16 shows the complete incubation reaction in the 
absence of SOD and catalase. Molecular weight markers are present on the extreme left 
of the gel. Results represent one of two repeat experiments.
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For this reason, and also due to a limited availability of ZM 10309, DNA damage assays 
were not performed using this compound.
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7.4 Discussion
ZM 81853 metabolism under hypoxic conditions has been demonstrated 
previously in the presence of mouse liver enzymes (Chapter 6). In order to establish the 
efficiency of bioreductive metabolism by particular enzyme preparations, kinetic analysis 
can be performed to determine the apparent affinity (Km) and also the rate at which 
metabolism occurs (Vmax). Several studies have previously used enzyme kinetics as a 
means of investigating the association between metabolism of bioreductive agents and 
particular enzymes ; CB 1954 (Boland et a i, 1991); E09 (Walton et al., 1991); 
Tirapazamine (Fitzsimmons et a i, 1994; Walton & Workman, 1990); mitomycin C 
(Beall et al. , 1994a). In this current chapter, the kinetics of ZM 81853 metabolism by 
both DEX-induced mouse liver microsomes and cytosol have also been studied. The 
results suggest that although ZM 81853 may have a lower Km for cytosolic compared to 
microsomal enzymes (Km 130.4 |iM and 374.3 |iM, respectively), the speed of the 
reaction (Ym ax  ) was, in fact, considerably slower (15.2 compared with 170.9 
nmol/min/mg protein). The ratio Vmax / Km also indicated that ZM 81853 may be a 
better substrate for microsomal enzymes. To further investigate the possible role of 
NADPH : cytochrome P450 reductase in metabolism, and indeed, activation of ZM 
81853 under hypoxic conditions, kinetic analysis and DNA damage assays in the 
presence of a purified, recombinant human form of the enzyme were performed. ZM 
81853 was shown to be a good substrate for the enzyme (Km 241.8 |iM and Wmax
5264.4 nmol/min/mg protein) and, perhaps even more importantly, was also shown to be 
metabolised to a DNA damaging species under hypoxic conditions.
In this present study, the kinetics of ZM 81853 loss in the presence of DEX- 
induced mouse liver enzymes was investigated. ZM 81853 had previously been shown to 
be metabolised to a greater extent by microsomal as opposed to cytosolic enzymes 
(Chapter 6). This finding was further supported by the fact that the rate of reaction 
(Vmax) in the presence of microsomal enzymes was significantly higher than with 
cytosolic enzymes (approximately 11-fold, p<0.001). Interestingly, the Km of ZM 81853
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for microsomal enzymes was also significantly higher (approximately 3-fold, p<0.001). 
This may indicate a weaker interaction between the enzyme(s) and the substrate. The 
ratio Vmax /  Km also indicated that ZM 81853 may act as a better substrate for 
microsomal enzymes compared to cytosolic enzymes. Previous studies (Sugiura et al., 
1976) involving several N-oxides have shown that compounds such as imipramine N- 
oxide, tiaramide N-oxide and N, V-dimethylaniline V-oxide undergo reduction by rat liver 
microsomes. Km and Vmax values for these compounds were shown to be in the range 
0.2 - 0.4 mM and 2.5 - 3.2 nmol/min/mg protein. It is of interest, therefore, that although 
Km of the novel N-oxide ZM 81853 for mouse microsomal enzymes was higher than that 
obtained for cytosolic enzymes, it was in fact comparable with earlier studies of N-oxides 
(Sugiura et al., 1976). In addition, the rate of reduction was approximately 60-fold higher 
in the case of ZM 81853 (Vmax 170 compared to 2.9 nmol/min./mg protein), suggesting 
that this compound acts as a better substrate for reduction by microsomal enzymes. It is 
important to note, however, that the experiments by Sugiura et al (Sugiura et al. , 1976) 
were performed using microsomes isolated from different rodent species. It has been 
noted previously that differences in enzyme levels may be present as a result of species 
variation (Boobis et al. ~, 1990). More recently, Walton and colleagues (Walton & 
Workman, 1990) have reported Km and Vmax values in the range of 1.1 - 1.7 mM and 
790 - 1100 nmol SR 4233 lost/min/mg protein, respectively for metabolism of 
tirapazamine by mouse liver microsomes. Clearly, the rate of reduction of tirapazamine 
is much greater (approximately 11-fold) than for ZM 81853, although the Km value 
suggested that the interaction with microsomal enzymes may be higher in the latter case. 
Overall, however, tirapazamine appeared to be the better substrate for microsomal 
enzymes when compared to ZM 81853 as shown by the significantly higher ratio Vmax / 
Km (675 compared to 0.49).
From the present studies, therefore, ZM 81853 appears to be a better substrate for 
microsomal enzymes than the tertiary N-oxides, imipramine V-oxide, tiaramide N-oxide 
and N, V-dimethylaniline N-oxide, but, tirapazamine appeared to be significantly better 
again as a substrate for these enzymes.
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A role for both NADPH : cytochrome P450 reductase and NADPH : cytochrome 
P450s has been postulated for tirapazamine (Walton & Workman, 1990). Current studies 
suggest that a similar situation occurs in the case of ZM 81853 (Chapter 6). In contrast, 
however, only NADPH : cytochrome P450 enzymes have been shown to be responsible 
for metabolism of the tertiary A-oxides in the presence of rat microsomal protein (Sugiura 
et a i,  1976). NADPH : cytochrome P450 enzymes are known to be dependent upon the 
presence of NADPH : cytochrome P450 reductase for their metabolic activity (Peterson 
& Prough, 1986). The enhanced reduction efficiency observed for ZM 81853, and indeed 
for tirapazamine, may be a result of both a direct and an indirect role for NADPH : 
cytochrome P450 reductase in the metabolism of these compounds. The ability of 
NADPH : cytochrome P450 reductase to act directly on ZM 81853 was investigated with 
the use of a purified enzyme preparation. Similar studies were not performed with 
NADPH : cytochrome P450s or indeed, for carbonyl reductase, however, for two reasons 
; firstly, no purified enzyme preparations were available for use, and secondly, the role of 
these enzymes in the metabolism of ZM 81853 was shown to be only minimal (Chapter 
6).
To further investigate the direct involvement of NADPH : cytochrome P450 
reductase in the reductive metabolism of ZM 81853, kinetic analysis in the presence of 
purified, human NADPH : cytochrome P450 reductase was performed. Studies using 
enzymes purified from both rat and human livers have been previously reported for 
tirapazamine, and have confirmed a direct role for the involvement of NADPH : 
cytochrome P450 reductase in its reductive metabolism (Fitzsimmons et al., 1994; 
Walker et al., 1994). In this current study, metabolism of ZM 81853 was investigated in 
the presence of a purified, recombinant form of human NADPH : cytochrome P450 
reductase. Comparisons between different purified enzyme forms have been made and 
show that they act in a similar manner (Lewis, A.D., personal communication). In this 
particular study, ZM 81853 was shown to be a good substrate for purified NADPH : 
cytochrome P450 reductase with an apparent Km and Vmax of 241.8 |xM and 5264.4 
nmol of ZM 81853 lost/min/mg protein, respectively. The predominant involvement of
122
NADPH : cytochrome P450 reductase, as indicated by chemical inhibition studies 
(Chapter 6), was supported further by the fact that the Km values of 374.3 and 241.8 |iM 
for microsomes and purified enzyme, respectively, were similar. As expected, the rate of 
reduction of ZM 81853 by purified NADPH : cytochrome P450 reductase was at least 30- 
fold higher than that found in the presence of microsomal enzymes (5264.4 and 170.9 
nmol/min/mg protein respectively), once again emphasising an important and direct role 
for this enzyme in reduction. The Vmax / Km ratios, in this case, were 20.1 and 21.8 
dependent upon which kinetic plot was used, suggesting, as expected, that ZM 81853 was 
a better substrate for the purified enzyme preparation. Kcat (the enzyme tiunover number 
reflecting the absolute rate of ZM 81853 loss to the enzyme / substrate complex) was 
determined and shown to be in the range 6.8 - 7.6/s, dependent upon the analysis used. In 
addition, the parameter Kcat/Km, which takes into consideration non-saturable 
conditions, was also determined and shown to be 0.03/|aM/s. Previous studies with 
tirapazamine (Fitzsimmons et al., 1994) reported a Kcat /Km value in the range of 5.56 - 
6.54/mM/s for WIN 64012 formation following tirapazamine reduction by purified rat 
NADPH : cytochrome P450 reductase. It is important to remember, however, that the 
latter studies were performed in the presence of purified rat enzyme, and that Kcat/Km 
was in fact representative of metabolite formation, not compound loss. These two 
differences may account for the fact that ZM 81853 appeared to be the better substrate for 
NADPH : cytochrome P450 reductase.
Whilst a direct role for human NADPH : cytochrome P450 reductase in the 
metabolism of ZM 81853 has now been demonstrated in this chapter, the precise effect of 
reduction by this enzyme or indeed other one-electron-reducing enzymes within the cell 
remains unknown. Earlier cytotoxicity studies using a panel of human breast tumour cell 
lines revealed that ZM 81853 was capable of causing a high degree of selective toxicity 
under hypoxic conditions (Chapter 4). The selectivity of ZM 81853 was comparable with 
that observed for tirapazamine. The mechanism of action and hence, the observed 
cytotoxicity, for tirapazamine has been postulated to be through one-electron reduction to 
form a nitroxide free radical (Lloyd et al., 1991). This radical is believed to exert its
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effect by DNA damage via hydrogen abstraction from sugar residues. DNA damage 
arising from the reduction of tirapazamine in the presence of several one-electron- 
reducing enzymes has been demonstrated (Fitzsimmons et al., 1994; Laderoute et al. , 
1988; Walker et al., 1994). Due to the similarities between tirapazamine and ZM 81853 
in both cytotoxic effects (Chapter 4) and reduction in the presence of purified NADPH : 
cytochrome P450 reductase (this Chapter) it was thought likely that the novel compound, 
ZM 81853, would undergo a similar mechanism of action as tirapazamine. To investigate 
this further, DNA damage assays were performed. Under hypoxic conditions, ZM 81853 
was metabolised by purified human NADPH : cytochrome P450 reductase to a DNA 
damaging species capable of causing strand breaks in plasmid DNA. Complete 
conversion from the supercoiled plasmid DNA (Form I) to the relaxed, circular 
conformation (Form II) occurred, a result which was indicative of single strand breaks. 
DNA damage, however, was reduced by 20 - 30% in the presence of SOD and catalase. 
As SOD and catalase are known to interfere with the action of oxygen radicals (Fisher & 
Gutierrez, 1991), this result suggested that incomplete expulsion of air had occurred 
during the experiment. If this had been the case, back-oxidation to ZM 81853 from the 
reduction product could have occurred with the production of oxygen radicals as a by­
product. This is similar to the explanation postulated for a similar effect shown with 
tirapazamine (Fitzsimmons et al., 1994). The remaining damage (70 - 80%), however, 
was not affected by the presence of SOD and catalase and therefore may have been 
caused by the formation of radicals such as nitroxides, as shown for tirapazamine 
(Fitzsimmons et al., 1994; Lloyd et a i,  1991). Further studies involving, for example, 
electron spin resonance (ESR), would be required in order to identify the exact nature of 
any such radical. In contrast to the damage seen under hypoxic conditions, the degree of 
damage under oxic conditions was much lower (approximately 40% conversion to the 
relaxed, circular configuration). The presence of SOD and catalase, however, reduced the 
level of damage still further, resulting in only 10 - 20% conversion of the DNA to the 
relaxed, circular configuration (Form II). This finding suggested that oxygen radicals 
such as superoxide are involved in the DNA damage observed under oxic conditions. The
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oxygen radicals would form by back-oxidation from the reduction product. Importantly, 
however, complete inhibition by SOD and catalase was not achieved, thereby implying 
that other radicals such as nitroxides play a role in DNA damage even under oxic 
conditions. Similar conclusions were made from the studies on tirapazamine in the 
presence of purified rat and human NADPH : cytochrome P450 reductase (Fitzsimmons 
et a i ,  1994; Walker et a i, 1994). Importantly, ZM 81853 did not produce double strand 
breaks in the DNA even at high enzyme and drug concentrations, unlike tirapazamine 
(Fitzsimmons et aL, 1994), suggesting that overall, the DNA damage observed in the 
presence of ZM 81853 was less extensive.
The results of this present chapter support the earlier finding that NADPH : 
cytochrome P450 reductase played a role in the reductive metabolism of ZM 81853. 
Furthermore, reduction in the presence of this enzyme was shown to result in single 
strand breaks in plasmid DNA. Important to the therapeutic action of these compounds, 
NADPH : cytochrome P450 reductase has been identified in many human tumour cell 
lines (Chapter 2) and normal cells from breast, skin and prostate tissues (Baron et al. , 
1983). In addition, NADPH : cytochrome P450 reductase activity within human glioma 
biopsies (Rampling et at. , 1994 and within this thesis) has been demonstrated. Also of 
potential importance is the fact that nuclear localisation of NADPH : cytochrome P450 
reductase has been demonstrated in rat liver (Cahill & White, 1990), thereby enabling 
activation of ZM 81853 even closer to the DNA than would be the case for cytosol or 
microsomal reduction.
In summary, reduction of ZM 81853 by purified, recombinant human NADPH : 
cytochrome P450 reductase was demonstrated, although it was found to be less efficient 
than that of tirapazamine. Importantly, however, reduction of ZM 81853 resulted in the 
production of a DNA damaging species. A possible mechanism of action for ZM 81853 
may, therefore, be via one-electron reduction to form a nitroxide radical product which is 
capable of causing DNA damage. Such a pathway has already been proposed for 
tirapazamine (see Chapter 1, Figure 1.5). Further studies would be required to determine
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whether a radical species is formed on ZM 81853 one-electron reduction, and whether 
this is the species responsible for causing the DNA damage observed.
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CHAPTER 8 
GENERAL DISCUSSION
The aims of this thesis which were initially set out at the beginning of the project 
have been achieved. The aims were :
(i) To measure the level of expression and activity of reductase enzymes within a 
panel of human tumour cell lines derived from various tumour tissue origins.
(ii) To determine whether this information could be used within the National Cancer 
Institute database to establish correlations between different enzyme activities and 
sensitivities towards both existing and novel anticancer agents.
(iii) To establish the potential of three structurally distinct and novel compounds to 
act as hypoxia-selective bioreductive anticancer agents.
(iv) To extend the above study to determine structure-activity effects of a small series 
of quinoxaline di-A-oxides.
(v) To investigate the enzymology and DNA damaging capacity of any of the above 
compounds that were shown to act as possible hypoxia-selective bioreductive anticancer 
agents.
The results of this thesis contribute towards a better understanding of the 
enzymology of human tumour cells and also towards the future application of an 
enzyme-directed approach to bioreductive drug development.
The attainment of information regarding enzyme expression within human 
tumours has been proposed as an important factor for the future success of an enzyme- 
directed approach to anticancer drug development (Workman, 1994; Workman & 
Walton, 1990). While expression of a number of enzymes have been reported (see for 
example, Baron et al. , 1983; Cresteil & Jaiswal, 1991; Schlager & Fowls, 1990), these 
studies have involved only limited numbers of tumour types. In an attempt to improve 
the current situation, this thesis has investigated enzyme expression in over 60 human
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tumour cell lines in a collaborative project between the NCI, EORTC and the U.K. CRC 
(Chapter 2). Heterogeneity of expression was demonstrated both within and between cell 
lines from different origins. Importantly, however, clear patterns of expression within 
different tumour cell origins emerged. This was particularly pronounced in the case of 
DT-diaphorase (see Chapter 2, Section 2.3.1 for more details). The results are generally 
consistent with previous findings using smaller numbers of human tumour cell lines. For 
example high DT-diaphorase activity was seen in lung and colon cell lines (Patterson et 
al. , 1994; Plumb et al. , 1994a; Plumb gf j / . , 1994b; Robertson et al. , 1992; Robertson 
et al. , 1994; Smitskamp-Wilms et al. , 1994). The establishment of such patterns from 
the analysis of human tumour cell lines could prove to be extremely valuable in forming 
the platform for successful targeting of anticancer agents to specific tumour types based 
upon the enzymology of the tumour (and, of course, nature of the drug).
A possible problem, however, is how applicable such measurements are to the in 
vivo situation. This issue was addressed, to a limited degree in this thesis, by comparing 
enzyme activities in human tumour cell lines to previously published data involving 
tumour biopsies (for a more detailed discussion see Chapter 2, Section 2.4). Enzyme 
activities such as DT-diaphorase were observed to be lower in tumour samples 
(Rampling et al. , 1994; Schlager & Powis, 1990) compared to cell lines. Interestingly, 
and importantly for therapeutic action, normal tissues have been reported to have lower 
enzyme activities than tumour tissues (Schlager & Powis, 1990). A plausible 
explanation, therefore, is that contamination of tumour biopsies by normal tissue, i.e. 
stroma, can occur upon surgical removal, thereby resulting in underestimation of 
enzyme activity within the biopsy sample. This may also explain the findings of de 
Wazier and colleagues (de Waziers et al. , 1991) who reported no change in DT- 
diaphorase activity between tumoural and normal tissues. The use of human tumour cell 
lines essentially rules out this problem. As a result, they provide an invaluable tool with 
which to study the enzymology of many different tumour histiotypes.
The NCI annually screens approximately 20,000 compounds of distinct chemical 
structure in the aforementioned panel of in vitro human tumour cell lines (Boyd & Pauli,
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1995). It has been proposed that incorporation of relevant biochemical and molecular 
parameters into the database would provide additional means of identifying mechanisms 
of action of potential anticancer agents (Boyd & Pauli, 1995). Such a proposal was 
tested in this thesis by the incorporation of enzyme activities into the database, and 
subsequent statistical analysis (in collaboration with Dr. K. Pauli, NCI) to search for 
correlations between enzyme activity and sensitivity towards the many anticancer agents 
already screened through the NCI programme. Several interesting correlations between 
DT-diaphorase activity and cell sensitivity were discovered in the analysis (see Chapter 
3, Sections 3.3 and 3.4 for more details), including those of the quinone-containing 
compound streptonigrin, and the clinical agent 5-FU. Perhaps the most significant 
finding of this study with regards to the controversy in the current literature was the 
clear correlation shown between sensitivity towards mitomycin C and DT-diaphorase 
activity across the human tumour cell line panel. A great deal of controversy has 
surrounded the role of this enzyme in mitomycin C activation (FR oss et al. , 1994 and 
references therein), in particular concerning a lack of correlation between the 
aforementioned parameters (Robertson et al., 1992). This current study strongly 
supports a role for DT-diaphorase in the activation of mitomycin C under aerobic 
conditions. Furthermore it also provided a means of establishing in more detail those 
individual tumour types which were either sensitive or resistant to different bioreductive 
agents. In the case of E09, for example, cell lines high in DT-diaphorase activity such as 
lung and colon were more sensitive towards E09 than those low in activity such as 
leukaemia and lymphoma cell lines (Chapter 3; Figure 3.3). Whilst this result was not 
surprising considering the known involvement of DT-diaphorase in the activation of 
E09 under oxic conditions (Plumb et a i, 1994a), it demonstrated that the incorporation 
of enzyme activities into the NCI database as an additional biochemical parameter 
proved to be an invaluable resource with which to study mechanisms of action of 
potential new and existing anticancer agents. Interestingly, this study current study 
revealed no significant correlations involving either NADPH : cytochrome P450 
reductase or NADH : cytochrome b5 reductase. Whilst this thesis has focused on only
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three enzymes, further studies to determine the activities of other important bioreductive 
enzymes, for example, carbonyl reductase and xanthine oxidase / dehydrogenase, would 
significantly increase the potential of such an application in the NCI database. In light of 
recent reports concerning the role of one-electron reducing enzymes such as NADPH : 
cytochrome P450 reductase in the activation of E09 under hypoxic conditions (Plumb & 
Workman, 1994; Plumb et a i, 1994b), the incorporation into the NCI database of 
cytotoxicity data under hypoxic conditions would also prove to be extremely valuable. 
This would of course apply to all other potential bioreductive anticancer agents.
As discussed in the introduction to this thesis, a number of bioreductive 
anticancer agents have been, or are currently, undergoing clinical trial. However, muscle 
cramping and dose-limiting toxicity have proved problematic during their progress 
(Doherty et al. , 1994; Schellens et al. , 1994). In an attempt to identify more potent and 
hypoxia-selective agents for use in an 'enzyme-directed' bioreductive programme 
(Workman, 1994; Workman & Walton, 1990), the potential of three groups of novel 
compounds, with diverse molecular structures, to act as hypoxia-selective anticancer 
agents was investigated in this thesis (Chapter 4). These particular compounds were 
selected in conjunction with ZENECA Pharmaceuticals, due to their structural 
similarities towards some of the more active agents (see Chapter 4, Figure 4.1 for 
structures) currently in development. The NCI routinely use a large panel of in vitro 
human tumour cell lines as an initial screen for potential anticancer agents. The 
knowledge gained by determining enzyme activity levels within the NCI panel was put 
to further use by selecting a small panel of cell lines, based upon their enzyme activity 
levels, with which to screen the novel compounds under investigation. As both one- and 
two-electron reducing enzymes are known to be important in the metabolism of 
bioreductive anticancer agents (Chapter 1), this was seen as a means of predicting 
possible mechanisms of action of the compounds. Neither the nitroheterocyclic agent, 
ZM 29362, nor the nitroacridine, ZM 33191, exhibited the potential to act as selective 
bioreductive agents. Interestingly, however, ZM 33191 was at least as potent as the 
indoloquinone bioreductive agent E09 under oxic conditions. Activation of E09 by DT-
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diaphorase under oxic conditions is known to result in DNA alkylation (Bailey et al. , 
1994b; Maliepaard et al. , 1995); therefore, it is possible that ZM 33191 acted in a 
similar manner. Such a mechanism of action was further supported by the fact that DNA 
adduct formation has also been proposed as the mechanism of action, under oxic 
conditions, of the nitroacridine, nitracrine (1-NC) which is similar in structure to ZM 
33191 (Konopa et al. , 1983; Pawlak et al. , 1983). While ZM 33191 may still have a 
future as an anticancer agent under oxic conditions, Denny and colleagues (Denny et al., 
1992; Siim e ta l . , 1994; Wilson e ta l . , 1992) are currently developing new analogs of 1- 
NC in an attempt to identify structures which display more hypoxic-selectivity.
A more detailed study involving a small series of structurally-related quinoxaline 
di-A-oxides revealed that ZM 81853 was the only compound with the potential to act as 
a bioreductive anticancer agent, as it exhibited similar hypoxic-selectivity to the 
benzotriazine di-A-oxide, tirapazamine, a bioreductive compound currently in clinical 
trial. To further investigate the metabolic properties of these quinoxaline compounds, 
sensitive HPLC methods were developed to allow detection of each compound (Chapter 
5). Successful assays were established for all of the compounds concerned. Further 
similarities between ZM-81853 and tirapazamine were revealed in subsequent studies 
(Chapters 6 and 7) as ZM 81853 was metabolised by the one-electron reducing enzyme 
NADPH : cytochrome P450 reductase to a species capable of causing single strand DNA 
damage, under hypoxic conditions. Although a four-electron reduced product (identified 
in collaboration with Dr. D. Watson, University of Strathclyde, U.K.) was detected by 
HPLC analysis as the predominant metabolite following incubation in the presence of 
mouse liver enzymes, it is unclear at this stage whether this was, in fact, the DNA 
damaging, and hence, cytotoxic species. Further studies involving isolation of this 
product, and subsequent cytotoxicity and DNA damage experiments would determine 
whether this was the case. As ZM 81853 is likely to undergo an one-electron reduction 
under hypoxic conditions, the most likely metabolic pathway for the compound would 
involve four sequential one-electron reductions resulting, ultimately, in production of the 
four-electron reduced product. Due to the similarities in metabolic properties of
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tirapazamine and ZM 81853, it is possible that the mechanism of action of the latter 
compound under hypoxic conditions would be similar to that of tirapazamine (Lloyd et 
al. , 1991). Hence, DNA damage would arise from the action of a toxic radical species. 
Certainly, DNA damage experiments ruled out a possible influence of oxygen radicals 
(Chapter 7, Section 7.3.3.). Importantly, studies such as those previously performed for 
tirapazamine (Lloyd et al., 1991) would identify whether a radical species is involved, 
and if so, determine the nature of that radical.
As mentioned previously, ZM 81853 was the only compound from a small 
series of quinoxaline di-A-oxides to demonstrate the potential to act as a bioreductive 
anticancer agent. Unfortunately, however, this compound did not appear to be any more 
potent or hypoxia-selective than the benzotriazine di-A-oxide, tirapazamine, which is 
currently in Phase II clinical trial in combination with cisplatin and shortly seeking 
approval for Phase III clinical trial. These findings were consistent with a more detailed 
study, at ZENECA Pharmaceuticals, involving 15 structurally-related 2-cyano-l, 4- 
quinoxaline di-A-oxides including ZM 81853 (Monge et al. , 1995). Importantly, 
however, this latter study revealed that substitution of a strong electron withdrawing 
group (Cl, F, CF3) in the R7 position (Figure 8.1) increased the overall activity of the 
compounds e.g. IC90 0 3 - 15 |iM; HCR up to 340 compared to tirapazamine. In 
addition, preliminary in vivo data suggested that these compounds may have greater 
therapeutic benefit over tirapazamine. Clearly, therefore, further studies involving 
selected compounds from this quinoxaline di-A-oxide series are warranted and may 
provide a potential bioreductive agent with greater potency and hypoxic-selectivity over 
tirapazamine.
The development of effective bioreductive anticancer agents is an important 
concept with regards to overcoming the problem of resistant hypoxic cells within solid 
tumours. One of the principle problems arising during clinical trials, however, has been 
the dose-limiting toxicity caused by these agents (see Chapter 1 for more details). This 
frequently arises from a lack of specificity towards hypoxic cells. In the case of E09, for 
example, the reversible kidney toxicity observed during Phase I clinical trial (Schellens
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•7
R,
CN
R3 R6 R7 P
([iM)
HCR MTD
(mmol/kg)
NH2 H H 30 80 -
NH(CH2)3N(CH3)2 H Cl 0.4 250 0.055
NH(CH2)3N(CH3)2 H F 0.6 170 0.07
NH(CH2)3N(CH3)2 H CH3 0.3 340 <0.05
NHCOCH3 H Cl 15 50 -
tirapazamine - - 30 75 0.3
Figure 8.1 Characteristics of a series of novel quinoxaline di-/V-oxides 
compared to tirapazamine.
P=dose for 1% V-79 survival in N2; HCR=ratio of equitoxic doses in air/nitrogen; 
MTD=maximum tolerated single dose (mice).
[taken from Monge eta/, 1995]
et al., 1994) maybe attributed to the aerobic metabolism of the drug by DT-diaphorase, 
which is known to be present at high levels within normal kidney tissue (Schlager & 
Powis, 1990). In order to improve the long-term prospects of bioreductive anticancer 
agents, specificity of action must therefore be improved. The aforementioned study 
involving quinoxaline di-N-oxides may prove to be important, therefore, in the future 
development of more specific agents.
Denny (Denny, 1995) recently proposed that the design of agents with narrower 
ranges of reduction potentials would improve the specificity of activation of 
bioreductive anticancer agents. It was also proposed that the development of enzyme- 
specific bioreductive agents, based upon current knowledge regarding enzyme 
expression within both normal and tumour tissues would be important. An exciting new 
concept introduced quite recently, is that of antibody-directed enzyme prodrug therapy 
(ADEPT) (Anlezark et a l . , 1992; Bagshawe, 1987; Bagshawe et al. , 1994; Knox et a l . , 
1993). This approach involves the conjugation of drug reducing enzymes to a tumour- 
selective monoclonal antibody and subsequent specific localisation of this complex to 
the tumour site. Local activation of an inactive prodrug would then occur at the tumour 
site. This process is particularly promising with regard to the use of non endogenous 
enzymes, as the whole process would then be extremely specific towards the tumour of 
interest. One promising example is that of the monofunctional alkylating agent CB 1954, 
which has previously been shown to be a much better substrate for rat DT-diaphorase 
(isolated from rat Walker tumour cells) than for human DT-diaphorase (Boland et al. , 
1991). Conjugation of the rat form of DT-diaphorase, or indeed the more active 
nitroreductase purified from Escherichia coli (Anlezark et al. , 1992), to a tumour- 
selective antibody could improve the potential of CB 1954 to act as an anticancer agent, 
by creating an extremely tumour specific reaction. Studies are currently underway 
involving the tumour selective antibody A5B7 (Knox et al., 1993). Furthermore, this 
technique also has the potential for improving the bioreductive activity of different 
agents by conjugating enzymes of interest to hypoxic regions of tumours. Although 
promising, however, potential problems may arise with ensuring localisation of the
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enzyme to the tumour site in sufficient quantities, and also location of the inactive 
prodrug to the tumour site. Similar proposals have also been introduced involving gene- 
directed enzyme prodrug therapy (GDEPT), involving the specific insertion of a gene of 
a particular enzyme into the tumour site.
To date, bioreductive anticancer agents have been developed with the view to 
overcoming the problem of hypoxic cells within solid tumours via production of toxic 
species. This treatment usually takes place alongside that of chemotherapy or 
radiotherapy in order to kill both the oxic and hypoxic fractions of the tumour. A further 
exciting area in bioreductive drug development, however, has been the introduction of 
hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs) (Denny & Wilson, 1993). 
In addition to killing hypoxic cells upon activation, these agents also release cytotoxins 
into the surrounding oxic cells and cause cell death. Two such agents, namely SN 
25246, a nitrobenzyl mustard quaternary salt, and SN 24771, a cobalt-nitrogen mustard 
complex have both been shown, in vitro, to exhibit some potential as HPDCs (Denny et 
al. , 1994; Wilson gr a / . , 1994).
In summary, this thesis has increased awareness as regards to the importance of 
understanding enzyme expression within human tumour cell lines and perhaps, 
therefore, more importantly, within human tumours. In addition, a small series of 
structurally distinct compounds has been evaluated for their potential to act as 
bioreductive anticancer agents. Unfortunately, although the quinoxaline di-A-oxide ZM 
81853 showed similar in vitro characteristics (HCR's in cytotoxic studies, and metabolic 
activity in the presence of different enzyme preparations) as the benzotriazine di-A- 
oxide tirapazamine, it did not appear to have the potential to be any better than 
tirapazamine as a bioreductive agents. More detailed studies within ZENECA 
Pharmaceuticals, however, indicated that several compounds within a larger series of the 
quinoxaline di-A-oxides (Monge et al., 1995) could prove to be better bioreductive 
anticancer agents than tirapazamine (Figure 8.1). Overall, however, it is believed that the 
future for bioreductive anticancer agents must be dependent upon the ability to improve
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both selectivity and potency of the agents, using mechanisms such as ADEPT and 
GDEPT, for example.
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#  Manipulation of Tumor Oxygen and Physiology
DIRECT MEASUREMENT OF pOj DISTRIBUTION AND BIOREDUCTIVE 
ENZYMES IN HUMAN MALIGNANT BRAIN TUMORS
R o y  R a m p lin g ,  Ph .D., MBBS,* G a r t h  C r u ic k s h a n k ,  Ph .D., M.D.,^ 
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Glasgow; and *CRC Dept, o f Medical and Radiation Oncology, Glasgow, Scotland, UK
Purpose: To measure the oxygen status of human malignant brain tumors i n  v i v o  and to determine the activities 
and expression of bioreductive enzymes in these same human brain tumor samples, as a means of assessing their 
suitability as targets for bioreductive drug therapy.
Methods and Materials: A polarographic oxygen electrode was used to measure the intratumoral oxygen tension 
in twenty patients with malignant brain tumors during open brain surgery, performed under standard anaesthetic 
conditions. S ix different tracks, each with a path length of 22 mm, were recorded per patient representing 192 
readings. Following pO  ^measurements the tumors were resected and stored in liquid N% for subsequent bioreductive 
enzyme analysis. Eight human malignant brain tumors were assessed, by enzyme activity and western blot expression, 
for the presence of various bioreductive enzymes. These enzymes included DT-diaphorase, NAD H  cytochrome b5 
reductase, and NADPH cytochrome P-450 reductase. O f these eight gliomas analyzed six samples were incubated 
with the bioreductive drug tirapazamine, in the presence of cofactor(s), to establish whether human brain tumors 
could metabolize this compound.
Results: Both the high grade intrinsic and metastatic brain tumors showed significant regions of hypoxia. All the 
tumors subjected to e n z y m e  p r o f i l i n g  contained the bioreductive enzymes, DT-diaphorase, NADH cytochrome b5 
reductase and NADPH cytochrome P-450 reductase. Also all six of the brain tumors investigated could metabolize 
tirapazamine to the two-electron reduction product.
Conclusion: These findings would favor primary brain tumors as suitable targets for bioreductive therapy.
Human brain tumors. Glioma, Tirapazamine (W IN 59075, SR 4233), Enzyme profiling, Bioreductive enzymes, 
DT-diaphorase, NADPH cytochrome P-450 reductase, NADH cytochrome b5. Reduction of tirapazamine, Bio­
reductive therapy, pO  ^ distribution. Hypoxia.
INTRODUCTION
Bioreductive drug activation depends on the oxygen status 
and enzyme concentration-activity profile of the target 
tissue. In selecting tumors as potential targets for such 
drugs it is important to know that these parameters exist 
within a particular tumor to determine whether the drug 
is likely to be metabolized to its active form.
Direct measurements of partial oxygen pressure (pO:) 
using a tube type sensor have suggested that hypoxia exists 
within brain tumors but the spatial resolution of the tech­
nique is limited (6). Indirect measurements of oxygen sta­
tus have yielded conflicting results with the presence of 
hypoxic areas being questioned (3). No direct measure­
ments of intratumoral p02  have been reported using micro
electrode techniques. Our aim was to use such methods 
to determine the profile of pO] in the micro environment 
of brain tumors. The demonstration of significant regions 
of hypoxia inside these tumors would recommend brain 
tumors as potential targets for bioreductive drugs provided 
that the enzymes involved in the bioreductive drug acti­
vation were present.
Tirapazamine (SR 4233; WIN 59075 or 1,2,4-benzp- 
triazine 1,4-di-A-oxide) is a lead bioreductive compound 
which is currently undergoing Phase I clinical trial in 
Stanford, Harvard and Glasgow Universities. Interest­
ingly, this drug has been shown to be metabolized by a 
variety of enzymes as indicated in Figure I. These enzymes 
include the one-electron reducing enzymes NADH cy­
tochrome b5 reductase, xanthine oxidase, and NADPH
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Fig. 1. Scheme for tirapazamine (WIN 59075; SR4233) reduction.
cytochrome P-450 reductase, and also the two-electron 
reducing enzyme DT-diaphorase which bypasses the re­
active drug radical intermediate (15, 17). In addition to 
hypoxia, therefore, these enzymes must be present within 
the tumor to activate the drug to the therapeutic species.
As a consequence, the purpose of this study was to 
investigate both the degree of hypoxia which exists within 
human brain malignancies and also, on resection of these 
tumors, the presence of enzymes which can reduce bio­
reductive agents—a concept we describe as enzyme pro­
filing (17). The ability of these human brain tumors di­
rectly to metabolize the bioreductive drug tirapazamine 
was also studied.
METHODS AND MATERIALS
Oxygen measurements
The entire study was approved by the ethical committee 
of the Institute of Neurological Sciences, Glasgow, UK. 
All patients were given verbal and written information 
concerning the study and gave their written consent prior 
to participation. Twenty patients with a clinical and ra­
diological diagnosis of malignant brain tumor (primary 
or secondary) were entered into the study. All patients 
were receiving corticosteroids, two had undergone pre­
vious craniotomy and one had also received prior radio­
therapy. All patients underwent anaesthetic with preox­
ygenation and alfentanil combined with atricurium bolus 
injection. Subsequent maintenance was with isofluorane 
(0.5-1.0%) or propofol infusion (0.5-1.0 mg/Kg/h). 
Halothane was specifically avoided. Controlled ventilation 
was used with a fractional inspired oxygen maintained 
between 0.4-0.5 with the arterial pCO: kept between 3.5- 
4.5 KPa.
The patients head was held in a fixator' to reduce 
movement. A self-adhesive silver chloride anode was po­
sitioned on cleaned skin, usually over the mastoid process. 
The oxygen probe  ^was then carefully calibrated. During 
this period a craniotomy was performed and the dura 
opened. A 10-min equilibration period was allowed after 
which samples were removed for blood gas analysis and 
the p0 2  readings were begun.
Tissue oxygen tension (pO?) was measured using a 300 
^m needle electrode" containing a 12 ^m concentric 0 2 - 
sensitive, membrane covered, gold wire cathode held at 
—700 mV relative to an indifferent Ag/AgCl anode. Ox­
ygen reduced at the cathode resulted in a current directly 
proportional to the p02. Using a microprocessor con­
trolled micromanipulator, multiple spatially separate 
measures of p02  were collected automatically over a step 
length of 700 //m (1.0 mm advance, 0.3 mm backstep). 
The electrode was inserted through the open craniotomy 
under direct vision. Normally six tracks, each with a total 
path length of 22 mm, were recorded per patient repre­
senting 192 readings. After each track the probe returned 
automatically to the starting position. It was then reangled 
a few degrees and a new track begun. A 6 MHz. 16 mm 
ultrasound probe was used to locate the margins of the 
tumor and confirm the needle trajectory. The p02 values 
were plotted automatically as frequency histograms with 
a intervals of 2.5 mmHg. Following the procedure the 
probe was recalibrated.
Following all the p02 measurements, the tumor in­
cluding all areas sampled by the oxygen probe was re­
sected. In some instances pathologic samples were pre­
served in liquid nitrogen for subsequent bioreductive en­
zyme analysis. Post measurement intraoperative and 
postoperative management proceeded as normal and no 
complications relating to the p02  measurements were en­
countered.
‘ Patients heads were restrained in a Mayfield fixator during 
pO; measurements.
- The polarographic oxygen electrode micromanipulator and
microprocessor were supplied by Eppendorf Ltd.. Hamburg, 
Germany.
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Bioreductive enzym e measurements and metabolism o f  
tirapazam ine
Resected tissue was homogenized as described by 
Adams et al. (I) with the S9 fraction prepared by differ­
ential centrifugation. Levels of bioreductive enzymes such 
as DT-diaphorase, NADH cytochrome b5 reductase, and 
NADPH cytochrome P-450 reductase were determined 
using a modification of the cytochrome c reduction 
method (11). Confirmation of the expression of the DT- 
diaphorase and NADPH cytochrome P-450 reductase en­
zymes in the human malignant glioma tumor samples 
was carried out by western blot analysis as described by 
Lewis et al. (7). The DT-diaphorase and NADPH cyto­
chrome P-450 reductase antibodies used in the western 
blot analysis were kindly provided by Dr. R. Knox, ICR, 
Sutton, UK and Dr. C. R. Wolf, ICRF, Dundee, UK, 
respectively. Selected tumor homogenates (3 mg/ml) in­
cluding the murine EMT 6 tumor were incubated with 
1.5 mM tirapazamine (WIN 59075; SR 4233) and 10 mM 
NAD(P)H in 50 mM Tris HCl pH 7.5 for 0-30 min at 
37°C. Reduction of the drug to metabolite(s) were quan­
tified by HPLC analysis (10).
RESULTS
Oxygen m easurem ents in human brain malignancies 
The pOa values determined in 20 human brain tumors 
were presented as frequency histograms. This form of 
presentation is illustrated in Figure 2 for the pooled data 
from the ten patients with glioblastomas. The mean, me­
dian, and 90th percentiles from the individual histograms 
were used to describe the distribution. The results for all 
20 patients are shown in Table 1 together with the tumor 
histology and an approximate measure of their sizes.
Table I. Intratumoral tissue oxygen tension results 
for human malignant brain tumors
Relative frequency %
50
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faim
10 20 30 40
P 0 2  m m H g
50 60
Patient
no.
Tumor
pathology
Max
dim*
(mm)
Median
P02^
(mmHg)
% pO; values 
<2.5^  
mmHg
1 Glioblastoma 36 24.3 9.5
2 Glioblastoma 46 3.2 43.7
3 Glioblastoma 32 19.3 22.5
4 Glioblastoma 34 5.4 35.5
5 Glioblastoma 64 2.5 56.7
6 Glioblastoma 37 4.5 47.0
7 Glioblastoma 45 0.1 67.2
8 Glioblastoma 63 5.4 39.5
9 Glioblastoma 38 7.7 30.5
10 Glioblastoma 37 0.1 68.5
11 Anaplastic 30 10.0 19.5
12 Anaplastic 45 42.3 9.0
13 Anaplastic 38 5.0 41.5
14 Intermediate 39 3.7 22.5
15 Low grade 41 6.4 0
16 Bronchus 43 14.1 1.5
17 Bronchus 46 3.0 29.5
18 Breast 36 4.3 46.5
19 Breast 35 4.5 32.5
20 Melanoma • 30 23.7 20.0
Fig. 2. Histogram o f pO? incidence in ten patients with glio­
blastoma. Pooled data; N  = 10, n -  2486, median value 7.4 
mmHg.
* Max Dim (mm) is an approximate measure of the tumor 
size estimated by CT scan.
 ^Measurement o f pO; distribution was determined as de­
scribed in the Methods and Materials section. The median pO; 
values and the number of pO; values less than 2.5 mmHg were 
calculated from histogram plots. A typical example o f a plot is 
shown in Figure 2.
which were estimated from CT scan images. Presented 
also in this Table is a measure of the number of pO; 
readings for each tumor recorded to be less than 2.5 
mmHg, a level of pO] which is thought to be radiobio- 
logically important.
The pooled median pO] value for the ten patients with 
glioblastoma was determined to be 7.4 mmHg. In this 
tumor type, a high percentage (28%) of low pO] values 
were recorded indicating a radiobiologically significant 
hypoxic component in all glioblastomas studied. By def­
inition anaplastic (WHO Grade 3) astrocytomas do not 
contain regions of necrosis. Interestingly, however, in our 
study these also show hypoxic regions, with up to 41.5% 
of recorded values in individual tumors being under 2.5 
mmHg. Noticably, the median pO] values were generally 
higher in this small series than for the glioblastomas. Of 
obvious interest was the single low grade tumor which, 
when measured by this method, recorded no p02  values 
< 2.5 mmHg. This is in contrast to the mixed group of 
metastatic tumors which demonstrated marked hypoxia. 
Taken together, these results confirm the expected pattern 
of increasing hypoxia with increasing tumor aggressiveness 
and rapidity of growth. Other interesting clinical infor­
mation obtained from this study included the lack of cor­
relation between the percentage of low p0 2  values and 
the patient age, sex, tumor position, size, the arterial p0 2 , 
or PCO2.
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Bioreductive enzym e expression in human brain 
malignancies
Eight human malignant brain tumors were assessed for 
bioreductive enzyme activity. The results of this study are 
shown in Table 2. All the tumors investigated expressed 
DT-diaphorase, NADH cytochrome b5 reductase and 
NADPH cytochrome P-450 reductase activity. The levels 
between the tumor samples varied, however. An 18-fold, 
10-fold, and 8-fold range in DT-diaphorase, NADH cy­
tochrome b5 reductase, and NADPH cytochrome P-450 
reductase activity, respectively, was measured between the 
tumor samples. Interestingly, the low grade glioma had 
the highest overall bioreductive enzyme content. This high 
level of expression of bioreductive enzymes, in particular 
DT-diaphorase and NADPH cytochrome P-450 reduc­
tase, was confirmed in the brain tumor samples by western 
blot analysis (data not shown). To investigate whether the 
human malignant brain tumors could metabolize biore­
ductive drugs, six of the brain tumors were incubated with 
the bioreductive agent tirapazamine (WIN 59075; SR 
4233) in the presence of cofactor. The results of this ex­
periment are shown in Table 3. All the brain tumors in­
vestigated could metabolize tirapazamine to the 2-eIectron 
reduced product (WIN 64012; SR 4317). The murine tu­
mor EMT 6, which was used as a control in this experi­
ment, gave a value for the rate of formation of WIN 64012 
of 5.56 nmol/min/mg protein.
DISCUSSION
It has long been recognized that the presence of hypoxia 
in tumors can modify their response to therapy. Tradi­
tionally, hypoxia has been considered a disadvantage to 
be overcome. However if agents are used that are selec­
tively cytotoxic to hypoxic cells, then their presence in a 
tumor may be seen as an advantage to be exploited. Tir-
Table 2. Bioreductive enzyme activities measured 
in human malignant brain tumors
Table 3. Rate o f metabolism of Tirapazamine (WIN 59075; 
SR 4233) by human malignant brain tumors
Tumor
pathology
Enzyme activity (nm ol/m in/mg)
DT-
diaphorase
Cytochrome 
b5 reductase
Cytochrome 
P-45 reductase
Glioblastoma 21.1 21.1 9.9
Sarcoma 57.1 87.8 19.3
Low grade
glioma 182.9 180.0 39.7
Glioblastoma 25.3 16.1 7.7
Glioblastoma 10.1 23.6 12.8
Glioblastoma 27.0 30.7 5.3
Glioblastoma 114.1 32.1 42.9
Glioblastoma 24.5 20.4 15.3
Tumor pathology
Tumor
number
Rate o f WIN 
64012 formation 
(nmol/min/mg)
Sarcoma T3 2.56
Low grade glioma T5 2.09
Glioblastoma T7 1.06
Glioblastoma T8 0.84
Glioblastoma T9 1.21
Glioblastoma T14 1.10
Note: The enzym e activity measurements for DT-diaphorase, 
NADH cytochrom e b5 reductase and NADPH cytochrome P- 
450 reductase were carried out as described in Methods and 
Materials. The results presented are the average o f at least two 
measurements.
Note: The human brain tumor samples were incubated with 
tirapazamine as described in Methods and Materials. The rate 
o f formation o f WIN 64012 (SR 4317) was found to be linear 
with time and quantified by HPLC as described in Methods and 
Materials.
apazamine is such an agent which, by undergoing a one- 
electron reduction in a hypoxic environment, forms cy­
totoxic free radicals ( 17). These radicals, if formed close 
enough to the cellular DNA, can cause strand breaks and 
potentially cell death. The early clinical development of 
this drug is now almost complete. Further development, 
will require the identification of suitable targets, that is, 
tumors in which there is a sizeable hypoxic fraction and 
an appropriate enzyme complement. This is known as 
enzyme profiling of tumors (17).
Since Thomlinson and Gray (12) postulated the pres­
ence of hypoxic cells in human tumors many attempts 
have been made to measure the pO: directly. The use of 
direct electrode methods began with animal tumor model 
work in the 1970s (2, 13) but it was not until the devel­
opment of the polarographic micro-electrode that any 
sustained program of work was undertaken to determine, 
by direct measurement, the pOz distribution in human 
tumors ( 14). This work has demonstrated the existence 
of hypoxic regions in cancers of the breast and cervix. 
Furthermore, there have been suggestions that the hypoxia 
correlates with response to treatment with radiation (9).
There has been one previous attempt directly to mea­
sure the pOz in human brain tumors (6). In this study, a 
single measurement was made using a 700 ^m Clarke 
electrode. In 12 malignant gliomas the average pOz was 
found to be 15.3 ± 2.3 mmHg (range, 5-38). This figure 
was much lower than that measured in normal brain and 
demonstrated relative hypoxia in the tumor tissue. How­
ever, this method had a slow response time (90 s) and did 
not provide any spatial information. Our results give a 
similar average figure, but show that at a microscopic level 
the pOz varies dramatically within the tumor with many 
values falling below 2.5 mmHg. This is a level of hypoxia 
which is significant for the activation of bioreductive 
agents, and also, at which the tissue is likely to demonstrate 
hypoxic radio-resistance. Heterogeneity of pOz levels was 
also a feature of measurements reported by Kallinowski 
in both animal model systems and in human breast and
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cervix tumors in situ  (5). This heterogeneity is likely to 
comprise both spatial and temporal components, as has 
been discussed by Chaplin (4).
Hypoxia arising within tumors can offer the potential 
of a novel approach to therapy, using bioreductive drug 
therapy (4, 17). The levels of hypoxia required for drug 
activation are similar to those at which cells develop hyp­
oxic radioresistance, that is, ~  0-10 mmHg. Hypoxia of 
this order has been demonstrated in all but one of the 
intracranial tumors investigated in this study. In partic­
ular, the high grade gliomas show particularly large hyp­
oxic components which may well contribute to their 
known radioresistance. Therapeutic strategies directed 
specifically at viable and possibly clonogenic hypoxic cells 
using bioreductive therapy may well prove beneficial.
Tirapazamine has been shown to have considerable 
anti-tumor activity under hypoxic conditions in animal 
model and in vitro systems (8). While the oxygen profiles 
measured in this study suggest that high grade gliomas 
may be a good target for bioreductive therapy, the appro­
priate enzyme profile must also exist within the tumor. 
In this study, we have demonstrated that bioreductive 
enzymes are present within the human brain tumor ma­
lignancies and these tumors can also reduce the drug pre­
sumably via the therapeutic drug radical. Interestingly, 
this reduction was calculated to be at ~  50% of that of 
the murine EMT 6 tumor, a tumor which is sensitive to 
tirapazamine.
Data in mice have shown that tirapazamine can cross 
the blood-brain barrier to produce high levels within the 
brain (16). As a consequence, all the conditions appear 
to be met which allow access and appropriate metabolism 
of the drug. All patients with high grade gliomas will die 
from their disease. Median survival without treatment is 
less than 6 months. Radiation alone may double this sur­
vival, but the prognosis is still short and patients are never 
cured. If the hypoxia demonstrated in this study contrib­
utes to the radioresistance of these tumors then a com­
bination of tirapazamine with radiation may improve the 
survival prospects for this difficult group of patients.
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ABSTRACT
Background: Numerous enzymes metabolize anticancer agents, including
bioreductive drugs. Tumor enzyme expression may affect treatment outcome aswell 
as influence new drug devlopment strategies but we have only limited information on 
drug metabolizing enzyme levels in human tumors and cell lines.
Purpose: 1) To characterize systematically the expression of three drug metabolizing 
reductase enzymes across the different histiotypes in the NCI human tumor cell line 
panel. 2) To correlate the results with sensitvity to the established bioreductive agent 
mitomycin C and the related indoloquinione E09, currently in phase 11 clinical trial 
with the EORTC.
Methods: 69 human tumor cell lines from 9 histiotypes were assayed for DT- 
diaphorase, NADPH : cytochrome P450 reductase and NADH : cytochrome b5 
reductase using cytochrome c reduction methodology. Where appropriate, protein 
expression was determined by Western blot and mRNA by reverse-transcriptase 
polymerase chain reaction. In vitro antitumor activity was determined under aerobic 
conditions using sulforhodamine B to measure cell mass. The relationship between 
enzyme activities and drug sensitivity (GI50) was assessed by the COMPARE 
analysis, with significance tested by the Pearson Correlation Coefficient.
Results : Compared to DT-diaphorase activities which were generally high,
cytochrome P450 and b5 reductase were both relatively low across the panel. Levels
of all three varied both between and within histiotypes, but clear patterns did emerge. 
For example, DT-diaphorase was relatively low in leukemic, ovarian and breast lines 
but high in non-small cell lung, colon, CNS and melanoma. In several instances 
expression patterns agreed with data reported for clinical tumor material. Activities 
of cytochrome P450 and b5 reductase did not correlate with chemosensitvity, whereas 
a clear relationship was seen between DT-diaphorase levels and response to both E09 
and mitomycin C (Pearson Correlation Coefficient = 0.446, p < 0.0013 for E09, and 
0.424, p < 0.0005 respectively).
Conclusions: Bioreductive enzyme expression is heterogeneous across human tumor 
cell lines and tissue-specific patterns are apparent. DT-diaphorase expression is 
predictive of sensitivity to mitomycin C and E09, supporting a role for DT- 
diaphorase in the mechanism of action of these bioreductive quinone alkylators.
Implications: 1) The results may be used to support the enzyme-directed approach to 
bioreductive drug development. 2) Incoporation of these and other 
biochemical/molecular parameters into the relational data base should enhance the 
capability of the NCI human tumor panel to predict the mode of action and activity of 
existing and novel agents.
INTRODUCTION
In many cases, antitumor agents require metabolism in order to exert their antitumor 
activity. A good example of these are the so-called bioreductive drugs which require 
enzyme-catalyzed reduction (7). Preferential bioactivation in tumour versus normal 
tissue may provide a means of achieving improved therapeutic selectivity. One 
approach to establish the importance of a given reductase in the activation of an 
individual bioreductive agent within intact cells is to determine the correlation 
between the activity of that particular reductase enzyme and drug sensitivity across a 
panel of appropriate cell lines. For example, this approach has been applied to 
demonstrate the clear involvement of DT-diaphorase (NAD(P)Hi-quinone 
oxidoreductase; E.C. 1.6.99.2) in the activation of the investigational indoloquinone 
drug E 09  under aerobic conditions (2-7 and reviewed in reference 8). E09 is 
currently undergoing Phase 11 clinical trial with the EORTC (European Organisation 
for Research and Treatment of Cancer) (9,10) and may have a particular value against 
tumors rich in the DT-diaphorase enzyme. Although mitomycin C is also reduced by 
DT-diaphorase, and there is evidence that this enzyme may be involved in the drug's 
activation within intact cells (reviewed in references 11,12), the results obtained in at 
least one cell line panel have challenged this view (3).
The US National Cancer Institute (NCI) annually screens more than 10,000 
compounds of defined chemical structure against an in vitro panel of over 60 different 
human cell lines derived from tumors with a spectrum of histologies and organs of 
origin (13). Use of computer methods such as the COMPARE program (13,14), 
neural networks (15) and Kohonen self-organizing mapping (16) to mine the data 
base of at least 42,000 compounds so far evaluated against the cell line panel, 
provides a unique means by which to identify the potential mode of action of 
established agents and novel chemical entities. The inclusion of relevant biochemical 
and molecular parameters within the same relational data base would provide an 
additional method of identifying critical factors influencing in vitro antitumor 
activity.
In a collaborative activity between the NCI, the EORTC and the UK Cancer Research 
Campaign, we have piloted this approach by determining the expression of three 
selected bioreductive enzymes, namely DT-diaphorase, NADPH : cytochrome P450 
reductase (E.C. 1.6.2.4) and NADH : cytochrome b5 reductase (E.C. 1.6.2.2) The
pattern of expression both within and between cell lines from different tissue origins 
is described and the potential utility of this new resource is illustrated by the 
correlation observed between enzyme expression and antitumor activity of the 
established anticancer agent mitomycin C and the investigational indoloquinone drug 
E09.
MATERIALS AND METHODS 
Chemicals and Reagents
NADH, NADPH, cytochrome c, bovine albumin, menadione, dicumarol and aprotinin 
were all purchased from Sigma Chemical Co. (Poole, Dorset, U.K.). TE MED and 
ammonium persulphate were obtained from BIORAD Laboratories (Richmond, 
U.S.A.) while the acrylamide / bis acrylamide (30% w/v) was purchased from Severn 
Biotech Ltd. (Kidderminster, U.K.). RNAzol™B was from Biogenesis Ltd. 
(Bournemouth, U.K.), while purified MMLV-RT, DTT and 5x First strand Buffer 
were all obtained from Gibco BRL (Paisley, U.K.). The hexamer primers used in the 
reverse transcriptase reaction were from Pharmacia (Milton Keynes, U.K.) while all 
other reagents used in the Polymerase Chain Reaction were in a kit supplied by 
Perkin Elmer Cetus (Beaconsfield, U.K.).
Enzyme Preparations and Specific Antibodies
Highly purified preparations of rat Walker tumor cell DT-diaphorase and rat liver 
NADPH : cytochrome P450 reductase were provided by Dr. R. Knox (ICRF 
Department of Molecular Pharmacology, Sutton, U.K.) and Prof. C. R. Wolf (ICRF 
Laboratory of Molecular Pharmacology, Dundee, U.K.), respectively. In each case, 
a specific polyclonal antibody raised against the purified rat enzyme was provided.
Cell Lines
A range of tissue-specific human tumor cell lines were grown to confluence in RPMI 
1640 containing 5% serum, and cells were either harvested using l^psin  (0.25%) / 
EDTA (ImM) solution or, for suspension cell lines, by centrifugation. These were 
susequently frozen at -70^C until use. Pellets were thawed and resuspended in 
0.45ml of PBS and 0.05ml aprotinin (10%). Cell suspensions were sonicated for 
3x1 Os, ensuring that vials were kept on ice as often as possible, and then spun down 
(15,000rpm) using a Biofuge 15 microfuge (Heraeus, Germany) for 20 minutes at 
40c  to obtain an S9 supernatant. This S9 supernatant containing a mixture of 
cytosolic and microsomal proteins. Aliquots (40ql) of S9 supernatant were removed 
and stored at -70^C until use. The Pierce Microtiter Plate BCA Assay (77) was used 
to measure total protein content of each cell sonicate.
Measurement of DT-diaphorase, NADPH : Cytochrome P450 Reductase and 
NADH : Cytochrome bg Reductase Activity
An indirect, coupled assay system was used to determine DT-diaphorase activity 
within the S9 cell sonicates. Activity was assayed by measuring cytochrome c 
reduction at 550nm on a spectrophotometer (Perkin Elmer) in the presence of NADH. 
Standard reaction conditions contained cytochrome c (77 jiM), NADH (200pM), as 
cofactor, menadione (10|iM) as an intermediate electron acceptor, and 0.14% bovine 
serum albumin in a final volume of 1 ml 50mM Tris HCl buffer (pH 7.5). The 
activity attributable to DT-diaphorase was that which was inhibited by dicumarol 
(10|iM), a known inhibitor of DT-diaphorase (75).
NADPH : cytochrome P450 reductase and NADH : cytochrome b5 reductase activity 
were measured using a direct assay system as both enzymes were able to reduce 
cytochrome c in the presence of cofactor alone (NADPH and NADH, respectively). 
Conditions used, therefore, were as described above but in the absence of menadione. 
A range of volumes of S9 supernatants (2.5|i to 25|il) were added to the reactions to
ensure that the amount of protein added, gave a linear rate of reaction. Appropriate 
controls were performed to determine background rates of reduction within the 
reactions. In addition, a 1:600 dilution of purified rat DT-diaphorase and an HT-29 
cell sonicate were used in the assay as positive and standardized controls.
All reactions were carried out at 37®C and initiated by the addition of the cell 
sonicate. Rates of reduction were calculated from the initial linear part of the reaction 
progress curve and units of enzyme activity were expressed as nmoles of cytochrome 
c reduced/min/mg of protein. An extinction coefficient for cytochrome c of 21.1 
mMcm'l was used in the calculation.
Polyacrylamide Gel Electrophoresis and Western Blot Analysis
The level of DT-diaphorase protein within each cell sonicate was determined by gel 
electrophoresis and Western blot analysis. For detection of DT-diaphorase, samples 
were run on a 12% separating gel. Samples were diluted to a 1 mg/ml protein 
concentration in boiling mix (10% stacking gel buffer, 2% SDS, 5% b- 
mercaptoethanol, 10% glycerol and 0.005% bromophenol blue) and boiled for 5 
minutes. 50|ig of protein was loaded into each lane. A purified preparation of rat 
DT-diaphorase were used as a positive control (0.1|ig loaded). Samples were 
subjected to electrophoresis at 50rnA for 2 hours and subsequently at 6mA overnight. 
A semi-dry graphite electroblotter (Millipore Corporation, U.S.A.) was used to 
transfer proteins from the gel onto an Immobilon-P transfer membrane (Millipore 
Corporation, U.S.A.). Following blocking for 1 hour with 5% non-fat milk in a buffer 
containing Tris (50mM), Saline (0.9% NaCl) and Tween 20 (0.05%), pH7.9 (TEST 
pH7.9), a primary antibody was applied for 1 hour (1:500 dilution in TEST pH7.9 for 
DT-diaphorase) at room temperature. The primary antibody had been raised against 
the rat Walker tumor protein, and was known to crossreact with the human form of 
the enzyme. The membrane was washed (in TEST pH7.9) and a 1:5000 dilution of 
Protein A linked to Horseradish Peroxidase (Amersham International pic, Amersham, 
U.K.) was applied for 15 minutes at room temperature. Following further washing (in 
TEST pH7.9), the membrane was processed using an Enhanced Chemiluminescence 
kit (Amersham International pic, Amersham, U.K.). The level of protein present 
within each cell sonicate was analysed by densitometric methods using a Molecular 
Dynamics Laser Densitometer with Image Analysis Software (Protein Databases 
Incorporated, New York, U.S.A.).
Detection of DT-diaphorase and NADPH : Cytochrome P450 Reductase 
Expression by RT-PCR
RNA from individual cell pellets was isolated using the RNAzol™ B method 
described by Chomczynski & Sacchi (79). This method was carried out as described 
in the manufacture's protocol and involved several steps including homogenization, 
RNA extraction, RNA precipitation and an RNA wash. The final preparation of RNA 
was diluted down to a Ipg/ql concentration. Reverse transcriptase was performed at 
37°C for 1 hour in the presence of RNA (l|il of a Iqg/ql stock), Hexamer primers 
(O.ljig), MMLV-RT (lOU), dNTP’s (2mM), 5X First strand buffer and DTT (lOmM). 
Following this procedure, the cDNA was diluted 1:5 with distilled water and stored at 
70°C until the polymerase chain reaction was carried out. For each cell line, several 
dilutions of the cDNA were used in the polymerase chain reaction starting at lOOng 
cDNA. These dilutions had previously been found to be in the linear portion of the 
reaction for each enzyme concerned. A separate master reaction mix (primers, Perkin 
Elmer PCR buffer, dNTP’s, Amplitaq, distilled water) was made up for each enzyme 
under investigation i.e. DT-diaphorase, NADPH : cytochrome P450 reductase, the 
human ribosomal 28S protein (used as a positive control) and an internal standard (no 
cDNA). The DT-diaphorase primers used in this study are those detailed by 
Horikoshi et al (20) and consist of (a) bases 392 - 413 of the DT-diaphorase coding 
sequence (27) and (b) bases 640 - 661 of the DT-diaphorase coding sequence (27). 
For NADPH : cytochrome P450 reductase, the primers were selected from the
sequence of the human cDNA (22). A positive control was performed alongside DT- 
diaphorase and NADPH : cytochrome P450 reductase involving the use of primers 
against the ribosomal 28S gene selected from the sequence detailed in Gonzalez et al
(23). For each reaction, 20|il of reaction mix was added to 5|il of cDNA and then 
overlaid with 50ql mineral oil. A negative control was performed in which no cDNA 
template was present. All reaction tubes were then spun for a few seconds and placed 
in the thermal cycler (PREM™III, LEP Scientific, Milton Keynes, U.K.). The 
program consisted of the following steps ; denature (95®C for 45secs.), anneal (60®C 
for 45secs.), extension (72°C for 2mins.l5secs.). This was repeated for 35 cycles and 
then a final extension at 72°C for 7mins. was performed before holding reactions at 
4°C. Products were run on a 2% agarose gel in 0.5% TBE, and then stained with 
ethidium bromide (Iqg/pl) before being photographed under UV transillumination.
Cytotoxicity Testing
Sensitivity of the human tumor cell lines to mitomycin C and E09 were determined 
using standard procedures at the US National Cancer Institute. Results were 
expressed using the standard calculated response parameters GI50 (drug 
concentration causing a 50% reduction in the protein increase within the test wells 
compared to the control wells i.e. 50% growth inhibition); TGI (drug concentration 
resulting in total growth inhibition) and LC50 (drug concentration causing a 50% 
reduction in protein present in the test well at the end of drug treatment, compared to 
that at the start i.e. 50% cell kill). For a more full description see (24). Cultures, in 
the logarithmic phase of growth, were incubated with test agents for 48 hours, and the 
end point of the assay the amount of protein present was determined by the 
Sulforhodamine B (SRB) method (25). Briefly, adherent cells were fixed in situ for 
60 minutes at 4^0 using 50qL cold 50% (wt/vol) trichloroacetic acid (TCA) (final 
concentration 10%). Supernatant was then discarded and 96 well plates rinsed five 
times with deionized water and then dried. Fixed cells were stained at room 
temperature for 10 minutes with 0.4% (wt/vol) SRB dissolved in 1% acetic acid. 
SRB was poured from the 96 well plates and 1% acetic acid used to rinse the plates 
five times. Once the plates were dry, the dye was solubilized using lOmM unbuffered 
tris base (pH 10-10.5) for 2-5 minutes. Optical densities were read on an automated 
spectrophotometric plate reader at 515nm. In the case of suspension cells, the method 
is essentially the same, except that at the end of the drug incubation period the settled 
cells are fixed to the bottom of the plates by adding 50|iL of 80% cold TCA (final 
concentration 16%).
Statistical Analysis
The sensitivity data of anticancer drugs tested against the NCI cell line panel are 
routinely and conveniently displayed as COMPARE analysis plots {13,14). For a 
given drug, these COMPARE plots illustrate on a log 10 scale the deviation from the 
mean sensitivity calculated across all cell lines in the panel. This is known as the 
mean graph. We have used the same method to display our enzyme activity data for 
the NCI panel.
The relationship between enzyme activity and cell sensitivity (using the parameter 
generally employed by the NCI for sensitivity analysis; GI50 values) within the 
human tumor cell line panel towards both mitomycin C and E09 was determined 
using the COMPARE program (13,14). Statistical anaylsis in the form of the Pearson 
Correlation Coefficient was used to determine the degree of similarity between 
cytotoxicity towards E09 and mitomycin C, and enzyme activity.
RESULTS
Enzyme Activity Measurements
A total of 69 human tumor cell lines from 9 different tissue origins were analysed for 
DT-diaphorase, NADPH : cytochrome P450 reductase and NADH : cytochrome b5 
reductase enzyme activities using standard methodolgy based on reduction of 
cytochrome c .
a) DT-diaphorase
Figure 1A represents a mean graph of log DT-diaphorase activity within the cell line 
panel. It is clear that although there is considerable variation in levels of enzyme 
activity across the panel, patterns of high and low enzyme activity expressing groups 
do occur. For example, those cell lines originating from tumors of the colon, CNS, 
non-small cell lung and melanoma histiotypes show higher than average activities 
while the leukemic, breast and, to some extent, ovary lines show lower than average 
activities. Nevertheless heterogeneity of expression can be seen within as well as 
between particular tumor types. For example, it is interesting to note that of the two 
prostate cell lines assayed, one was found to express relatively high DT-diaphorase 
activity while the other expressed a much lower level.
For clarity and as an example of the intra-tumor heterogeneity of expression. Tables 1 
and 2 show more details of the enzyme activity measurements for eight CNS and 
melanoma cell lines. In the case of the CNS group, DT-diaphorase activity was 
shown to vary approximately 12-fold between the cell lines. The range of DT- 
diaphorase activity within the melanoma group was slightly higher at 19-fold. 
Similar results were obtained for the other tissue-specific groups of cell lines, 
although it is interesting to note that measurable levels of DT-diaphorase activity 
could be detected in only two out of five leukemia and lymphoma lines.
b) NADPH : Cytochrome P450 Reductase
The activity of NADPH : cytochrome 450 reductase within the panel of cell lines is 
represented in Figure IB in mean graph format. Although differences in enzyme 
activities existed both between and within the different groups of cell lines, the 
variation was less pronounced than that for DT-diaphorase. In addition, the overall 
level of NADPH : cytochrome P450 reductase activity was lower than that for DT- 
diaphorase. Despite the lower overall range, patterns of high and low enzyme activity 
expressing groups did emerge. Cell lines originating from the colon, melanoma, 
kidney and to some extent the ovarian and leukemic lines were found to have enzyme 
activities above the average level. In contrast, cell lines from the lung (both non­
small cell and small cell) and breast possessed activities which were below average. 
The range of NADPH : cytochrome P450 reductase activities within individual 
selected histiotypic groups of cell lines is illustrated in more detail in Tables 1 and 2. 
In the case of the CNS cell lines (Table 1), NADPH : cytochrome P450 reductase 
activity was lower than that of DT-diaphorase and varied only 2-3-fold between cell 
lines. This pattern was true for all of the groups of cell lines studied.
c) NADH : Cytochrome bg Reductase
A mean graph of log NADH : cytochrome b5 reductase activity within the cell line 
panel is shown in Figure 1C. Similar to NADPH : cytochrome P450 reductase, the 
overall level of NADH : cytochrome b5 reductase activity was lower than that for 
DT-diaphorase. As with the other two enzymes under study, patterns of high and low 
enzyme expressing groups were found. For example, cell lines from the CNS, 
melanoma and kidney expressed activities which were higher than average. In 
contrast, cell lines from the lung (both non-small cell and small cell), ovary and, to 
some extent the breast, possessed activities which, with the exception of one ovarian 
cell line, were below average. Although the activity of NADH : cytochrome b5 
reductase was higher than that of NADPH : cytochrome P450 reductase in the CNS 
group (Table 1), and indeed in many of the other groups studied, the range between 
the highest and lowest cell lines was similar at 2-3-fold.
DT-diaphorase Protein Expression
To complement the enzyme activity measurements, all human tumor cell lines within 
the panel were analysed for DT-diaphorase protein expression. DT-diaphorase 
protein was detected in 65 out of a total of 69 cell lines. As for the enzyme activities, 
a wide range of protein expression was found both within and between different 
tumor types. Examples of the results obtained in melanoma and CNS cell lines are 
shown in Figure 2. All of the melanoma lines studied were found to express DT- 
diaphorase with the range of levels clearly seen in Figure 2A. Figure 2B clearly 
shows the results of Western blot analysis for detection of DT-diaphorase protein in 
cell lines originating from the CNS. Here the range of DT-diaphorase expression was 
even greater, with some cell lines having relatively high levels of expression (Lanes 
1, 2, 5 and 7) and others showing little or no detectable protein (Lanes 3, 4 and 8).
To determine whether the observed wide range of enzyme activities could be 
explained by a correlation with the DT-diaphorase protein content of the cell line, the 
results obtained with two different endpoints were compared. Enzyme activity and 
protein expression were found to correlate extremely well in the vast majority of cell 
lines studied. For illustration, the comparison between DT-diaphorase activity and 
protein expression in the eight CNS cell lines is shown in Figure 3 (correlation 
coefficient = 0.872). Correlation coefficients for all of the other tissue groups 
investigated were in the range 0.394 - 0.938. The small number of discrepancies 
found between DT-diaphorase protein expression and enzyme activity were mainly 
confined to a few of the breast or ovarian cell lines which had very low levels (data 
not shown).
Detection of DT-diaphorase and NADPH : Cytochrome P450 Reductase by RT- 
PCR
To explore the reasons underlying those few instances in which weak correlations 
were seen between DT-diaphorase protein expression and enzyme activity within the 
breast and ovarian cell lines, the more sensitive RT-PCR assay for DT-diaphorase 
RNA was performed. All human tumor cell lines originating from the breast, and as a 
control four cell lines originating from the CNS, were assayed for both DT- 
diaphorase and NADPH : cytochrome P450 reductase RNA levels using RT-PCR.
In the case of the human breast tumor cell lines, all nine were found to express DT- 
diaphorase RNA although a wide range of levels were observed (data not shown). 
The level of NADPH : cytochrome P450 reductase RNA in breast lines was 
extremely low in most of the lines investigated and was undetectable in others. In the 
case of CNS, DT-diaphorase RNA was detectable in all four cell lines investigated, 
with a range in values once again observed. NADPH : cytochrome P450 reductase 
RNA was detected only at very low levels in some of the CNS cell lines.
Correlation between cell sensitivity towards anticancer agents and enzyme 
activity
A COMPARE analysis was carried out to investigate the correlation between DT- 
diaphorase activity and cell sensitivity to the bioreductive quinones E09 and 
mitomycin C under aerobic conditions. Figure 4 shows the patterns of differential 
cytotoxicty (GI50 (A), TGI (B) and LC50 (C)) in the form of the mean graph for 
E09. Each of the individual parameters show that leukemic and ovarian cell lines 
were the most resistant, while those originating from the melanoma, colon, renal, 
CNS, small cell and non-small cell lung cancer appear to be more sensitive towards 
E09. The results for mitomycin C (figure 5) were found to be somewhat different 
with cell lines originating from breast, ovaries and colon being relatively resistant and 
those from the CNS and melanoma being more sensitive towards mitomycin C.
A statisical analysis of the data was performed using the Pearson Correlation 
Coefficient. The results of the 42,000 compounds screened against the NCI panel
indicated that quinone compounds such as E09 and mitomycin C were among those 
compounds exhibiting the best correlation between the GI50 and DT-diaphorase 
activity under investigation. For example, a Pearson Correlation Coefficient of 0.446 
(p < 0.0013) was obtained for E09 (Figure 6), whilst for mitomycin C (not shown) 
the coefficient was 0.424 (p < 0.0005). A similar trend for correlations with the other 
parameters TGI and LC50 were also observed. In contrast, no correlation was found 
between NADPH : cytochrome P450 reductase or NADH : cytochrome b$ reductase 
activities, and sensitivity towards either mitomycin C or E09. It should be noted that 
five of the cell lines used in the analysis exhibited extremely low levels (or none) of 
DT-diaphorase activity and as such, lie apart from the others in figure 6.
DISCUSSION
The results described in this paper represent one of the first in a series of ongoing 
studies to characterize selected important biochemical and molecular parameters 
across the entire NCI panel of more than 60 human tumor cell lines. The existing 
relational data base on the in vitro anti tumor activity of at least 42,000 discrete 
chemical entities permits the assignment of a putative mechanism of action to both 
established and novel compounds (13-15,26). The addition of biochemical and 
molecular parameters allows the growing data base to be interrogated to determine the 
likely involvement of these parameters in the antitumor mechanism.
The selected biochemical parameters, in this study, were the activities of the enzymes 
DT-diaphorase, NADPH : cytochrome P450 reductase and NADH : cytochrome b5 
reductase. These are among the reductases known to be involved in activation of 
bioreductive anticancer agents, including quinones, nitro compounds and A-oxides
(1). Additional enzymes are also involved in bioreductive activation, including for 
example cytochrome P450s, xanthine oxidase and xanthine dehydrogenase. DT- 
diaphorase was selected because of the current degree of interest in its potential 
involvement in the activation of various bioreductive agents, particularly quinones 
(8,27). NADPH : cytochrome P450 reductase has also been extensively investigated 
for its role in the metabolism oFa wide range of bioreductive agents (28,29). NADH ; 
cytochrome b5 reductase has been less extensively studied but has been shown to 
have the ability to bioactivate mitomycin C (30). A further, practical advantage of 
selecting these particular reductases is the similarity in the analytical methodology, 
which facilitated the efficient processing of the samples. To help interpret the 
enzyme activity information and also to assess technical feasibility for future clinical 
studies, the amount of protein (DT-diaphorase) and messenger RNA (DT-diaphorase 
and NADPH : cytochrome P450 reductase) were also analyzed by Western 
immunoblotting and RT-PCR, respectively. Additional reductases could also be 
examined in a similar fashion but given the extensive nature of the work involved to 
characterize expression across close to 70 cell lines, it was felt appropriate to restrict 
the initial analysis to three drug metabohzing reductase enzymes.
In addition to providing a valuable resource for the future analysis of mechanism of 
action of potential anticancer compounds tested in the NCI screen, the present study 
represents the most comprehensive characterization to date of the bioreductive 
enzymes examined against human tumor cell lines in vitro (for previous studies see 
for example, references 3,4,31).
It is clear that the expression of bioreductive enzyme activities showed a considerable 
degree of heterogeneity of expression both within a particular histotype and between 
the 69 tumor cell lines of different origins. In the case of DT-diaphorase, for 
example, a relatively high degree of expression was seen in non-small cell lung 
cancer, colon, CNS and melanoma cell lines. Relatively low activities were noted in 
leukemic, ovarian and breast cell lines. Other studies using smaller panels of cell
lines have also shown similar patterns of DT-diaphorase expression. For example, 
high levels of DT-diaphorase activity have been observed within human tumor cell 
lines originating from the lung and colon (3,4,7,31,32) while very low levels in 
leukemias have also been noted (7). In addition, enzyme activity measurements have 
been carried out using human tumor samples. Schlager and Powis (33) showed that 
DT-diaphorase was enhanced (compared to paired normal tissue) in tumors of the 
lung and colon, results very much in line with the tumor cell lines in this study. 
Similar to our study using human tumor cell lines, Schlager and Powis (33) found that 
DT-diaphorase was also enhanced in breast tumors but interestingly our breast cell 
lines contained higher levels of DT-diaphorase activity compared to the tumor data. 
This is not unusual, since we ourselves noted that the level of DT-diaphorase activity 
was also found to be higher within the CNS human tumor cell lines when compared 
to a human glioma biopsy panel (28). These differences, however, may be partly 
explained by problems concerning tissue aquisition, such as the amount of 
contaminating normal tissue present (generally normal tissue has lower enzyme 
activity (33)) within the tumor. In order to answer this question more fully, therefore, 
more work is required in the investigation of reductase levels within human tumors. 
Interestingly, in comparison with DT-diaphorase, the activities in the panel (and 
tumors) observed for NADPH : cytochrome P450 reductase and NADH : cytochrome 
b5 reductase were in general much lower.
Overall only a low number of cell lines within the NCI panel were found to lack DT- 
diaphorase enzyme activity completely. Interestingly however, one out of ten 
(i.e. 10%) non-small cell lung cancer lines studied was found to lack DT-diaphorase 
activity. This finding was in agreement with the frequency of a point mutation in the 
DT-diaphorase gene reported by Rosvold et al (34) and more recently by Ross et al
(12) in lung cancers and may be an indication of the presence of this point mutation in 
our cell lines lacking DT-diaphorase activity. Further studies would be required to 
establish this.
As an initial test of the ability to use the enzyme activity measurements to investigate 
involvement in in vitro antitumor activity, we interrogated the data base with respect 
to two selected compounds, namely the clinically used, prototype bioreductive agent 
mitomycin C and the structurally related, novel indoloquinone agent E09 which is 
currently undergoing Phase II clinical trial (9). The former was selected as an 
established agent for which a number of enzymes are known to be capable of 
bioactivation (30,35-38). Moreover, whereas DT-diaphorase is thought to be one of 
these, a previous study in a panel of 15 human tumor cell lines found no correlation 
between DT-diaphorase expression and cytotoxicity (3). E09 was selected as a 
developmental drug in which a strong correlation between DT-diaphorase expression 
and cytotoxicity has been seen in several smaller studies but for which information on 
the role of additional reductases is lacking (for review see reference 8). Our results 
showed that in this much larger cell line panel, covering a wider range of tumor 
histiotypes, a highly significant correlation was seen between DT-diaphorase 
expression and sensitivity to both E09 and mitomycin C. In contrast, there was no 
significant relationship between sensitivity to either drug and activities of either 
NADPH : cytochrome P450 reductase or NADH : cytochrome b5 reductase. These 
results would suggest that DT-diaphorase is an important enzyme in the activation of 
these bioreductive quinones in intact cells whereas the other enzymes are much less 
important or not involved at all.
The correlation shown in Figure 6 for E09, and similar data for mitomycin C, suggest 
that although DT-diaphorase is a major determinant of cellular sensitivity to E09 and 
mitomycin C it is clearly not the only one. This is not suprising. Not only may other 
activiating and detoxifying systems be involved, but factors such as intrinsic 
sensitivity to DNA alkylation and DNA repair capacity will also play a role. It is a
feature of the large NCI panel that individual parameters can be identified from a 
multivariant data base.
It should be emphasized that the correlations reported above concern the cytotoxicity 
of E09 and mitomycin C under aerobic exposure conditions. The sensitivity of the 
NCI human tumor cell line panel to these drugs has not been determined under 
hypoxic conditions and the present configuration of the screen would not permit this. 
Very recent studies have shown that different results can be obtained under aerobic 
versus hypoxic environments (4,31,39) but the significance of these differences for 
the in vivo situation remains, at present, unclear.
In summary, the expression and, importantly, the functional activity of three 
reductase enzymes has been determined across the NCI human tumor cell line panel. 
The results reveal interesting differences within and, in particular, between cell lines 
from different tissues of origin. Heterogeneity in the expression patterns of DT- 
diaphorase were especially noteworthy. The correlations observed between enzyme 
activity and tumor cell line sensitivity to the indoloquinone E09 and to mitomycin C 
suggest that the inclusion of the enzyme activity measurements within the relational 
data base should allow similar questions to be asked across the 42,000 or more 
discrete chemical entities that have been screened to date. It should be possible to 
determine not only whether particular compounds are activated by the reductases 
concerned, but also where reductive metabolism leads to deactivation in intact cells. 
This suggests a possible role for the cell line panel in predicting metabolic 
detoxification of xenobiotics. Moreover, new agents under study in the panel can also 
be analysed in a similar way. A potential practical application of this knowledge is 
the targeting of particular agents to certain tumor types, depending on the levels of 
activating and deactivating enzymes, as suggested by the 'enzyme-directed' approach 
to bioreductive drug development (4,8,31,39-41). A caveat is that whereas the 
patterns of expression displayed in the cell lines are in many cases consistent with 
expression in fresh clinical tumor specimens, more information on the latter is 
required to underpin the enzyme-directed approach. In addition, prospective clinical 
studies would be needed to determine clinical utility. Finally, this study has 
illustrated the feasibility and value of measuring biochemical and molecular 
parameters as potential aids to the diagnostic power of the NCI human tumor panel to 
investigate the potential mechanism of action of existing agents and new chemical 
entities.
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FIGURE LEGENDS
Fig 1 : Mean graphs of log DT-diaphorase (A), NADPH : cytochrome P450 reductase 
(B), and NADH : cytochrome b5 reductase (C) activities within the NCI cell line 
panel. For each enzyme, the mean activity for all of the cell lines is represented by a
vertical line through individual plots (these mean activities being 199.5, 14.8 and 38.0 
nmoles cytochrome c reduced/min/mg protein for DT-diaphorase, NADPH : 
cytochrome P450 reductase and NADH : cytochrome b5 reductase respectively). 
Horizontal bars show, on a logarithmic scale, the individual enzyme activities for 
each cell line relative to the mean value. Those cell lines with activity below the 
mean lie to the left of the vertical line. Cell lines which contain no enzyme activity 
are indicated with (-). MG_MID, Delta and Range are defined as the calculated mean 
value of the panel; the number of logiQ units by which the values for the individual 
lines of the panel differs (+ or -) from the MG_MID value and the number of log 10 
units by which the value for the most sensitive line differs from the least sensitive 
line, respectively.
Fig 2 : DT-diaphorase protein expression within melanoma (A) and CNS (B) tumor 
cell lines. In the melanoma panel, lanes 1 - 8 represents S9 supernatant fractions 
prepared from SKMEL2; SKMEL5; SKMEL28; M14; M19MEL; MALME; 
UACC62 and UACC257 cell lines respectively. In the CNS panel, lanes 1 - 8  
represents S9 supernatant fractions prepared from SNB19; SNB75; SNB78; SF268; 
SF295; SF539; U251 and XF498 cell lines respectively. A purified preparation of the 
rat Walker form of DT-diaphorase (33kD) was run as a standard in each case.
Fig 3 ; Correlation between DT-diaphorase protein expression and enzyme activity 
within eight CNS tumor cell lines. OD x MM is defined as an integrated area under 
the curve over a fixed width of band.
Fig 4 : Patterns of differential cytotoxicity of the indoloquinone E09 towards human 
tumor cell lines. For each cell line, the GI50 (A), TGI (B) and the LC50 (C) are 
obtained. These different measures of in vitro antitumor activity are described in 
Materials and Methods and in reference 24. For each parameter, a mean log is 
determined and is defined as the mean of the log 10 of the individual values for that 
parameter. The difference between the logio of each cell line and the mean log is 
then determined , to yield positive values for cell lines more sensitive than average 
(bars projecting to the right) and negative values for cell lines less sensitive than 
average (bars projecting to the left). For definition of MG_MID, Delta and Range see 
legend of figure 1.
Fig 5 : Patterns of differential cytotoxicity of mitomycin C towards human tumor cell 
lines. For each cell line, the GI50 (A), TGI (B) and the LC50 (C) are obtained. These 
different measures of in vitro antitumor activity are described in Materials and 
Methods and in reference 24. For each parameter, a mean log is determined and is 
defined as the mean of the log 10 of the individual values for that parameter. The 
difference between the log 10 of each cell line and the mean log is then determined , to 
yield positive values for cell lines more sensitive than average (bars projecting to the 
right) and negative values for cell lines less sensitive than average (bars projecting to 
the left). For definition of MG_MID, Delta and Range see legend of figure 1.
Fig 6 : Correlation between E09 sensitivity and DT-diaphorase activity. The 
parameter used in the analysis shown is that of GI50. The statistical analysis used is 
the Pearson Correlation.
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